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Sommaire 
 
Le trouble déficitaire de l'attention avec hyperactivité (TDAH) et le tabagisme ont un lien établi. 
Les personnes atteintes d’un TDAH sont plus portées à développer une dépendance à la cigarette, à 
débuter le tabagisme plus jeune et ont plus de difficultés à cesser de fumer. Il est maintenant connu 
que le traitement du TDAH modifie ces interactions. Bien que les psychostimulants soient le 
traitement pharmacologique de choix pour le TDAH, les effets secondaires indésirables de ces 
substances réduisent considérablement l’utilisation par ceux qui veulent cesser de fumer, surtout 
s’ils utilisent déjà des substances ayant des propriétés stimulantes, tel que la nicotine, pour les 
aider. Cette étude a comme objectif d’évaluer l’efficacité potentielle d’un traitement de 
neurofeedback chez des adultes atteints d’un TDAH et qui, malgré l’utilisation d’un timbre de 
nicotine, n’arrivaient toujours pas à cesser de fumer. Quatre participantes qui ont rencontré les 
critères de recherche pour le TDAH ont reçu 12 à 14 séances de neurofeedback pendant qu’elles 
continuaient un traitement avec un timbre de nicotine. L’efficacité de l’intervention en 
neurofeedback est évaluée selon un devis de recherche à cas unique avec lignes de base multiples 
établies en fonction des participants. L’analyse post-intervention révèle que trois des quatre 
participantes ont réduit de façon significative leur dépendance sur la nicotine à la suite du 
traitement. Le neurofeedback déjà connu comme traitement efficace du TDAH, dans le cas de 
dépendance à la nicotine, peut améliorer la tolérance aux symptômes de sevrage en passant par une 
amélioration de l’attention. 
 
MOTS-CLÉS : Trouble déficitaire de l’attention avec hyperactivité (TDAH), neurofeedback, 
sevrage, nicotine 
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Le contexte de l'étude 
   Le trouble déficitaire de l'attention avec hyperactivité (TDAH) et le tabagisme figurent parmi 
les problèmes psychiatriques et comportementaux les plus courants et les plus coûteux auxquels 
la société doit faire face de nos jours. Plus de 37 000 Canadiens sont décédés prématurément à 
cause du tabagisme en 2007 et il est prouvé que le tabagisme est relié à plus de deux douzaines de 
maladies et de conditions physiques problématiques (Santé Canada, 2007). Le TDAH est un 
trouble neurodéveloppemental impliquant des problèmes d’attention, d'hyperactivité et 
d'impulsivité (APA, 2000). Dans le monde, on estime à 5,3 % la proportion des enfants et des 
adolescents atteints du TDAH (Polanczk, Silva de Lima, Horta, Biederman & Rohde, 2007) et 4 à 
4,5 % des adultes (Kessleer, Chiu, Demler, & Walter, 2005). Le TDAH a été longtemps considéré 
comme un trouble lié à l'enfance, mais il est désormais admis que 40 à 60 % des enfants 
diagnostiqués continuent de répondre aux critères diagnostiques à l'âge adulte (Barkley, Fischer, 
Smallish, & Fletcher, 2002; Biederman, Petty, Evans, Small, & Faraone, 2010; Kessler et al., 
2010). 
   Les adultes et les adolescents atteints du TDAH sont plus susceptibles de commencer à fumer à 
un plus bas âge et de progresser plus jeune vers un usage régulier de la cigarette (Breyer, 
Burgetova, & Roper, 2009; Galéra, Fombonne, Chastang, & Bouvard, 2004; Molina & Pelham, 
2003). Ils fument beaucoup plus que la population en général et il y a un lien direct entre les 
symptômes du TDAH et le nombre de cigarettes fumées (Pomerleau, Downey, Stelson, & 
Pomerleau, 1995). Les symptômes de sevrage chez cette population clinique sont plus importants 
(Knott et al., 2008), ils recommencent à fumer plus rapidement (Humfleet et al., 2005) et un plus 
petit nombre d'entre eux, en particulier les hommes, cessent de fumer définitivement (McClernon 
& Kollins, 2008). Bien que pour les troubles liés à l'utilisation de certaines substances, le TDAH 
  
en tant que facteur de risque peut être attribuable presque complètement à la présence d'autres 
comorbidités, dans le cas de la consommation de nicotine, le TDAH semble être un facteur de 
risque direct (Biederman et al., 2006a; Breyer et al., 2009; Pomerleau et al., 2003; Wilens et al., 
2008 ).  
   Aujourd'hui, la plupart des chercheurs croient qu'un traitement pharmacologique précoce du 
TDAH peut modifier ces interactions et améliorer les résultats de la désaccoutumance au tabac 
(Wilens et al., 2008), mais les conclusions de plusieurs études importantes ne soutiennent pas ce 
constat. Cela est particulièrement notable dans le rapport du MTA (the NIMH Collaborative 
Multisite Multimodal Treatment Study of Children with ADHD; 2009), qui révèle qu'un traitement 
aux stimulants administré tôt n'a pas procuré d’avantage à long terme dans l’utilisation de la 
cigarette chez des patients comparativement à un groupe témoin non médicamenté (Molina et al., 
2009). De plus, une préoccupation demeure concernant ces traitements médicamenteux qui, selon 
certaines études en laboratoire, pourraient même accroître le risque du tabagisme (Silverstone & 
Dardashova, 2012). Néanmoins, le consensus actuel semble soutenir le constat que le traitement 
pharmacologique dans l’enfance dans le cas du TDAH ne contribue pas aux abus de substance 
éventuels (incluant la cigarette), mais qu’il n’en protège pas non plus.  
   Cependant, des traitements combinés utilisant des médicaments pour le TDAH et un timbre de 
nicotine pour la cessation tabagique ont obtenu un certain succès, bien que les résultats aient été 
limités, étant donné l’impact de certains facteurs tels que les effets secondaires et la composition 
de l’échantillon (Covey, Manubay, Jiang, Nortick, & Palumbo, 2008; Winhusen et al., 2010). En 
tant que tel, un traitement alternatif contre le TDAH combiné à un traitement pour cesser de fumer 
sans contribuer à des effets secondaires potentiels serait utile. 
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   Le neurofeedback est un traitement non pharmacologique alternatif du TDAH, qui vise la 
régulation de l'activité électrique du cerveau. Grâce à de nombreuses études menées entre 2006 et 
2009, il est de plus en plus reconnu comme une approche efficace contre les symptômes du 
TDAH. Une métaanalyse récente effectuée par Arns, de Ridder, Strehl, Breteler et Coenen’s 
(2009) indique les valeurs moyennes de l'ampleur de l'effet, dont 1,02 pour l'inattention, 0,71 
pour l'hyperactivité et 0,94 pour l'impulsivité. Les importants coûts individuels, sociaux et des 
soins de santé reliés à la comorbidité entre le tabagisme et les troubles de l'attention justifient le 
nombre croissant de projets de recherche ayant pour but d'élucider l'impact de différents 
traitements du TDAH sur le tabagisme. 
   
Les fondements théoriques de l'étude 
   Bien que le lien entre le TDAH et le tabagisme soit désormais reconnu, il reste maintenant à 
déterminer la nature de ce lien, ce qui n’a pas été évident étant donné non seulement la nature 
imprécise du diagnostic chez l’adulte, mais également à cause de la présence de comorbidités 
importantes qui brouillait les conclusions des écrits (Gray & Uphadhyaya, 2009). De plus amples 
recherches s’avèrent nécessaires afin de trouver une réponse complète, mais il y a néanmoins 
suffisamment d`indices dans les écrits pour établir qu’il y a un lien neurobiologique particulier 
entre l’aspect d’inattention du TDAH et la dépendance à l’usage du tabac. (Burke, Loeber, White, 
Stouthamer-Loeber, & Pardini, 2007; Lerman et al., 2001; Tercyak, Lerman, & Andrain, 2002). 
Le TDAH et ses « présentations » 
     Les critères pour un diagnostic de TDAH ont été modifiés avec la 5e édition du Diagnostic 
and statistical manual of mental disorders publié en mai 2013 par l’American Psychiatric 
Association (DSM-V). La présente étude, ainsi que la majorité des études citées dans ce texte, a 
utilisé les critères du DSM-IV-TR, donc il serait utile de réviser les derniers changements 
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(American Psychiatric Association, 2000).  Le TDAH se trouve maintenant dans la catégorie des 
troubles neurodeveloppementaux, ce qui souligne que le TDAH peut être présent aux différentes 
étapes de la vie, mais avec des manifestations particulières dépendamment de l’âge. Il y a 
maintenant trois présentations au lieu de trois sous-types : inattention prédominante ; 
hyperactivité/impulsivité prédominante ; et mixte. Le nombre de symptômes qui doivent être 
identifiés pour un diagnostic chez l’enfant n’a pas changé (toujours six pour chaque présentation) 
mais pour l’adolescent (17 ans et plus) et l’adulte, le nombre est maintenant établi à cinq. Les 
comportements problématiques doivent produire des effets négatifs sur le fonctionnement ou le 
développement dans au moins deux milieux de vie de la personne et être à un degré qui ne 
correspond pas au niveau de développement approprié à l’âge de la personne (c.-à-d. être plus 
fréquent et plus sévère que ce qu'on observe chez des personnes d'un niveau de développement 
similaire). Les symptômes doivent maintenant être présents avant l’âge de 12 ans, alors 
qu’antérieurement le DSM-IV exigeait l’apparition de symptômes avant l’âge de 7 ans. Quelques 
exemples des symptômes d’inattention sont : ne parvient pas à prêter attention aux détails; fait 
des fautes d’inattention; a du mal à soutenir son attention; semble souvent ne pas écouter; ne se 
conforme pas aux consignes; a souvent du mal à s’organiser. Pour la présentation de la 
prédominance hyperactivité/impulsivité, les symptômes sont par exemple : a du mal à se tenir 
tranquille ; parle trop ; a souvent du mal à attendre son tour ; interrompt souvent les autres ; 
démontre une agitation excessive. Il y a plusieurs controverses par rapport à l’établissement du 
diagnostic du TDAH. Bien que certains déficits cognitifs (attention et fonctions exécutives) soient 
souvent identifiés comme étant associés au TDAH, certains auteurs estiment que des tests 
neuropsychologiques ne sont pas nécessaires à l’évaluation diagnostique (Haavik, Halmoy, 
Lundervold, & Fasmer, 2010). Ces tests facilitent surtout l’identification des accommodements 
qui peuvent être utiles pour le bon fonctionnement de l’individu.  
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   L’hétérogénéité des profils cognitifs et comportementaux associés  au diagnostic du TDAH, en 
plus du manque de consensus sur la façon de diagnostiquer le trouble, surtout chez les adultes,  et 
plus particulièrement dans le contexte de recherches sur les comorbidités (tels que les abus de 
substances) fait qu’il est difficile de déceler sans équivoque le lien entre la cigarette et le TDAH 
en utilisant les écrits scientifiques actuels. Néanmoins, ce qui ressort de cette quantité de 
recherche semble suggérer que l’inattention joue un rôle unique dans le développement du 
tabagisme chez les personnes avec le diagnostic. 
Le rôle des sous-types du TDAH et le degré de sévérité 
   Plusieurs études ont établi que les risques pour le tabagisme peuvent être associés à chaque 
dimension du trouble, mais de façons divergentes (Burke, Loeber,White, Stouthamer-Loeber, & 
Pardini, 2007). Selon une revue attentive des écrits effectuée par Looby (2008), il apparaît 
clairement que l'hyperactivité/impulsivité n'est pas invariablement reliée à l'usage précoce du 
tabac. Elle est plus souvent considérée comme contribuant à mener avec le temps à une forte 
consommation de tabac et serait également reliée à la présence du trouble de la conduite ou à 
d'autres facteurs psychosociaux (comme l'usage du tabac dans la famille). L'impulsivité aurait 
toutefois un effet direct sur la capacité à cesser de fumer une fois la cigarette est devenue une 
habitude (Covey, Manubay, Jiang, Nortick, & Palumbo, 2008). Par contre, l'inattention semblerait 
être particulièrement associée au risque de développer une dépendance à la nicotine (Lerman et 
al., 2001).  
   Ce lien est tellement important que le degré de sévérité associé aux difficultés d’inattention est 
souvent corrélé avec le nombre de cigarettes fumées et la dépendance à la nicotine, que ce soit 
dans une cohorte avec un diagnostic ou pas (Fuemeller, Kollins & McClernon, 2007; Lerman, 
2001). Certains auteurs suggèrent que même sans diagnostic formel, la présence de symptômes 
d’inattention importante pourrait augmenter le risque du tabagisme et que ces personnes méritent 
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alors d’être ciblées pour un traitement. Chez 65 % des garçons et 33.3 % des filles diagnostiqués 
dans l’enfance, les symptômes du TDAH diminuent suffisamment pour que le diagnostic 
s’estompe. Mais des difficultés reliées au diagnostic, tel que le tabagisme, peuvent persister à un 
point tel que le bien-être de la personne reste hypothéqué. Dans une étude qui examinait les 
difficultés adultes de ces enfants une dizaine d’années plus tard, 38 % des garçons et 11 % des 
filles fumaient. En comparaison, 15 % du groupe de contrôle masculin non diagnostiqué dans 
l’enfance et 4 % des filles sans diagnostic utilisaient la cigarette. En conclusion, l’inattention joue 
un rôle significatif par rapport à la dépendance à la nicotine, mais est-ce que l’impact de ce 
facteur est direct ou passe par une comorbidité quelconque?  Bien entendu, la dépendance à la 
nicotine n’est pas la seule comorbidité qui jumelle le TDAH. Dans la mesure de comprendre 
l’interaction entre l’inattention et l’utilisation de la cigarette, il faut d’abord se pencher sur les 
recherches examinant l’usage d’autres substances et d’autres problèmes de santé mentale.  
Le TDAH, le tabagisme et les troubles liés à l’utilisation des substances (TUS) 
   Il y a eu un consensus voulant que les individus atteints du TDAH ont un risque accru de 
développer des troubles liés à l'utilisation de nombreuses substances incluant l'alcool, la 
marijuana, la cocaïne, les méthamphétamines et la cigarette, mais les premières études traitant du 
TDAH et des TUS ne distinguaient pas le tabagisme de la consommation d'autres substances 
(Biederman, Wilens, Wick, Faraone, & Spencer, 1998). Le tabac a souvent été étudié 
conjointement avec d'autres substances, possiblement à cause de son omniprésence et de l'usage 
répandu de la cigarette chez les personnes ayant reçu un diagnostic de maladie mentale. En effet, 
dans un échantillon de patients ayant des troubles liés à l'utilisation de substances, presque tous 
les sujets (98,6 %) fumaient (Abrantes, Brown, & Tomlinson, 2003). Alors, quand on expliquait 
le risque élevé par la présence de comorbidités particulières, on tenait également pour acquis que 
le lien du TDAH et la cigarette s’expliquait de la même façon. Par exemple, le TDAH en tant que 
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facteur de risque pour la consommation subséquente de cocaïne peut être attribuable presque 
entièrement à la présence du trouble de la conduite (Barkley, Fischer, Smallish, & Fletcher, 
2004). 
   Lorsque le tabagisme est étudié indépendamment des autres substances, les résultats ne sont pas 
les mêmes. Comme pour les troubles liés à l'utilisation d'alcool ou de cocaïne, les chercheurs ont 
examiné le rôle de comorbidités telles que le trouble de la conduite, le trouble oppositionnel et 
d'autres états psychiatriques en lien avec l'usage du tabac, croyant qu’il y avait également un lien 
indirect entre le risque du tabagisme et le TDAH (Galera, Fombonne, Chastang, & Bouvard, 
2005). Deux études majeures contrôlant pour la psychopathologie mentionnent que de tous les 
TUS considérés, seul le risque de dépendance à la nicotine à vie est supérieur chez ces personnes 
(Biederman et al., 2006b; Molina & Pelham, 2003).  
   Des études récentes en neurogénétique ont démontré que les systèmes cholinergiques peuvent 
également être modifiés chez les personnes atteintes du TDAH, ce qui explique partiellement le 
lien entre la cigarette et le TDAH (Potter, Newhouse, & Bucci, 2006). Une hypothèse soutient 
que les mécanismes sous-jacents au TDAH et les effets physiologiques de la nicotine partagent 
un système commun de neurotransmetteurs (Wilens et al., 2008). Ces faits ont provoqué plusieurs 
projets de recherche sur les effets de la médication utilisée pour améliorer les symptômes du 
TDAH comme traitement pour la cessation du tabagisme.  
   Les psychostimulants constituent le traitement privilégié pour le TDAH. Une étude sur l'usage 
du méthylphénidate pompe osmotique élémentaire pour la voie orale (MPH OROS), 
conjointement avec des substituts à la nicotine, a conclu qu'il y avait un impact, mais mitigé, sur 
les résultats de désaccoutumance au tabac chez les adultes atteints du TDAH (Winhusen et al., 
2010). Les participants de cette étude ont réussi à diminuer minimalement le nombre de cigarettes 
quotidiennes, mais la cessation du tabagisme n’était pas suffisamment élevée pour être 
xvi 
 
 
significative. Bien que cette étude rapporte une réduction significative des symptômes du TDAH 
dans le groupe MPH OROS, elle note également un taux supérieur d'effets secondaires 
indésirables (tels que la dyspepsie, le rythme cardiaque élevé, l’hyperactivité accrue, des 
palpitations) causés par le traitement combiné. Ces désagréments peuvent avoir contribué aux 
symptômes de sevrage, déjà difficiles, vécus par les participants et peuvent avoir éclipsé tout 
avantage relié à l'amélioration des symptômes du TDAH, relativement au groupe non 
médicamenté atteint du TDAH. Une alternative thérapeutique causant peu ou pas d'effets 
secondaires lorsqu'administré adéquatement serait alors potentiellement bénéfique pour les 
adultes avec un TDAH qui veulent cesser de fumer. 
 
Le neurofeedback,  l'attention et le TUS 
   Le neurofeedback, aussi connu sous le nom de rétroaction biologique 
électroencéphalographique (EEG), est un traitement alternatif non invasif pour plusieurs états, 
mais a jusqu’à maintenant servi principalement à traiter les crises épileptiques et le TDAH, pour 
lesquels il est reconnu comme un traitement efficace et fondé sur des données probantes (Yucha 
& Montgomery, 2008; Sherlin, Arns, Lubar, & Sokhadze, 2010). Le neurofeedback, qui a 
réellement débuté dans les années 1960 et 1970, est une forme de rétroaction biologique utilisant 
des capteurs sur la tête d'un individu afin de lui procurer l'information en temps réel sur ses ondes 
cérébrales. L'entraînement par le neurofeedback est une technique de conditionnement opérant 
visant à renforcer ou à inhiber des ondes cérébrales particulières. L'activité EEG se divise en 
différentes bandes de fréquences. Les ondes de moins de 4 Hz sont les ondes delta (ondes lentes 
correspondant à l'état de sommeil) ; les fréquences de 4 à 8 Hz correspondent aux ondes thêta 
(état somnolent, inattentif) ; les fréquences de 8 à 12 Hz correspondent aux ondes alpha (état de 
détente, éveil) ; enfin, les ondes de 12 à 30 Hz sont les ondes bêta (état actif, attentif). Le schéma 
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électroencéphalographique le plus courant identifié chez les enfants atteints du TDAH correspond 
à des ondes excessivement lentes dans les régions frontales du cerveau (Chabot & Serfontein, 
1996; Thompson & Thompson, 2003). Chez les adolescents et les adultes, l’état le plus associé 
avec l'inattention, vécue comme «l’esprit brouillon» a été nommé « thalpha » car il correspond à 
de basses fréquences allant de 6 à 10 Hz, ce qui englobe les ondes cérébrales thêta et alpha 
(Thompson & Thompson, 2003). Une étude récente comparant 34 adultes atteints du TDAH avec 
34 sujets témoins présente des résultats semblables à l’étude de Chabot et Serfontein (1996). Les 
patients atteints du TDAH ont démontré une densité de puissance absolue dans les bandes alpha 
et thêta significativement plus élevée que la norme (Koehler et al., 2002), une meilleure analyse 
statistique (Rossiter, 2004b) et des mesures plus précises grâce à l’imagerie par résonnance 
magnétique fonctionnelle (Levesque, Beauregard, & Mensour, 2006). Néanmoins, l'une des 
principales critiques sur la recherche dans ce domaine est le manque d'études cliniques 
randomisées (Loo & Barkley, 2005). Dans une étude rigoureuse publiée récemment dans le 
Journal of Child Psychology and Psychiatry, cette critique a été abordée (Gevensleben et al., 
2009). 
   Le neurofeedback a également servi à traiter les TUS depuis les années 1990. Le principal type 
d'entraînement dans ce domaine a été le protocole de rétroaction des ondes cérébrales alpha-thêta, 
développé par Peniston et Kulkosky (1989) pour le traitement de l'alcoolisme (Trudeau, 2005). 
Bien que de nombreuses études aient reproduit les résultats appuyant l'efficacité du protocole 
alpha-thêta en tant que cothérapie pour aider les alcooliques chroniques résistants au traitement, 
son efficacité à traiter les troubles liés à d'autres substances telles que la cocaïne, la marijuana et 
les stimulants s'est avérée moins concluante. Ce traitement a ensuite été modifié afin d'inclure un 
protocole additionnel souvent employé pour les problèmes d'attention. Cette adaptation du 
traitement a été nommée la modification Scott-Kaiser au Protocole Peniston (Scott, Kaiser, 
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Othmer, & Sideroff, 2005). Elle impliquait l'entraînement de sujets provenant d'une population 
hétérogène souffrant d'abus de substances à l'aide d'un protocole SMR-bêta, jusqu'à ce que leurs 
résultats d'attention à un test de performance continu soient normalisés, avant d’entamer le 
protocole alpha-thêta. Dans un essai clinique randomisé sur le protocole modifié, 77 % des 
participants du groupe expérimental étaient abstinents après 12 mois, comparativement à 44 % 
pour le groupe témoin.  
   En conclusion, bien que le neurofeedback ait déjà été utilisé avec succès pour les problèmes 
d'attention dans le contexte de différents TUS, il n’y a pas de recherches sur le neurofeedback 
dans un contexte de désaccoutumance au tabac chez les adultes atteints du TDAH.  
 
Les objectifs 
   L'objectif principal de cette étude consiste à évaluer l'effet du neurofeedback dans le contexte 
d'un traitement conventionnel de désaccoutumance au tabac chez les adultes souffrant à la fois du 
TDAH et de la dépendance à la nicotine. L'étude visera plus particulièrement à évaluer l'effet d'un 
protocole de traitement SMR-bêta sur la capacité des adultes atteints du TDAH de s'abstenir de 
fumer, en améliorant l’attention, dans le cadre d'un traitement de désaccoutumance au tabac sous 
forme de timbres à la nicotine.  
 
Hypothèse 
     L’intervention en neurofeedback servira à réduire de façon significative la dépendance à la 
cigarette telle que mesurée par une échelle évaluant la dépendance à la nicotine telle que définie 
par le DSM-IV-TR et sans aggraver les symptômes de sevrage, tels que mesurés par une échelle 
évaluant six dimensions du syndrome de sevrage, chez des fumeurs atteints du TDAH qui ne 
réussissent pas à abandonner le tabac malgré une thérapie de remplacement de la nicotine. 
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Méthode 
   Un protocole expérimental à cas unique a été utilisé pour évaluer les effets de l’intervention en 
neurofeedback (Kazdin, 1978). Afin de maximiser la validité interne de la recherche, des niveaux 
de base multiples en fonction des participants ont été utilisés dans ce devis (Kratochville & 
Levin, 2010). Le traitement en neurofeedback était donc introduit à différents moments pour 
chaque participant afin de réduire les effets possibles de facteurs externes sur les résultats.  La 
période de la première phase pendant laquelle le participant poursuivait son traitement avec la 
nicotine était entre une et trois semaines, permettant ainsi une stabilité du point de vue des 
mesures de base quotidiennes avant l’introduction de l’intervention.  
Déroulement 
   Le recrutement s’est fait parmi les patients de cliniques dans la région de l’ouest de l’île de 
Montréal et visait les personnes qui consultaient pour la cessation tabagique. Les participants 
potentiels ont été contactés par téléphone par la chercheure au fur et à mesure qu’ils se 
présentaient entre le printemps et l’automne de 2012. Les objectifs de l’étude ainsi que la nature 
de l'implication recherchée leur ont été brièvement expliqués et l’ASRS v1.1 ainsi que le FTND 
ont été administrés. Au premier rendez-vous le diagnostic du trouble attentionnel a été clarifié au 
moyen de la trousse d’évaluation du TDAH de CADDRA (The Canadian Attention Deficit 
Hyperactivity Disorder Resource Alliance); l’Échelle d’évaluation de Wender Utah et un test de 
performance continue (IVA+ Plus).  Sept personnes ont été recrutées initialement. Six femmes 
qui satisfaisaient les critères d’inclusion ont été retenues pour cette étude et ont signé un 
formulaire de consentement une fois les renseignements énumérés concernant le traitement, dont 
les risques et bénéfices potentiels. Deux participantes n’ont pas pu prévoir de disponibilités pour 
l’étude et se sont désistées. Quatre femmes se sont présentées à un rendez-vous additionnel pour 
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un éléctroencéphalogramme quantitatif (qEEG). Par la suite, les quatre participantes (VB, CR, 
JW, MT) ont été assignées à des niveaux de base préétablis, mais de façon non concurrente, car 
deux participantes ont débuté au mois de septembre (CR et JW), une au mois d’octobre (VB), et 
une à la fin décembre. (Des contretemps pour deux des participantes (VB et MT) ont nécessité la 
modification de la durée de deux niveaux de base.) La durée actuelle de la phase initiale sans 
traitement, avec des mesures quotidiennes de chaque variable dépendante, était sept jours pour la 
participante MT; huit jours pour JW; dix jours pour CR; et vingt jours pour VB. Le traitement a 
été initié les jours huit, neuf, onze et vingt et-un, et les mesures quotidiennes ont été maintenues 
pendant la phase intervention. Cette phase terminait quand un test de performance hebdomadaire 
continu indiquait une amélioration de l’attention. L’amélioration de l’attention objectivée par 
l’IVA+Plus constituait une condition d’arrêt du traitement, tout comme dans l`étude de Scott et 
al. (2005). Comme l’objectif ultime d’une intervention de cessation tabagique est l’arrêt complet 
de l’utilisation des cigarettes, l’évaluation de l’abstinence des participantes, utilisant la mesure de 
dépendance initiale, a été reprise dix semaines après la fin de la phase d’intervention. .  
Instruments de dépistage 
   FTND : Test de dépendance à la nicotine de Fagerström. Le FTND (voir Appendice2) 
mesure quantitativement la dépendance en six questions notées sur dix points (Heatherton, 
Kozlowski, Frecker, & Fagerstom, 1991). Le FTND est le test le plus connu et le plus utilisé par 
les chercheurs. Le coefficient de consistance interne (alpha de Cronbach) est 0,68 pour le FTND. 
Comme mesure de dépistage, le score FTND est suggéré par plusieurs auteurs pour identifier un 
fumeur avec une dépendance forte se situant à un score de plus de > cinq (Huang, Lin & Wang, 
2005). L’échelle a été validée en français (Etter, Duc, & Perneger, 1999). 
   ASRS v1.1 : L’échelle d’auto-évaluation des troubles déficitaires de l’attention avec 
hyperactivité de l’adulte (Organisation mondiale de la santé). Ce questionnaire de 18 items a été 
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conçu comme outil de dépistage pour les professionnels de la santé (voir Appendice 3). Il est basé 
sur les symptômes du TDAH adulte tels que rapportés dans le DSM-IV-TR (APA, 2000). La 
première partie du questionnaire constitue l’ASRS-6, un outil avec une fidélité test-retest de 0,58 
à 0,77, et un coefficient de consistance interne de 0,63 à 0,72 (Kessler et al., 2007). 
   IVA+Plus : Integrated Visual and Auditory Continuous Performance Test Plus. Ce test de 
performance continu (CPT) a fait partie de l’évaluation initiale de l’attention et a servi également 
comme mesure hebdomadaire pendant les deux phases de l’étude (Sandford & Turner, 2000). Le 
IVA+Plus est une épreuve cognitive, réalisée sur ordinateur, qui se distingue de la majorité des 
tests continus de performance, par le fait qu’il comprend des mesures en modalité auditive et 
visuelle intégrées (voir Appendice 5 pour un exemplaire du rapport). L’indice global pour 
l’attention (Full Scale Attention Quotient) mesure l’attention et les erreurs d’omission et 
démontre une fidélité test-retest de 0,66 à 0,75 (Seckler, Burns, Montgomery, & Sandford (1995). 
Le deuxième indice global mesure le temps de réaction et les erreurs de commission (Auditory 
and Visual Response Response Quotient) avec une fidélité test-retest de 0,37 à 0,41. Le 
IVA+Plus a été évalué pour la validité et la fidélité test-retest (intervalle de quatre semaines) 
auprès d’un échantillon de référence de personnes âgées de 6 à 70 ans. Il a également été utilisé 
comme mesure pour diverses populations cliniques infantiles (Tinius, 2003) et adultes (Corbett & 
Constantine, 2006; Quinn, 2003). 
Instruments de mesure 
   CDS-12 et CDS-5 : Cigarette Dependence Scale.  Le test CDS-12 devait être la mesure 
primaire de l’étude et a été complété quotidiennement tout au long de l’étude (Etter, 2005). Il a 
été choisi en partie parce qu’il fut développé à l’origine en français, puis traduit et validé en 
anglais. Le CDS-12 (voir Appendice 7) comprend 12 items qui mesurent différents aspects de la 
dépendance à la cigarette selon les critères du DSM-IV-TR (American Psychiatric Association, 
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2000) et de la Classification internationale des maladies CIM-10 (World Health Organisation, 
1992). Au moment d’analyser les données, la variabilité des scores du CDS-12 était trop 
importante pour bien interpréter les résultats. Le CDS-5, un instrument composé des 5 premières 
questions du CDS-12 et validé également comme mesure de la dépendance à la nicotine, a été 
substitué pour le CDS-12. La recherche démontre que ces deux instruments sont plus sensibles 
aux changements que la majorité des échelles évaluant la dépendance tabagique (Le Houezec, 
2010). Pour le CDS-12, un score jusqu’à 25 points indique une dépendance modérée, entre 25 et 
44 points une dépendance moyenne et  >45 une forte dépendance. Le score moyen de 3009 
fumeurs a été établi à 44 points. Le CDS-12 possède de bonnes propriétés psychométriques avec 
un alpha de Cronbach de  0,84 et un test-retest de 0,83. Pour le CDS-5, les scores sont de 5 (faible 
dépendance) à 25 (forte dépendance). Le CDS-5 comme instrument de mesure de la dépendance à 
la nicotine a également été validé et la corrélation avec les niveaux de cotinine sanguine est 
légèrement plus grande que celle du CDS-12 (Sato, Sato, Nozawa, & Sugimura, 2012). 
   CWS-21 : Cigarette Withdrawal Scale. L’évaluation quotidienne des symptômes de sevrage 
s’est fait avec le CWS-21, une échelle en 21 items qui évalue les six dimensions suivantes du 
syndrome de sevrage : dépression-anxiété; besoin urgent de fumer; irritabilité-nervosité-
impatience; appétit-prise de poids;  insomnies; difficultés de concentration (voir Appendice 8). 
Cette échelle a été conçue spécifiquement pour la recherche et l’évaluation des traitements du 
tabagisme. Elle a été développée et validée en français (Etter, 2005), et validée en anglais (Etter 
& Hughes, 2006). Les valeurs de cohérence interne (alpha de Cronbach) sont entre 0,83 et 0,96 et 
des corrélations test-retest de 0,60 à 0,71.  
Traitement 
   Le neurofeedback est un processus graduel d'apprentissage du fonctionnement du cerveau. 
Suivant le protocole SMR-bêta, les fréquences thêta/alpha sont inhibées, et les fréquences bêta 
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(15-18) ou SRM (12-15) encouragées. Les participantes se sont présentées en moyenne trois fois 
par semaine dans un bureau de psychologue à Pointe Claire pour des séances d’entrainement 
d’une durée d’une heure. Avant d'entamer l’entraînement, des électrodes étaient posées à deux 
endroits sur le cuir chevelu (C3 et C4) selon le système international 10-20 (Jasper, 1958) et 
maintenues en place à l’aide d’une pâte adhésive. Les électrodes sur les lobes d’oreilles ont servi 
de références et de mise à la terre. Les électrodes étaient ensuite insérées dans une boîte têtière 
reliée à un système d’amplificateurs (le Procomp Infiniti de Thought Technology) qui digitalisait 
les signaux qui ont été envoyés à un ordinateur où un logiciel (Biograph Infiniti v. 5.1.2) 
enregistrait les ondes cérébrales. Les changements dans l’activité cérébrale se font par 
apprentissage en utilisant la rétroaction (feedback). Ainsi, le signal est traité et il fournit le 
feedback approprié montré sur l'écran de l’ordinateur. La rétroaction (feedback) des signaux du 
corps (bio/neuro) est considérée comme du renforcement positif et est révélée au participant par 
moyen d’un jeu à l’écran et par de la musique. En séance d'entrainement, la personne doit arriver 
à se concentrer pour diminuer les ondes thêta/alpha ciblées, et augmenter les ondes SRM. Quand 
elle arrive à le faire, le jeu avance et la musique joue. Si elle n’arrive pas à produire les ondes 
désirées, le jeu et la musique arrêtent. De cette façon, les participantes de cette étude ont appris 
comment contrôler leurs ondes cérébrales pour mieux gérer leur attention. Les séances ont 
terminé quand les scores d’attention soutenue sur l’IVA+Plus se sont normalisés, soit de 12 à 14 
rencontres. 
Considérations éthiques 
   Étant donné que le neurofeedback est une intervention thérapeutique peu connue, afin de bien 
informer les participantes, celles-ci ont reçu une description détaillée du traitement et une 
présentation au préalable de l’équipement utilisé afin que leur droit à un consentement libre et 
éclairé soit respecté. L’enregistrement de l’activité cérébrale est une technique non invasive, car 
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les électrodes sont d’application externe seulement. Il pourrait y avoir un risque de fatigue lors 
des sessions alors des pauses ont été prévues. De plus, une évaluation avec le qEEG a été incluse 
pour s’assurer que le protocole utilisé n’était pas contre-indiqué; par exemple, par la présence 
d’un excès d’ondes bêta à C3 et C4, car un utilisateur avec un tel profil risque d’avoir peu de 
résultats. Les effets secondaires indésirables rapportés par la recherche (p. ex., maux de tête 
légers, nausées) semblent être rares et réversibles avec le temps (Sherlin, Arns, Lubar, & 
Sokhadze., 2010), mais il est fortement recommandé qu’une évaluation électrophysiologique soit 
complétée avant même d'entamer un traitement pour minimiser les possibilités de difficultés, et 
pour éviter un traitement inefficace (Hammond & Kirk, 2007). 
 
Résultats 
   Deux types d’analyses ont été effectués. L’utilisation de mesures répétées (le CDS-5 et le 
CWS-21) a permis l’inspection visuelle de graphiques représentant les données pour chacune des 
phases du protocole (voir Figures 1 à 4). Cette évaluation s’est fait utilisant quatre critères 
d’interprétation : un changement de moyenne (comparer les moyennes entre les deux phases); un 
changement de niveau (les scores diminuent soudainement), un changement de tendance/pente; et 
la rapidité (ou latence) du changement (la vitesse à laquelle le changement survient à la suite de 
l’intervention). Les graphiques ont été construits utilisant le logiciel Single Case Visual Analysis 
Package (SCVA) de Bulté et Onghena (2012). Ce logiciel inclut plusieurs aides visuelles (comme 
p.ex., une ligne horizontale au niveau de la moyenne) pour faciliter la comparaison entre les deux 
phases de l’étude. 
   L’inspection visuelle semble indiquer que le niveau de dépendance à la nicotine (CDS-5) n’est 
pas stable pour les participantes pendant la phase A. En effet, trois des quatre participantes (VB, 
CR et MT) ont vécu une diminution des niveaux de dépendance initiale. Il y a eu, par contre, une 
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stabilisation ou une augmentation des scores pendant la dernière partie de la phase A (niveau de 
base) juste avant l’introduction du traitement qui visait l’amélioration de l’attention. La quatrième 
participante (JW) a démontré une augmentation de ses scores sur le CDS-5 à partir du premier 
jour. (Pour le devis à cas unique, un changement de direction de la pente met en évidence l’effet 
de la variable indépendante sur la variable dépendante même si le niveau de base n’est pas 
stable). Chez trois des quatre participantes (VB, CR et JW), on observe une baisse de la moyenne 
de la mesure de dépendance à la suite du traitement en neurofeedback. Il y a également un 
changement éventuel de la direction de la pente/tendance (la deuxième section de chaque phase) 
pour chaque étude de cas dans la direction espérée. 
   L’inspection visuelle des graphiques pour le CWS-21 (les symptômes de sevrage) indique qu’il 
y a eu peu de changement d’une phase à l’autre pour cette mesure chez les trois participantes qui 
ont réussi à diminuer leur dépendance. La dernière participante (MT) qui n’a tout de même pas 
réussi à diminuer la moyenne de sa dépendance à la nicotine a vécu une diminution importante de 
ses symptômes de sevrage pendant ce traitement qui améliorait son attention.  
    Afin de documenter davantage l’information issue de l’inspection visuelle, le Tau-U de Parker 
et Vannest (2009) a été calculé en utilisant une calculatrice en ligne (Vannest, Parker, & Gonen, 
2011). Cette méthode d’analyse statistique non paramétrique, spécialement développée pour les 
études de cas multiples, mesure l’ampleur de l’effet et en même temps contrôle un niveau de base 
non stable. Le Tau-U peut indiquer le pourcentage de scores indiquant une diminution dans la 
phase intervention, malgré la présence d’une tendance dans la phase A ou non. (Dans cette 
recherche, un niveau de base a dû être corrigé avant la comparaison entre les deux phases pour le 
CDS-5.) Les résultats pour chaque cas sont : VB = -74%, CR= -63 %; JW = -72%; MT = -8 %. À 
l’exception de  MT, ce sont des changements positifs modérés, mais significatifs selon un 
standard établi (> .4) par Parker et Vannest (2009). Une moyenne pondérée pour les quatre cas 
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uniques était : un Tau-U de -0,5346; un score Z de -5,9614; un intervalle de confiance de -0,3587 
à -0,7106 à 90 %; et une valeur-p de 0.  
   Quant au CSW-21, deux niveaux de base ont dû être corrigés par le logiciel et ensuite les 
comparaisons ont été effectuées. Les résultats sont présentés au Tableau 3 (p. 70). La moyenne 
pondérée pour cette variable était : un Tau-U de 0,2797; un score Z de -2,611; un intervalle de 
confiance de -0,1035 à -0,4559 à 90 %; et une valeur-p de 0,0090. Par rapport aux sous-tests du 
CSW-21, seulement des mesures d’envie (craving) ont diminué de façon significative suite à 
l’introduction du traitement, et seulement chez les deux participantes qui ont rapporté un nombre 
élevé de symptômes de TDAH.  
   Pour l’évaluation de l’abstinence, la FDA recommande une abstinence complète pendant quatre 
semaines pour établir l’efficacité d’un traitement de cessation (Hughes et al., 2003). Un suivi dix 
semaines après la fin du traitement a démontré qu’une participante (CR) avait rencontré ce 
standard. Deux autres (VB et MT) ont rapporté une dépendance à la nicotine telle que mesurée 
par le FTND significativement moindre qu’au début de l’étude. Une participante (MT) n’a pas 
donné suite aux appels de la chercheure. 
 
Discussion 
   Cette étude à cas uniques avec niveaux de base multiples visait à déterminer si la combinaison 
d’un entraînement en neurofeedback et l’utilisation d’un timbre de nicotine pouvait améliorer la 
cessation du tabagisme chez des adultes avec un TDAH. Ces personnes sont davantage aux prises 
avec la dépendance à la nicotine. Des études antérieures utilisant une combinaison de traitements 
traditionnels pour le TDAH, c.-à.-d. les psychostimulants, avec le timbre de nicotine ont vu une 
exacerbation des effets secondaires et des symptômes de sevrage, ce qui a probablement nui à 
l’effort de diminuer l’utilisation de cigarettes. Le neurofeedback, comme traitement non 
xxvii 
 
 
pharmacologique déjà connu pour les difficultés d’attention, évite ces complications. Trois des 
quatre participants ont réussi à diminuer d’une façon modérée, mais significative leur dépendance 
à la nicotine, pendant la phase intervention de l’étude, sans aggraver les symptômes de sevrage. 
Les résultats suggèrent que le neurofeedback SMR-bêta peut potentialiser l’utilisation du timbre de 
nicotine et contribuer à l’arrêt du tabagisme. 
   Toutes les participantes se sont améliorées sur des mesures d’attention soutenue au cours de 
l’étude, mais cette amélioration n’était pas constante.  À certains moments les scores étaient en 
dessous des scores initiaux au début de l’étude. Plusieurs facteurs expliquent ce fait. La 
dépendance n’est pas un phénomène uniquement physiologique. Les perceptions de l’individu face 
à sa dépendance à la cigarette, l’impact de facteurs psychosociaux, et l`hétérogénéité du diagnostic 
de TDAH ont eu des effets potentiellement considérables sur non seulement l’amélioration de 
l’attention, mais également sur les variables dépendantes.  Par exemple, le rôle du besoin urgent de 
fumer (craving), un élément qui prend de plus en plus d’importance dans la recherche sur la 
sévérité de la dépendance, a une relation complexe avec l’attention (Canterberry et al., 2013). Dans 
cette étude, la mesure du besoin urgent de fumer (incluse dans le CWS-21) s’est améliorée, mais 
seulement chez les deux participants qui ont rapporté plus de symptômes d’impulsivité sur l’ASRS 
v1.1. Il est alors difficile de conclure que c’était uniquement l’amélioration de l’attention visée par 
le protocole SMR-bêta qui a produit les effets observés. 
   Les résultats obtenus doivent être interprétés avec prudence en raison des limites importantes de 
cette étude. Un devis à niveaux de base multiples comporte certaines limites inhérentes à la 
généralisation des résultats, surtout étant donné le petit échantillon de participants, toutes des 
femmes. La validité des mesures autorapportées est parfois contestée dans la recherche des abus de 
substances et il a été impossible de contrôler totalement l’utilisation du timbre de nicotine. La 
recommandation est d’utiliser une mesure physiologique dans la mesure du possible (Patrick et al., 
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1994). Finalement, la méthode statistique employée (le Tau-U) est une approche encore peu 
explorée dans la recherche des cas uniques. Toutefois, les résultats de la présente étude sont 
similaires aux études précédentes de cessation tabagique utilisant un traitement pharmacologique 
pour le TDAH combiné à un timbre de nicotine (Winhusen et al., 2010). 
   En conclusion, les résultats modérés, mais significatifs de cette étude appuient l’hypothèse que le 
neurofeedback, malgré les mécanismes thérapeutiques inconnus, pourrait améliorer l’attention 
chez les personnes avec un TDAH et favoriser la diminution de la dépendance à la nicotine en 
combinaison avec l’utilisation d’un timbre de nicotine.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
  
 
 
 
   Attention deficit hyperactivity disorder (ADHD) and smoking are among the most common and 
most costly psychiatric and behavioural problems facing society today (Rehm & Perron, 2006). 
ADHD is a neurobehavioural disorder that involves inappropriate attention, hyperactivity and 
impulsivity that interferes with functioning or development. Worldwide, it is estimated that 5.3 % 
of children and adolescents have ADHD (Polanczk, Silva de Lima, Horta, Biederman, & Rohde, 
2007) and 4 to 4.5% of adults (Kessler, Chiu, Demler, & Walter, 2005). A more recent survey by 
the United States Center for Disease Control revealed that 11% of American school-aged children 
have been diagnosed with ADHD by a health-care provider (Visser et al., 2014). It was long 
considered a disorder of childhood but it is now recognized that 40 to 60 % of the children 
diagnosed with ADHD continue to meet diagnostic criteria for the disorder in adulthood 
(Barkley, Fischer, Smallish, & Fletcher, 2002; Biederman, Petty, Evans, Small, & Faraone, 2010; 
Kessler et al., 2010). A consensus statement of the world’s leading researchers for ADHD 
concluded, “there is no doubt that ADHD leads to impairments in major life activities, including 
social relations, education, family functioning, occupational functioning, self-sufficiency, and 
adherence to social rules, norms, and laws” (Barkley et al., 2002, p. 90).  
     More than 37,000 Canadians died prematurely due to tobacco use in 2007 and there is strong 
scientific evidence that smoking is related to more than two dozen diseases and conditions 
(Statistics Canada, 2011). ADHD adults and adolescents are more likely to start smoking at an 
earlier age and progress to regular use younger (Breyer, Burgetova, & Roper, 2009; Galéra, 
Fombonne, Chastang, & Bouvard, 2005; Molina & Pelham, 2003). They smoke significantly more 
than the general population and there is a linear relationship between ADHD symptoms and 
number of cigarettes smoked (Pomerleau, Downey, Stelson, & Pomerleau, 1995). The withdrawal 
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symptoms are more severe (Knott et al., 2008), they relapse more quickly (Humfleet et al., 2005) 
and fewer of these individuals, men in particular, quit definitively (McClernon & Kollins, 2008).  
   What is the connection between nicotine addiction and ADHD? In some substance use disorders 
ADHD as a risk factor is almost always accounted for by the presence of other co-morbidities. But 
in the case of nicotine use, ADHD appears to be an independent risk factor (Ameringer & 
Leventahl, 2013; Biederman et al., 2006a; Breyer, Burgetova, & Roper, 2009; Pingault et al., 
2013; Pomerleau et al., 2003; Wilens et al., 2008). The significant individual, social and health 
costs of the co-morbidity between smoking and ADHD justify the growing number of research 
projects seeking to elucidate the impact of early, as well as concurrent, treatments for ADHD on 
smoking behaviour. Although answers are not yet conclusive, understanding the impact of 
nicotine, a stimulant, on the inattention aspect of the disorder may provide a clue to solving the 
puzzle. 
      Many believe that prior treatment for ADHD can alter interactions between the two disorders 
and improve eventual smoking cessation outcomes. This belief is grounded in the numerous 
studies that have reported a decrease in overall substance use, including tobacco, following 
medication treatment in childhood (Chang, 2014; Wilens et al., 2008). Nonetheless, not all studies 
have reached these conclusions. One of the most comprehensive studies in the field (the NIMH 
Collaborative Multisite Multimodal Treatment Study of Children with ADHD) revealed that early 
stimulant treatment failed to provide any protection against, nor did it contribute to, subsequent 
nicotine addiction in the treatment group as compared to a non-medicated control group (Molina et 
al., 2009).  
   These findings speak to the complexity of the interaction between ADHD and nicotine 
dependence and the importance of identifying effective and novel ways of decreasing the risk of 
tobacco use conferred by the disorder. To that aim, investigations have focused on treatments 
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using stimulants and nicotine replacement products alone and together (Gehricke, Whalen, Jamner, 
Wigal, & Steinhoff 2006; Gehricke, Hong, Whalen, Steinhoff, & Wigal, 2009; Gehricke, Hong, 
Wigal, Chan, & Doan, 2011). Results have been contradictory with some laboratory studies with 
stimulants even showing an increase in smoking (Silverstone & Dardashova, 2012). Several recent 
studies combined a proven ADHD treatment and a proven nicotine dependence treatment to 
combat smoking in affected individuals. Yet again, results were equivocal, due in part to the 
presence of confounding side-effects (Covey, Manubay, Jiang, Nortick, & Palumbo, 2008; 
Winhusen et al., 2010). Finally, the increased risk of cardiovascular issues when nicotine 
replacement products are used concurrently with stimulants have led to recommendations that 
alternative treatments be found to provide options to clinicians and patients. 
   Neurofeedback is an alternative non-pharmacological treatment for ADHD which seeks to 
regulate the electrical activity of the brain. It is considered a form of operant conditioning and as 
such is eminently applicable to the practice of clinical psychology (Collura, 2014). Electrodes 
placed on specific sites on the skull record the electroencephalographic signal beneath. The 
digitized signal is then transformed by a computer which feeds the information back to the user. 
The resulting beta, alpha, theta and delta waves can subsequently be enhanced or inhibited in order 
to produce the rhythms selected by the neurotherapist. The sensorimotor rhythm, or SMR, is a low 
beta wave that can be recorded over the motor cortex, and “is connected to the brain’s intention to 
be still” (Collura, 2014). Learning to enhance an SMR signal is one of the main goals of 
neurofeedback treatment for ADHD and has garnered the greatest amount of research. A recent 
meta-analysis by Arns, de Ridder, Strehl, Breteler, and Coenen’s (2009) reported mean effect sizes 
for improvements following neurofeedback treatment: including 1.02 for inattention; 0.71 for 
hyperactivity; and 0.94 for impulsivity. Side effects appear to be minimal and transient (Sherlin, 
Arns, Lubar, & Sokhadze, 2010). This study will attempt to contribute to this body of research and 
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provide an alternative for clinical treatment of smoking in this clientele by examining whether a 
known neurofeedback treatment for attention can help smokers significantly reduce their 
dependency on tobacco. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Theoretical Context
 
 
 
ADHD, Smoking and Substance Use Disorders 
   Although the link between ADHD and smoking is now recognized, the debate as to how they are 
linked continues to fuel research and the bidirectional interaction between them is constantly being 
revised (Gray & Uphadhyaya, 2009). More study is needed to clarify the nature of this complex 
relationship, but there is nevertheless sufficient evidence emerging to suggest that a unique 
neurobiological link may exist between the inattention aspect of ADHD and tobacco addiction 
(Burke, Loeber, White, Stouthamer-Loeber, & Pardini, 2007; Lerman et al., 2001; Tercyak, 
Lerman, & Andrain, 2002). 
ADHD and its Presentations 
   It may be useful to first briefly review how the diagnosis of ADHD and its iterations have 
affected research into the condition. As of May 2013, ADHD has officially been recognized by 
the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) as a 
neurodevelopmental disorder (American Psychiatric Association, 2013). Prior to that date, the 
DSM-IV-TR listed ADHD as part of a group of disruptive behaviour disorders that included 
oppositional defiance disorder and conduct disorder (American Psychiatric Association, 2000). 
The convergence of genetic, neuroscience and behavioural research of the last decade has 
culminated in the recognition that ADHD shares commonalities with other neurodevelopmental 
disorders such as early onset, persistence over time, a high male to female ratio, genetic and 
environmental interactions, and identifiable patterns of altered brain function (Taylor, 2013). 
There are now three “presentations” of the diagnosis (previously referred to as subtypes); 
inattentive, hyperactive/impulsive and combined, with six or more symptoms from each category, 
resulting in behaviour that is inappropriate for the developmental level of the individual and that 
is disruptive or causes impairment in two or more settings. Another change in the diagnosis of 
ADHD is the recognition that teens and adults can now be officially diagnosed as long as 
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symptoms are present by age 12. For those 17 or older, only five symptoms from each category 
are now necessary. Examples of the symptoms of inattention are:  often fails to give close 
attention to details or makes careless mistakes in schoolwork, at work, or with other activities; 
often has trouble holding attention on tasks or play activities; often does not seem to listen when 
spoken to directly; often does not follow through on instructions. Examples of the symptoms of 
hyperactivity/impulsivity are: often fidgets with or taps hands or feet, or squirms in seat; often 
leaves seat in situations when remaining seated is expected; is often unable to play or take part in 
leisure activities quietly; is often "on the go" acting as if "driven by a motor"; often talks 
excessively. 
   First-line recommendations for treatment include stimulant medications such as 
methylphenidate and amphetamines, as well as targeted psychosocial interventions. Other non-
stimulant medications, usually atomoxetine and the anti-depressant buproprion, can be prescribed 
but research has indicated that the enhancement of noradrenergic neurotransmission afforded by 
stimulants provides the best chance of treating symptoms pharmacologically (Kolar, Keller, 
Golfinopoulos, Cumyn,  Syer, & Hechtman, 2008). An fMRI exploration of the effects of 
methylphenidate on resting brain networks confirmed its action as an indirect dopaminergic and 
noradrenergic agonist resulting in increased connectivity between seven different resting state 
networks, revealing the broad impact of the drug on the brain as a whole (Mueller et al., 2014). 
   The role of dopamine within the brain and its implication in many psychiatric and neurological 
disorders that also present with difficulties in attention and concentration is well-known. The 
dysregulation of the central dopaminergic system has long been suspected as the neurobiological 
basis of ADHD and it is for that reason that stimulants are so often initially effective given their 
action within this system (Hechtman, 2009). Atomoxetine is a selective inhibitor of presynaptic 
norepinephrine that can be used in the 10 to 30% of cases that do not respond to stimulants or 
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who experience unacceptable side-effects. Buproprion, also an option to stimulants, is an off-
label prescription for ADHD, as it was initially approved by the FDA for mood disorders or as a 
smoking cessation aid. Its mechanism of action not fully understood but it is also an inhibitor 
(albeit a weak inhibitor) of dopamine and norepinephrine reuptake (Sharma & Couture, 2014). 
All of the pharmacologic treatments for ADHD have potential side effects that require monitoring 
by a physician. For stimulants, the most common are insomnia, nausea, decreased appetite, 
elevated pulse, abdominal pain and mood lability. 
   The changes introduced by the DSM-5 resolved certain issues pertaining to the diagnosis, but 
there is still enormous debate and even controversy over the way this disorder is conceptualized 
and evaluated (Brown, 2009). The great heterogeneity that exists across people with the diagnosis 
and the inconsistent responses to the first line treatments for ADHD imply more changes will be 
proposed. This is perhaps most evident in the discussion over what has been termed executive 
function abilities. Russell Barkley, one of the foremost researchers and theorists in the field of 
ADHD has argued that executive function problems (response inhibition, working memory, 
regulation of emotion, self-speech and flexibility) should be considered as core deficits of ADHD 
(Barkley, 1997). Although it is as yet unclear exactly how executive functions are distinct and/or 
related to inattention and hyperactivity/impulsivity, Barkley has stated that a primary cause of 
ADHD is an inhibitory control deficit.  Executive function impairments most definitely influence 
nicotine dependence (Dolan, Bechara, & Nathan, 2008) so a discussion of smoking and ADHD 
cannot take place without explaining why this topic is not central this study. 
   There are difficulties with the definition of the term as well as a lack of universality amongst 
those diagnosed with the disorder. Furthermore the presence of these impairments in other mental 
health conditions is not negligible (Wilcutt, Doyle, Nigg, Faraone, & Pennington, 2005). 
Recently, Barkley has expanded his theory and proposed that ADHD is essentially an executive 
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function deficits disorder which includes impairments with all or most of the following skills: 
self-awareness; inhibition; non-verbal working memory; verbal working memory; emotional self-
regulation; self-motivation; planning and problem solving (Antshel, Hier & Barkley, 2014). He 
has gone so far as to suggest that the name be changed from ADHD to Executive Function 
Deficits Disorder (EFDD).  
   Furthermore, Barkley has proposed that a subset of those diagnosed with ADHD-Inattention 
may actually have an attention disorder that is distinct from ADHD resulting in a sluggish 
cognitive tempo that pervades all the individual’s activities (Barkley, 2010). These individuals 
also have executive function impairments, albeit with a different profile. These proposals would 
imply a major revision of our current idea of ADHD. Despite widespread agreement that 
executive function symptoms form part of the presenting problems of patients with ADHD, as 
well as a general consensus as to their importance clinically, the need for more research 
precluded their inclusion as formal criteria for ADHD. For this reason, they will not be dealt with 
specifically in our discussion. 
   The obvious complexities in the conceptualisation and diagnosis of ADHD have contributed to 
inconsistencies in the research and difficulties in pooling results to produce effect sizes across 
studies. Suffice it to say that there is a longstanding debate as to the adequate assessment of 
ADHD for diagnostic and research purposes (Coghill & Seth, 2011). There are as of yet no 
definitive tests or rating scales that exhibit high enough positive predictive value to validate the 
diagnosis of ADHD in either children or adults (Haavik, Halmoy, Lundervold, & Fasmer, 2010). 
The authors concluded that cognitive tests are neither sufficient nor necessary for a diagnosis of 
ADHD, yet they add to the clinical understanding of individual differences within the disorder. 
Recommendations by these same authors for diagnosis of adult ADHD include: a comprehensive 
clinical interview by a clinician who is knowledgeable in terms of the most important psychiatric 
11 
 
 
conditions and their combinations; collateral information from a significant other who has 
preferably known the patient in childhood; rating scales and self-reports for symptom assessment 
such as the Adult ADHD Self-Report Scale (ASRS) or the Conners’ Adult ADHD Rating Scale 
(CAARS); a scale for functional impairment such as the Weiss Functional Impairment Rating 
Scale (WFIRS) or the Wender Utah Rating Scale (WURS). A neuropsychological assessment, 
however, would be important to tailor treatment to the individual. A medical evaluation is 
absolutely necessary to rule out other conditions that could mimic ADHD symptoms (such as 
epilepsy or thyroid disorders) as well as allow for adequate monitoring of pharmacological 
treatment. 
   In research that relies on the participation of adolescents or adults (such as for smoking) the 
inclusion criteria used in the past to select participants has been a particularly thorny issue. For 
example, the DSM-IV-TR required that symptoms be present by age seven. It is not clear whether 
this was the standard in studies that investigated smoking and ADHD. In addition, while some 
studies required an official diagnosis made in childhood, many did not. In a review of the 
literature, it was noted that the assumption of ADHD was often made on the basis of retrospective 
adult self-reports of symptoms (Looby, 2008). Such self-reports are notoriously unreliable so 
cannot be used alone (Williamson, Combs, Berry, Harp, Mason, & Edmundson, 2014).  
   The outcome is that when the results of these studies are pooled, a great deal of specificity is 
lost.  It has therefore been a challenge to achieve interpretable results in explaining the 
relationship between nicotine, tobacco, ADHD and its component parts. As will be seen, 
inattention and impulsivity appear to confer different degrees of risk for nicotine dependence, so 
distinguishing between the types of presentations involved is important. No firm conclusions 
have as of yet emerged as to the exact role each deficit plays in nicotine addiction, although there 
is no longer any doubt that the role of each is significant and distinct. 
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Role of ADHD Subtypes/Presentations and Severity of the Disorder 
   The distinction between the different subtypes of ADHD, inattentive versus hyperactive and 
impulsive has often been overlooked in the research when cohorts of ADHD patients are grouped 
together, yet when hyperactivity/impulsiveness and inattention are examined separately, there are 
different smoking outcomes associated with each dimension of the disorder (Burke, Loeber, 
White, Stouthamer-Loeber, & Pardini, 2007; Rodrigues, Tercyak, & McGovern, 2008). These 
symptoms differ psychometrically and may stem from distinct genetic influences. Each dimension 
of the disorder contributes in unique ways to eventual tobacco addiction. 
   Lerman et al., (2001) reported that smoking was associated with ADHD inattentive symptoms 
whereas hyperactive symptoms were not. Participants recruited for a smoking cessation program 
from the general population were classified according to a self-report of inattention and/or 
hyperactivity symptoms. The analysis found a correlation between the inattention symptoms and 
the use of cigarettes. This results has been reported in a number of studies (Fuemeller, Kollins & 
McClernon, 2007).  In addition, participants endorsed smoking for stimulation purposes to 
alleviate problems with inattention. In another study, inattention was found to be associated with 
ADHD individuals taking up smoking in early adolescence, whereas hyperactivity/impulsivity was 
more closely associated with smoking initiation in early adulthood (Rodriquez, Tercyak, & 
Audrain-McGovern, 2008). When examined carefully, a reviewer concluded that 
hyperactivity/impulsivity was not consistently related to early cigarette use but is more often seen 
as a contributor to later heavy smoking, which in turn is related to the presence of conduct disorder 
or other psychosocial factors such as family smoking (Looby, 2008). Impulsivity has however a 
direct effect on the ability to quit smoking once it is a habit (Covey, Manubay, Jiang, Nortick, & 
Palumbo, 2008). Inattentive symptoms of ADHD on the other hand, are directly and systematically 
impacted by nicotine, whether administered clinically or obtained through cigarette smoking 
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through the stimulation of nicotinic acethylcholine receptors (Burke, et al., Levin et al., 1996). In a 
longitudinal study examining these relationships, inattention even appeared to predict the severity 
of the nicotine dependence (Pingault et al., 2013). In a national sample of American smokers with 
ADHD, results showed that after controlling for hyperactivity-impulsivity, only inattention was 
associated with smoking (Ameringer & Leventhal, 2013). 
   Severity of ADHD symptoms, as measured by the number of ADHD symptoms endorsed by 
respondents, were proportionally associated with reported tobacco use in a sample of 334 college 
students (Upadhyaya & Carpenter, 2008). In the Lerman et al. (2001) study, severity of the 
inattentive symptoms even in a “normal” population was correlated with greater urges to smoke. It 
has been argued that some form of functional impairment can occur even when there are 
insufficient symptoms to meet the threshold for a diagnosis, and that these individuals merit being 
identified for treatment (Faraone, Wilens, Petty, Antshel, Spencer & Biederman, 2007). This is 
especially the case in adults who may or may not have been diagnosed as children but who’s 
ADHD has lessened with age. In two separate studies that followed participants for an average of 
11 years, 65% of the boys and 33.3% of the girls diagnosed in childhood no longer met the DSM-
IV-TR criteria in young adulthood (Biederman, Petty, Evans, Small, & Faraone, 2010; Biederman, 
Petty, O’Connor, Hyder, & Faraone, 2012). Yet 78% of the boys and 77.1% of the girls still met at 
least one of the definitions of persistence devised by the authors. The definition of persistence 
varies from one researcher to another, but in this case persistent ADHD included cases that: 1) still 
met full criteria for the diagnosis, 2) met more than half (termed symptomatic ADHD) 3) did not 
meet those requirements but still exhibited impaired functioning and 4) were not impaired but were 
medicated. One of the primary dysfunctions associated with the persistence of symptoms was 
smoking. In the study looking at boys, 38% smoked at the 10-yr follow-up compared to 15% of the 
control group. For the girls, 11% were smoking 11 years later as compared to 4% of controls. 
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Other than the fact that the increased risk for smoking within this group suggests that these 
individuals should also be targeted for treatment, there appears to be some indication that 
individuals with more severe forms of ADHD (endorsing a greater number of symptoms) may 
need a treatment approach that is different from the less symptomatic group.  One study found that 
ADHD individuals with higher levels of attentiveness actually smoked more rather than less when 
treated with stimulants (Poltavski & Petros, 2006). 
Role of Comorbidities 
   At the outset, nicotine dependence was not the focus of addiction studies involving individuals 
with ADHD; probably because of the ubiquitous presence of smoking and the massive use of 
cigarettes by people diagnosed with mental health problems in particular. It is impossible to 
discuss the impact of ADHD on nicotine dependence without trying to account for the impact of 
the many significant comorbidities of the disorder on tobacco use. Of all cigarettes produced in the 
U.S., 44% are smoked by people with psychiatric disorders (cited in Mason, Walker, Wine, 
Knoper, & Tercyak, 2007). In one sample of patients with substance abuse and psychiatric 
disorders including ADHD, nearly all of the participants (98.6%) smoked (Abrantes, Brown, & 
Tomlinson, 2003). Nor was ADHD always examined in population and clinic-based studies of 
smoking, possibly because it was considered a disorder of childhood that faded with maturity and 
could therefore not be highly relevant in an older smoking population (McClernon & Kollins, 
2008). Eventually, it became clear that ADHD continues into adulthood and that people with 
ADHD have a greater risk of developing subsequent substance use disorders of all sorts including 
alcohol, marijuana, cocaine, methamphetamines and cigarettes amongst others (Biederman, 
Wilens, Wick, Faraone, & Spencer, 1998; Charach, Yeung, Climans & Lillie, 2011). 
Disentangling nicotine addiction from the influence of other comorbidities was essential to 
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recognize the association between ADHD symptoms and nicotine use, as well as understanding 
why this association exists. 
   A number of hypotheses were proposed to explain the connections between substance use 
disorders, smoking and patterns of psychopathology in this group of people. The hypotheses 
themselves changed depending on which symptoms of ADHD were examined (Tercyak et al., 
2002), which substance was being investigated (Latimer, Ernst, Hennessey, Stinchfield, & 
Winters, 2004), which additional co-morbidities were present (Lerman, 2001; Looby, 2008; 
Newcorn, 2008), and at what point in the lifespan treatment for ADHD was initiated, if at all 
(Manuzza et al., 2008; Dalsgaard, Mortensen, Frydenberg, & Thomsen, 2014).  
   Initially, the assumption was that there was a common psychosocial cause, such as familial 
dysfunction, underlying not only smoking and attention disorders but all substance use problems 
as well as comorbidities such as conduct disorder and oppositional defiance disorder (Biederman 
et al., 1995; Scahill et al., 1999). This belief was based on the fact that certain disorders coexist to 
a remarkably high degree within families that exhibit major dysfunction such as drug and alcohol 
abuse, exposure to violence, poor nutrition, and so on (Dolan et al.,2008; Wilson, 2007; Thapar, 
Cooper, Eyre, & Langley, 2013). For example, cocaine use and ADHD are highly correlated 
(Lambert & Hartsough, 1998) and are often accompanied by family pathology. The same is true of 
conduct disorder and cocaine use, as well as conduct disorder and ADHD – all are highly 
correlated and accompanied by high levels of family distress (Modesto-Lowe, Danforth, Neering, 
& Easton, 2010). The initial characterisation of behaviours resembling ADHD as a defect of 
“moral control” may have contributed a long standing bias to inquiries carried out thereafter 
(Charach et al., 2011). Even though familial heritability (both genetic and environmental) 
continues to be an element that confounds research into the comorbidities associated with ADHD, 
a consensus is emerging that the pathologies that co-occur within these families are the result of 
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common underlying causal factors and not vice versa although there is a great deal of interplay 
between them (Thapar et al., 2013). These as yet to be identified causal factors then contribute to 
promote more risk factors such as poor prenatal care, damaging parenting practices, 
socioeconomic hardship and instability, participation in deviant groups, etc., which can then 
become targets for interventions that will mediate the correlations that exist.  
   Ultimately, it was shown that ADHD as a risk factor for later cocaine use can almost completely 
be accounted for by the presence of conduct disorder (Barkley, Fischer, Smallish, & Fletcher, 
2004) although this finding does not always apply to young women (Galéra et al., 2004). 
Disruptive behaviour disorders have been implicated in the increased risk for alcohol, marijuana, 
and amphetamines in this population (Lee, Humphreys, Flory, Liu, & Glass, 2011). This is not, 
however, the case for smoking and ADHD, which appear to have an exclusive relationship which 
is independent of conduct disorder even though they are highly correlated with them (Ameringer & 
Leventhal, 2013; Charach et al., 2011). A very recent longitudinal study that tracked 1803 
participants over 15 years found that only inattention contributed to smoking dependence in 
adulthood whereas other substance abuse increased only when the diagnosis was associated with 
childhood oppositional defiance disorder (Pingault et al., 2015).  
   There are consistent findings that depression and anxiety alone are risk factors for smoking 
(Lerman et al., 2001, Mason et al., 2007). Many such mental health disorders are present when 
ADHD is found. A Montreal study reported that 71.9% of ADHD adults had one or more Axis 1 
disorders, and 50.9% had one or more Axis II disorders (Cumyn, French, & Hechtman, 2009). In 
another study, this time within a sample of substance abusing adolescents, different patterns of 
addictions were seen depending upon whether ADHD comorbid conditions were externalizing 
disorders such as oppositional defiance disorder or internalizing disorders such as depression 
(Abrantes et al., 2003). The question is that without the contribution of the comorbid pathologies, 
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does ADHD still confer increased risk for smoking? In the Montreal study, when compared with a 
group of non-ADHD patients also referred for mental health issues, the ADHD patients exhibited 
greater nicotine dependence. Eventually, two major studies that controlled for underlying 
psychopathology indicated that of all substance use disorders considered; only the lifetime risk for 
nicotine dependence was greater for those with ADHD (Biederman et al., 2006b; Molina & 
Pelham, 2003.)  
Role of ADHD Medication in Substance Use Disorders and Smoking 
    Another hypothesis that motivated a great deal of research into ADHD and substance use 
posited that stimulant treatment in childhood altered brain functioning in such a way that it 
actually predisposed people to addictions later in life (Lambert & Hartshough, 1998; Manuzza et 
al., 2003). Subsequent research has not always supported this hypothesis (Barkley, Fischer, 
Smallish, & Fletcher, 2003; Molina et al., 2007). In fact, it is the opposite that has garnered the 
most evidence to date; i.e., childhood treatment for ADHD can reduce the risk for many substance 
use disorders (Chang et al., 2014; Wilens, Faraone, Biederman & Gunawardene, 2003; Wilens et 
al., 2008). The use of stimulants, as well as the non-stimulants atomoxetine and buproprion 
(usually prescribed for depression and mood issues) frequently show decreased substance use 
subsequent to treatment, although in the case of severe drug toxicity, results continue to be mixed 
(Levin, 2007). There are nonetheless several important studies reporting that medications do not 
protect ADHD children from developing addictions as adults. They appear to confirm however 
that they do not contribute to subsequent drug abuse (Faraone, Wilens, Biederman, & Adamson, 
2007; Golden, 2009; Molina et al., 2013). An exception is the research that suggests that when 
ADHD treatment is only initiated in young adulthood, the risk of future polysubstance abuse is 
actually increased although more research is needed in this area (Kollins, 2008). 
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   Another exception appears to be the risk for nicotine dependence. Research findings have found 
that prior and concurrent pharmacological treatment for ADHD can decrease or increase the risk 
of tobacco use (Golden, 2009; Gray & Upadhyaya, 2008). A two year follow-up of high school 
students with ADHD found that those who were medicated smoked less than those who were not 
(Whalen, Jamner, Henker, Gehricke, & King, 2003).  A 2013 study that compared ADHD 
adolescents treated with extended-release methylphenidate to non-ADHD and non-treated ADHD 
comparators found that the non-treated ADHD group had higher levels of cigarette smoking 
(Hammerness et al., 2013). A neutral finding was reported in a multi-national European study of 
stimulants and substance use disorders in over 700 adolescents. There was a protective effect for 
other substance use disorders, but not for nicotine (Groenman et al., 2013). Another European 
study investigating methylphenidate in adult ADHD participants who were already smokers saw 
an increase in smoking two weeks after treatment initiation, as well as increased tobacco 
consumption three months later (Bron et al., 2013). In another trial, when several ADHD 
medications (methylphenidate, atomoxetine, dextroamphetamine, etc.) were compared to placebo, 
the medications reduced salivary cotinine levels in participants - supporting the contention that 
medication might improve smoking reduction (Gehricke et al., 2011). 
   In an attempt to isolate the effects of methylphenidate on nicotine use, a study was conducted 
on a group of smokers without ADHD, aged 17 to 27 years. Participants actually increased 
smoking following ingestion of methylphenidate, prompting the researchers of that study to 
speculate that methylphenidate increased the reinforcing effects of the nicotine through a 
synergistic effect of the drugs on dopamine levels (Rush et al., 2005). In a follow-up study, the 
same researchers administered methylphenidate to one group of healthy smokers and atomoxetine 
to another group hypothesizing that only the methylphenidate would increase smoking since 
atomoxetine is a norepinephrine transport inhibitor which does not have the same additive effect 
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on dopamine. There was a dose-dependent increase in the number of cigarettes, puffs and carbon 
monoxide levels for the methylphenidate (Vansickel, Stoops, Glaser, & Rush, 2007). (Both of the 
drugs were sufficiently active as to decrease food intake.) Varying results across studies only 
emphasize the complexity of the interactions involved. 
   Differential efficacy of medication in the treatment of nicotine dependence according to race 
and ethnic differences was highlighted in a multi-site, randomised controlled trial with OROS-
methylphenidate (OMPH) and the nicotine patch, which resulted in a significantly higher rate of 
four-week complete abstinence for non-Caucasians (Covey et al., 2010). Gender is another factor 
that should be included in all analyses because of the evidence that has begun to accumulate 
indicating that females with ADHD have different patterns of tobacco addiction and greater 
withdrawal symptoms upon abstinence (McClernon et al., 2011). 
   The fact that there are no clear conclusions as to whether prior or even current treatment for 
ADHD can protect affected individuals from being more vulnerable to nicotine dependence 
suggests that there is more to be understood in the etiology of smoking behaviour in this patient 
group. As has already been suggested, nicotine appears to relieve their symptoms and may be a 
significant reason such individuals are drawn to cigarette smoking. 
Self-Medication Theory 
      The theory that those with ADHD are self-medicating with cigarettes stems from two sources 
of repeated findings within the research. One is that the ingestion of nicotine actually improves the 
overt symptoms of the disorder as well as the emotional dysregulation and cognitive deficits 
experienced by those with ADHD, so when they experience the benefits of smoking they are 
reinforced to continue (Poltavski & Petros, 2005). The latter two symptoms are often unaffected or 
even aggravated with the use of stimulants (Potter, Schaubhut, & Shipman, 2014). The other 
theory is that once smoking has begun, possibly due to an impulsive urge to take risks, it is 
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maintained in order to avoid aversive withdrawal symptoms that are more severe than in smokers 
without ADHD. One would assume therefore that these outcomes are due to a brain-based link 
between ADHD symptoms and nicotine, and that ADHD medication could be compared to 
nicotine in terms of impact on those symptoms. 
   It has been proposed that the underlying mechanisms of ADHD and the physiological effects of 
nicotine share a common neurotransmitter system (Wilens et al., 2008). Recent neurogenetic 
studies indicate that cholinergic systems might also be altered in persons with ADHD, further 
explaining the connection between cigarettes and ADHD (Potter, Newhouse, & Bucci, 2006; 
Bacher, Rabin, Woznica, Sacco, & George, 2010). Central cholinergic systems are purported to 
sustain attention and working memory, two cognitive capacities known to often be impaired in 
ADHD patients. Krause et al. (2000), using positron emission tomography, showed similar effects 
of nicotine and methylphenidate on the dopamine transporter protein. As such, and given the 
significant number of ADHD patients who do not respond positively to the well-known stimulants 
in use, nicotinic agents are being developed as alternative pharmacological treatments for ADHD. 
   Nicotine when administered has long been shown to have a favourable impact on both 
dimensions of ADHD (Potter et al., 2014). When Gehricke et al. (2006) administered nicotine to 
non-smoking and smoking participants with ADHD, only inattentiveness significantly improved 
in both groups, yet in a replication the trial both dimensions of the disorder were significantly 
improved (Gehricke et al., 2009) Both studies used self-report to track the changes and 
inattentiveness was defined as difficulty concentrating and forgetfulness, as opposed to 
restlessness, impulsivity and impatience. In a study dating back to 1996, nicotine improved 
performance and mood within a cohort of ADHD participants on a number of cognitive tasks as 
well as one mood measure and one measure of global impairment (Levin et al., 1996). Eleven 
non-smokers and six smokers were compared following administration of a nicotine or placebo 
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patch following a night of abstinence. The improvement seen in the non-smokers confirmed that 
the overall benefits were not only due to a lessening of withdrawal symptoms. Two of the non-
smokers experienced side-effects (nausea and dizziness) important enough that the patch had to 
be removed. In another group, this time of non-smoking ADHD adolescents, a single low dose of 
nicotine significantly improved performance to varying degrees on a variety of cognitive 
measures (Potter & Newhouse, 2008). The improvements were largely the equivalent to their 
performance with a dose of methylphenidate except for the well-known Stroop test. The authors 
reported that the reduction of the Stroop effect was significant only with the nicotine patch, not 
the methylphenidate. This was in contrast to the Levin et al. study that had not seen any 
significant change in the Stroop effect in either group. Furthermore, the participants reported less 
irritability and less anxiety (similar to the Levin et al. study) in comparison to the 
methylphenidate trial. It should be emphasized however that of the eight participants in the study, 
three were excluded due to the side-effects of the initial dose of nicotine, and six had been 
regularly taking medication for ADHD (not administered the day of the nicotine patch trial) - 
possibly altering the results. Although this study examined a one-time dose effect, results may not 
be maintained with regular use of nicotine. An animal study using mice which were given the 
drug found that the reaction to the substance changed during treatment (Leach, Cordero & Gould, 
2013). Initially, the animals showed improvements in performance of a behaviour associated with 
inhibitory control, but the effects were not maintained with chronic consumption.   
   Smoking cessation has been shown to produce greater increases of depressed mood, insomnia, 
irritability and difficulty concentrating for those with greater levels of ADHD symptoms (Lerman 
et al., 2001; Pomerleau et al., 2003). The nicotine study by Gehricke et al. (2009) followed 25 
smokers and 27 non-smokers with ADHD in a smoking cessation program using either a patch or a 
placebo patch. All of the participants were treated during a two day non-smoking trial following a 
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wash-out period if they were medicated. The authors reported that although negative emotions 
such as anger and stress were reduced, the smoking participants did not report withdrawal relief on 
a measure designed to track symptoms such as craving, appetite, physiological and psychological 
withdrawal. The authors did point out that salivary cotinine levels in the smoking participants 
indicated that they might have been unable to totally refrain from smoking during the required 
abstinence period, so the relief they might have experienced with the patch was undermined.  
   In a follow-up study examining the effects of stimulant medication on the same measures, 
ADHD medication alone appeared to promote a reduction of withdrawal symptoms (with the 
exception of craving) accompanied by a reduction in salivary cotinine measures (Gehricke et al., 
2011). Again, this is in contrast to the findings of the earlier study which included four phases of: 
1) a combination of stimulant and patch; 2) patch only ;3) placebo and stimulant and; 4) placebo 
only. No real effects on emotional regulation were shown with the patch, although core ADHD 
symptoms improved in the first three conditions. The researchers had expected to see the 
potentiating effects of nicotine due to the medication. They speculated that perhaps the stimulant 
dosages were too low. These were trials that lasted no longer than two days each, which may not 
have generated sufficient opportunity to observe more interaction effects. (Given that these trials 
were only investigating the effects of nicotine on symptoms, no one was actually trying to quit 
smoking either, which might have altered symptoms further.)  
   An overnight abstinence from smoking study looking at a group with ADHD and a group 
without the diagnosis showed that the ADHD group had greater decrements in performance on a 
continuous performance test although they did not differentiate on reports of withdrawal 
(McClernon & Kollins, 2008). A longer abstinence period (12 days) however also showed a 
significant worsening of withdrawal severity among ADHD smokers, independent of ADHD 
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symptom change (McClernon et al., 2011). The latter study employed a self-report of ADHD 
symptoms to track changes, which might have been less reliable. 
Smoking Cessation with ADHD Medication and an NRT 
   Currently, the gold standard treatment for ADHD is psychostimulants. A randomised, placebo 
controlled trial, in an attempt to potentiate a known smoking cessation treatment with a known 
ADHD treatment, examined the use of osmotic-release oral system methylphenidate (OMPH) in 
combination with a nicotine replacement treatment (NRT). No difference was found in smoking 
cessation outcome for ADHD adults when compared to a placebo but there was a significant 
reduction in smoking in both groups (Winhusen et al., 2010). Furthermore, the OMPH group 
reduced their cigarettes per day to a slightly greater degree than the placebo ADHD group. There 
was no indication whether withdrawal symptoms were impacted differently, but it was reported 
that the OMPH group experienced significantly higher levels of dyspepsia, decreased appetite, 
increased heart rate and palpitations. When the results for the same cohort were re-analysed 
looking at racial/ethnic differences, there was a significant difference favouring cessation in the 
non-Caucasian/ethnic group (Covey et al., 2010). The authors were not able to explain this 
differential efficacy, but there are ethnic differences in the way cultures view all of the symptoms 
associated with ADHD, and other studies have shown that race can be a protective factor in 
smoking (Burke et al., 2007). 
   Interestingly, in another secondary analysis of the study results, withdrawal symptoms were 
found to be being stronger among the OROS treated patients than among the placebo treated 
patients. However, when the overlap of ADHD symptoms and withdrawal symptoms was 
controlled for, withdrawal symptoms (other than craving) were reduced in the medication group 
(Berlin, Hu, Covey, & Winhusen, 2011) A further analysis revealed that the most significant 
withdrawal symptom associated with successful abstinence in this study was that of craving 
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regardless of group membership, but ADHD participants experienced higher levels of craving 
overall. Although in this study, craving did not appear to be associated with either the treatment 
or the placebo group, the relationship between methylphenidate and craving aggravation had been 
previously established with immediate release methylphenidate (Rush et al., 2005; Vansickel et 
al., 2007).  
    Yet another post hoc analysis considered ADHD subtype as a factor influencing abstinence 
outcome (Covey et al., 2011). It was found that level of nicotine dependence (as measured by the 
Fagerström Test for Nicotine Dependence) was an additional confounder. There was a treatment 
effect according to subtype only when nicotine dependence was high (> 7), at which point ADHD 
with inattention did more poorly with OMPH and the patch versus the nicotine patch alone, 
whereas ADHD  with combined symptoms did better with the conjoint treatment. They did not 
attempt to disaggregate racial/ethnic groups by ADHD subtype, nor did they report on the 
association of craving with ADHD subtype in this analysis. It is possible that the adverse effect of 
the medications may have contributed to and confounded the already difficult withdrawal 
symptoms experienced by all the participants, but may have had an even greater impact on the 
inattention group, thereby neutralising any advantage the change in ADHD symptoms might have 
given them over the non-medicated ADHD group just as in the original study. 
   In summary, these very important reports of a trial that combined OMPH with a nicotine patch 
found the following: a significant level of withdrawal symptoms in the ADHD group; a 
significant reduction in ADHD symptoms in the OMPH group overall;  significant side-effects in 
the medication group; greater abstinence for non-white smokers with the medication; negative 
outcomes for highly dependent inattentive subtype smokers; and no effect on craving in ADHD 
participants when the overlap between withdrawal symptoms and ADHD symptoms are 
considered.  
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   Given the laboratory studies that have shown increased smoking in adult non-ADHD 
participants when stimulants are used, some researchers recommended that non-stimulants should 
be prescribed for ADHD in smokers. One study combined bupoprion and nicotine patches. Those 
with ADHD showed lower abstinence rates than non-ADHD participants, but in this case, the 
smokers with inattention had better odds of quitting with the medication than the smokers with 
hyperactivity/impulsivity (Covey et al., 2008). This highlights yet again the divergence of 
findings between the two dimensions of the disorder. The reported side-effects of the medication 
were significant in this study (sleep disturbance: 37.9% of participants; dizziness: 36.5%; 
agitation 27.1%; skin rash: 22.5%; headache: 20.9%, nausea: 19.4%). In conclusion, treatments 
for ADHD symptoms can also have a significant impact on the dependence and withdrawal 
symptoms of smokers. An alternative treatment that would not produce the potentially 
confounding effects one sees with medication would prove clinically useful for this population.  
 
Neurofeedback and Attention 
   Neurofeedback represents a brain-based alternative that has few if any side-effects when 
administered properly by appropriately trained practitioners. It can potentially reduce ADHD 
symptoms, particularly in the ADHD-Inattentive subtype, without aggravating withdrawal 
symptoms. Also known as electroencephalographic (EEG) biofeedback, it is a non-invasive and 
alternative treatment for a number of conditions, but it is primarily for the treatment of epileptic 
seizures and ADHD that it has been recognised as evidence-based and efficacious (Yucha & 
Montgomery, 2008; Sherlin et al., 2010; Gevensleben et al., 2013). Neurofeedback is a self-
regulation modality that really began in the 1960s and 1970s. It is a form of biofeedback that uses 
surface sensors on the head and ears to provide real-time information to an individual on the state 
of their brainwaves. 
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   Neurofeedback training is an operant conditioning technique used to reinforce or inhibit 
specific brainwaves (Demos, 2005). EEG activity is typically divided into distinctly named 
frequency bands. Brainwaves that are less than 4 Hz are called delta waves (brainwaves often 
associated with a slow wave sleep state); 4 to 8 Hz are theta waves (a drowsy/inattentive state); 8 
to 12 Hz are alpha waves (a relaxed/wakeful state); and 12 to 30 Hz are beta waves (an 
active/attentive state).  
   In 1972, Barry Sterman published a case study that demonstrated a complete cessation of 
seizures in a woman who successfully learned to increase certain frequencies over the 
sensorimotor strip using feedback. It was Sterman’s work investigating electroencephalographic 
patterns associated with inhibition in both animals and humans that led to the identification of 
what is now called the sensorimotor rhythm frequencies (SMR), generally 12-15 in adults and 12-
14 in children. These frequencies are called SMR only when they are produced across the 
sensorimotor strip. The application of SMR training has been central to the development of 
neurofeedback treatment for seizures and ADHD (Monastra et al., 2005). Sterman has proposed 
that mechanism of effect of SMR neurofeedback training on attention lies in decreased 
somatosensory and motor interference in cognitive processing.  
   In terms of neurofeedback research as it pertains to ADHD, the focus has been primarily on 
children. The most common electroencephalographic pattern found in this population is an excess 
of slow wave activity in the frontal regions of the brain, although other patterns have also been 
identified (Chabot & Serfontein, 1996; Clarke & Barry, 2004; Lansbergen, Arns, van Dongen-
Boomsma, Sponk, & Buitelaar, 2011; Loo et al., 2013; Lubar, 1991; Monastra et al., 1999; 
Ogrim, Kropotov, & Hestad, 2012; Snyder et al., 2008). Successful alterations in brainwaves, and 
subsequent improvements in ADHD behaviours, have for the most part involved training in 
frontal, central and midline regions of the brain (Arns, Drinkenburg, & Kenemans, 2012; 
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Gevensleben et al., 2009; Gevensleben et al., 2013; Kaiser & Othmer, 2000; Lévesque, 
Beauregard, & Mensour, 2006; Lubar & Shouse, 1976; Monastra, Monastra, & George, 2002; 
Thompson & Thompson, 1998). 
   One of the first successful uses of neurofeedback as a treatment was in 1976. Lubar and Shouse 
(1976) used a training regime that sought to reinforce 12-14 Hz and inhibit 4-7 Hz at the vertex of 
the brain in an 11 year old presenting with hyperactivity. The training effect was a tripling of 
SMR levels associated with improved performance in the classroom, as measured by a decrease 
in out-of-seat behaviour and more school work being completed. In addition, improvements in 
oppositionality were reported. To ensure that gains were due to the biofeedback, a reversal study 
design was used and the boy was trained to decrease his SMR activity to baseline levels and 
increase theta over 38 sessions. A loss of the behavioural improvements followed, but they were 
regained when the subject once again successfully trained to increase SMR and decrease theta. 
The study was replicated using one electrode at the vertex of the brain (the international 10/20 
site Cz) with four more participants diagnosed with hyperkinesis (Shouse & Lubar, 1979). SMR 
enhancement became a fundamental protocol in much of subsequent neurofeedback research and 
continues to be an essential part of neurofeedback training today (Demos, 2005; Russell-Chapin 
et al., 2013). 
     As in any emerging treatment, initial inquiries were for the most part on a small scale but 
results were highly encouraging (Linden, Habib, & Radojevic, 1996; Lubar 1991; Rossiter & 
LaVaque, 1995; Tansey, 1993). Their success led to case studies and controlled research designs 
with larger numbers of participants, providing a more rigorous examination of the technique. 
Positive outcomes were nonetheless maintained and included improved behavioural symptoms 
and academic performance (Monastra et al., 2002), as well as improvements in a variety of 
cognitive measures (Kaiser & Othmer, 2000; Fuchs, Birbaumer, Lutzenberger, Gruzelier & 
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Kaiser 2003). One striking report came from a multi-case study which presented results from 111 
patients who consulted at a clinic in Ontario (Thompson & Thompson, 1998). Their findings 
provided evidence that neurofeedback training with an emphasis on SMR enhancement could 
lead to an average increase of 12 points on the Wechsler Full Scale Intelligence Quotient. These 
same researchers have pursued their work with ADHD patients but now report remarkable 
success with clients diagnosed with Aspergers. 
 Normalising Brain Profiles 
   The advances brought on by improved computer analysis of the EEG produced a wave of 
research in the field of neurometrics. Neurometrics is the quantification of useful measures of the 
EEG in order to produce objective classifications of the resulting profiles (John et al., 1977). This 
work brought an important dimension to the practise of neurofeedback. Comparisons of EEG 
features obtained from patients with specific disorders to values obtained from a population of 
normal individuals led to the creation of databases that permitted the detection of EEG profiles 
that deviated from the norm (John, Prichep, Fridman, & Easton, 1988; Thatcher & Lubar, 2009). 
   With the identification of ‘normal’ and ‘non-normal’ profiles within the EEG, clinicians were 
able to develop a variety of training protocols that were designed, in the case of ADHD for 
example, to inhibit slow brainwaves and stimulate faster ones in order to ‘normalise’ brain 
function. The enhancement of higher levels of beta (anywhere from 12 to 20) was often combined 
with the inhibition of theta in an attempt to improve symptoms (Arns, de Ridder, Strehl, Breteler, 
& Coenen, 2009; Carmody, Radvanski, Wadhwani, Sabo, & Vergara, 2001). SMR enhancement 
was not always included in these new protocols and a select few even had success with protocols 
that had no inhibition of theta (Kropotov et al., 2005). The majority however, focused on 
improvements in the ratio of theta to beta as measured at the vertex (Cz). Based on the hypothesis 
that children with ADHD could not produce the higher levels of beta, Joel Lubar proposed the 
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theta/beta ratio as an indicator of the dysfunction (Lubar, 1991). It became the sine qua non of 
ADHD neurofeedback research and development. 
     Until recently, three primary brainwave profiles have consistently been seen to appear more 
frequently in young patients with ADHD, both inattentive and combined, when compared to 
participants without the diagnosis (Chabot, di Michele, & Prichep, 2005; Clarke & Barry, 2004;  
McGee, Clarke, Barry, McCarthy & Selikowitz, 2005; Clarke et al., 2011). As mentioned, the 
majority exhibit cortical slowing in anterior regions. This profile corresponded nicely to a theory 
proposed in the early 1970’s that these children were hypoaroused (Chabot & Serfontein, 1996). 
This group has included individuals with high levels of frontal theta and frontal alpha and is 
considered a pattern of ‘cortical hypoarousal’. The second most frequent pattern to be observed is 
one of excessive activity over frontal regions. These patients were believed to have a 
‘hyperaroused’ profile, but a recent investigation of ADHD participants with this profile has 
shown that despite decreased theta/beta ratios and greater relative beta activity when compared 
with normally developing participants, they are not actually hyperaroused as measured by skin 
conductance levels, but can be hypoaroused similarly to those characterised with high theta 
(Clarke et al., 2013). Furthermore, many of these participants respond to stimulants, supporting 
the idea of hypoarousal within the central nervous system (Chabot, Orgill, Crawford, Harris, & 
Serfontein, 1999). A third EEG subtype called the maturational lag profile in children is so named 
because of the presence of increased anterior delta and theta waves with low beta, which is 
typical of young children (Chabot et al., 2005). Ambiguity in the analysis of brain profiles stems 
from the fact that all of the above-mentioned profiles have also been observed in control 
participants without a diagnosis, albeit to a much lesser degree (Arns, Gunkelman, Breteler, & 
Spronk, 2008). These are not the only profiles seen in participants with ADHD, who can also 
exhibit more ‘normal’ brain patterns, but the majority do manifest clear deviations 
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neurophysiologically. The advances in the fields of neuroimaging and neurochemistry, as well as 
in the genetics of brain development, support this contention (Cortese, 2012). 
The Theta/Beta Ratio 
    There was the hope that the EEG would yield a biomarker for ADHD. Many DSM-IV-TR 
ADHD symptoms are common to other psychiatric disorders, as well as to normal variations in 
maturity amongst childhood and adolescent behaviours. Rating scales have frequently been used 
as the basis of an ADHD diagnosis, and although they have been shown to easily identify 
someone with ADHD symptoms (sensitivity), they have been poor in distinguishing ADHD from 
other disorders (specificity) (Quintana, Snyder, Purnell, Aponte & Sita, 2007). The many 
difficulties inherent in the process of diagnosing ADHD have spurred an interest in finding a 
diagnostic tool that is both sensitive and specific to ADHD. Finding a biological indicator of the 
disorder that would reduce the number of false positives would be clinically very valuable. 
Following upon Lubar’s work, the theta/beta ratio became a likely candidate. 
   A study conducted in 1999 sought to establish the theta/beta ratio as a means of accurately 
identifying children with ADHD (Monastra et al., 1999). The researchers believed they were 
successful in proving the usefulness of the theta/beta ratio by correctly identifying 86% of the 
participants with ADHD and 96% of the non-ADHD participants in a combined group of 482 
children. Despite the varying clinical presentations of the different subtypes of ADHD, it was 
believed, perhaps precipitously, that the theta/beta ratio could serve as a tool in the diagnosis of 
the disorder. This hypothesis appeared to be supported by the many successful treatments based 
on improving the theta/beta ratio in patients through neurofeedback training (Arns et al., 2009). 
   Although ultimately the data resulting from subsequent examinations of the ratio has proven 
equivocal (Lansbergen, Arns, Dongen-Boomsma, Spronk, & Buitelaar, 2011; Liechti et al., 2013; 
Loo et al., 2013; Ogrim et al., 2012), its initial promise as a neurometric for ADHD  led to 
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numerous inquiries which contributed additional pieces to the puzzle over the last decade. 
Despite recent FDA approval of a diagnostic tool for ADHD based on the theta/beta ratio, up-to-
date research indicates that the difference between the theta/beta ratio of ADHD groups and 
normal groups has been diminishing over the years (Arns, Connors & Kraemer, 2012). A study 
published in the same journal reported that the ratio of their normal control group was higher than 
traditional control groups (Loo et al., 2013). The ratio’s capacity therefore to distinguish reliably 
between the groups is also diminishing. The authors conclude that the theta/beta ratio can no 
longer be considered a diagnostic measure even though it is still found more often amongst 
children with ADHD. What does appear to have been confirmed, however, is that the presence of 
high amplitudes of theta in central and frontal locations are markers for the presence of 
inattention and executive function disorders, but that like ADHD itself, the heterogeneity of 
symptoms involved in the diagnosis cannot be represented by one EEG signature alone (Ogrim et 
al., 2012). Although it remains to be seen, the theta-beta ratio may still qualify as an RdOC 
(Research Domain Criteria) biomarker, an endophenotype characterizing a treatment-responsive 
group that cuts across phenomenological diagnostic categories such as ADHD subtypes (Arnold 
et al., 2013). It has been argued that a low theta/beta ratio should primarily signal to 
diagnosticians who might use the ratio in the context of an ADHD assessment to investigate more 
carefully as symptoms are likely to be due to other conditions (Snyder, Rugino, & Stein, 2015), 
   As the qEEG gains ground as a means of choosing the right treatment for patients, more work is 
being done to understand the relationship between the EEG pattern and responsiveness to all 
treatments, not just neurofeedback. An important element that has been re-emphasized, especially 
in more recent work, is the problem associated with the use of fixed frequency bands in assessing 
individual patients. Brainwaves are not only identified by the frequency of the wave, but also the 
morphology of the wave in the EEG.  Digital filters of the EEG such as the Fourier Transform, 
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make assumptions as to the morphology of waves that are artificial and can sometimes lead to 
ambiguities (Collura, 2014). As a result, when band widths are fixed, unusually high or low 
frequencies which would be considered a particular type of brainwave such as alpha, are 
sometimes identified as another variant, for example, theta. Although it is common knowledge 
that the individual alpha peak frequency can vary in individuals, this element has not been 
factored into a great deal of the research of the last twenty years. It may also prove to be one of 
the main reasons neurofeedback research outcomes have varied to the extent they have, in a very 
similar fashion to medication research outcomes. 
   Arns et al. (2008) pointed out the importance of establishing the individual alpha peak 
frequency when assessing for an excess of theta in the front of the brain. By the age of ten, the 
alpha peak frequency is around 10 hertz. If however, an individual has a slowed alpha peak 
frequency (below 8.5-9), what is interpreted as a theta excess in the front of the brain might 
actually be alpha waves intruding frontally. One study that found a significant difference between 
an ADHD group and a control group based on the theta/beta ratio found the significance 
disappear when slowed alpha peak frequencies were taken into consideration (Liechti et al., 
2013). Given that the sources within the brain of alpha and theta waves are not the same, a 
misinterpretation of slowed waves could have an effect on the success of the treatment.  For 
example, it has been suggested that alpha is more responsive to a selective serotonin reuptake 
inhibitor, whereas theta is better addressed with a stimulant (Johnstone, Gunkelman & Lunt, 
2005). The qEEG will produce the same misinformation unless it is analysed by an expert with 
significant experience. Research using qEEGs needs to address this concern in order to draw 
proper conclusions, so although qEEG-driven neurofeedback is gaining ground as clinical 
treatment because it avoids the difficulties inherent in applying a single treatment to a 
heterogenous condition such as ADHD (Arns et al., 2012b), the research in this area is in its 
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infancy. Most research designs are not qEEG-based and continue to use a single protocol that has 
been shown to be clinically useful in treating a diagnosed condition. 
   These latest developments will alter the entire approach of neurofeedback training as more 
research into the complex sources of dysfunctional neuroelectrical patterns emerges. Most 
important for this study, however is the choice between two recognized “attention” protocols; the 
theta/beta ratio training, a mainstay of neurofeedback, and SMR training. Interestingly, the 
ubiquitous SMR enhancement protocol is often recommended as a standby when qEEG 
deviations are unclear, or when the qEEG is not used to direct protocol choice (Arns et al., 
2012b).  
Adult ADHD EEG Profiles 
   Most of the previous discussion has centred on children as they have been the focus of much of 
the research into the use of neurofeedback for ADHD. The initial two main patterns of frontal 
slow frequencies, and a smaller percentage with an excess of fast frequencies, persist in 
adolescents and adults as well although results across studies can vary (Clarke et al., 2008; Keune 
et al., 2011; Liechti et al., 2013; White, Hutchens, & Lubar, 2005). The pattern most associated 
with inattention has been termed ‘thalpha’ because it encompasses slow frequencies from 6-10 
Hz which include theta and alpha brainwaves (Thompson & Thompson, 2003). These authors 
have also identified a group of adults who exhibit attention problems because of their tendency to 
ruminate rather than ‘drift off.’ They present with high levels of fast frequencies, often within the 
22-35 Hz range (beta frequencies nicknamed by the Thompson’s as busy-brain frequencies), but 
the main profile for adults appears to be the ‘thalpha’ pattern. A study comparing 34 adults with 
ADHD and 34 control participants confirmed these findings (Koehler et al., 2009). The ADHD 
patients showed a significant increase of absolute power density in alpha and theta bands. 
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Another study found a correlation between increased beta levels and rating-scale measures of 
attention problems and metacognition in adults (Ogrim et al., 2012).  
.Medication Control Studies 
    Brain profiles and their relationship to behaviour patterns are pertinent not only to the field of 
EEG biofeedback. The frequent presence of divergent brain-based patterns, even amongst groups 
with similar behavioural problems, has been proposed as an explanation as to why the outcomes 
to methylphenidate and amphetamines can be unpredictable (Gunkelman, & Johnstone, 2005). It 
appears that the effectiveness of medication can be improved upon if the choice is based on the 
neurophysiological profile rather than on a set of behavioural symptoms, as is current practise 
(Collura, 2014). Decades of pharmacological studies have nonetheless provided significant 
outcomes that establish a minimum that must be met by newer treatments. It was inevitable that 
stimulants serve as an active control in research designed to assess the effectiveness of 
neurofeedback as a treatment option for ADHD 
   Seven clinical studies have compared neurofeedback to either a medication treatment group, or 
a multi-modal treatment group that included medication (Duric, Assmus, Gundersen & Elden, 
2011; Fuchs et al., 2003; Monastra et al., 2002; Nazari, Querne, De Broca & Berquin, 2011; 
Meisel, Garcia-Banda, Cardo & Moreno, 2013; Rossiter & LaVaque, 1995; Rossiter, 2004b). Not 
all of these studies were random-controlled trials although two of the most recent assigned 
participants randomly to the treatment conditions (Duric et al., 2011; Meisel et al., 2013). In 
arguing the case against randomisation to a control treatment with medication, the assertion is 
that parents may have strong viewpoints for or against medication. This may explain why one of 
the RCT’s mentioned above had one third of their patients drop out before the study could begin 
(Duric et al., 2011). 
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    A year-long multi-modal study conducted in a school setting combined known interventions 
for ADHD including medication (Ritalin), parent training/counselling, a school program and 
neurofeedback (Monastra et al., 2002). All of the 100 children enrolled in the study participated 
in the medication, parent counselling and school support (CCC), and all 100 were assessed to 
ensure that they exhibited a high theta/beta ratio indicating cortical hypoarousal. The 
neurofeedback treatment was added on for 51 of the children, who received an average 34 weekly 
sessions of the Lubar theta/beta protocol (CCC+B). The children were reassessed twice at the end 
of the year using rating scales for teachers and parents, and a computerised test of attention. The 
author concluded that the short-acting Ritalin used probably accounted for the results of the CCC 
group which indicated that despite improvements over the year, they were still considered 
impaired when assessed by teachers and parents on a behaviour rating scale. The neurofeedback 
group did not exhibit the equivalent impaired behaviour although they received the same dosage 
of Ritalin as the CCC group. A further assessment was performed following a medication wash 
out of one week. Whereas all of the CCC group’s measures returned to pre-treatment baselines, 
the CCC+B group maintained their improvements. Effect sizes in this study were large for 
combined neurofeedback, parental training, initial medication and school intervention treatment 
(ES=2.22 for inattention; 1.22 for hyperactivity). 
   A German study, also conducted in a clinical setting, gave parents the choice of treatment with 
medication or with neurofeedback (Fuchs et al., 2003). The authors argued that this option would 
enhance treatment compliance although they recognised that they were therefore not able to 
control for non-specific factors affecting the outcomes. They reported that the 22 children who 
were assigned to the 36 sessions of neurofeedback completed the treatment, whereas one of the 
12 children who chose medication was unable to continue due to side-effects. Both groups had 
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significant improvements on parental rating scales of behaviour as well as two tests of attention, 
but neither surpassed the other. 
   A replication of one of the first comparison studies between neurofeedback and stimulants 
(LaVaque & Rossiter, 1995) was conducted with a larger sample size (62 children), improved 
matching of the treatment and control group, and better statistical analysis (Rossiter, 2004b). 
(Participants chose whether or not to be part of the medication treatment group.) The 
neurofeedback group’s post-treatment scores on the Behavior Assessment System Children 
(BASC) and Brown Attention Deficit Disorder (BADD) fell within the average, non-impaired 
range after the training. The BASC is a report scale that examines different dimensions of 
psychopathology in children (hyperactivity; attention; externalising; internalizing) and the BADD 
scale is a checklist of primarily executive function symptoms. Only the internalizing scale was in 
the average range prior to the treatment. Both treatment groups exhibited equivalent 
improvements on a continuous performance test. The neurofeedback used by Rossiter in this 
study targeted the left hemisphere (at C3) for children with inattention and daydreaming, the right 
hemishphere (at C4) for those with impulsivity and distractibility, or both for a combination of 
the two dimensions. 
   One of the few studies to randomise patients to one of three treatment groups (a neurofeedback 
group, a methylphenidate group and a neurofeedback with methylphenidate combined group) 
reported significant improvements on a parent rating scale for the 30 or so children in each group, 
with no significant differences between the groups (Duric et al., 2011). The neurofeedback group 
received 30 sessions of theta inhibition and beta enhancement at CZ. Finally, one of the most 
recent studies comparing medication and neurofeedback also randomised participants to either a 
methylphenidate group or a theta/beta neurofeedback group (Meisel et al., 2013). (This study also 
had to contend with participants dropping out of the study following randomisation due to a 
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preference for a specific treatment). Pre-post results showed improvements in both groups on 
certain measures (symptom scales and a parental impairment scale), although only the 
neurofeedback group showed improvement on teacher rated changes in academic performance. 
Effect sizes for the pharmacological group tended to be larger. Treatment in the pharmacological 
group, as well as improvements, were maintained at two and six month follow-ups, whereas 33% 
of the neurofeedback group were shown to have maintained improvements without continued 
neurofeedback treatment. It should be noted that eight of the initial twelve neurofeedback 
participants eventually resorted to medication in the follow-up period. The investigators excluded 
those children in the analysis, but this is an important consideration. 
    A tentative conclusion is that when there is no pre-selection, positive outcomes appear to be 
similar in both treatment approaches. But when patients were pre-selected for a specific EEG 
pattern that the treatment protocol then addressed specifically, neurofeedback outcomes surpassed 
those of medication (Monastra et al., 2002). Ultimately, the variety of brain profiles included in 
the typical cohort of ADHD patients probably explains why neither medication nor 
neurofeedback (when training is not specific to a profile) have predictable outcomes. Perhaps 
information on the direct effects of ADHD medication on the EEG will add to the discussion. 
   Unfortunately, a review of studies exploring that very question only complicates matters, as it 
reveals many inconsistencies and contradictions in the research. Some have reported the 
normalisation of the hypoaroused or frontal slow profile with stimulants (Clarke et al., 2003) 
while others have not (Arns et al., 2008; Chabot et al., 1999; Lubar, Swartwood, Swartwood, & 
Timmerman, 1995). Yet the ‘busy brain’ variant with excessive beta can also respond to 
stimulants. There is also evidence that anticonvulsants have been found to improve symptoms in 
some ADHD clients (Gunkelman & Johnstone, 2005). Arns et al. (2008) report that 
amphetamines appear to be most effective for cases of high frontal alpha (slowing in the front of 
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the brain) particularly when the alpha peak frequency is low. Taken altogether, these findings 
would suggest that although an examination of the EEG may predict responsiveness to 
medication, it might prove to be even more useful in predicting whether or not neurofeedback 
would be the most effective form of treatment for some clients. Much more research is needed in 
this area, but some of the knowledge garnered to date is helping resolve questions that have long 
been unanswered. 
Recent Random Controlled Trials 
    As mentioned, one of the major criticisms of the research in the field has been the lack of 
randomised controlled studies (RCT) (Loo & Barkley, 2005). Although there had been several 
controlled studies prior to 2005, there were drawbacks associated with a number of them, such as 
small sample size or what were considered subjective outcome measures. Since that time there 
has been a surge of renewed scientific study relating to neurofeedback as a treatment for ADHD. 
A few of the more significant studies will be briefly reviewed. 
    One of the first RCT’s with a major impact on the field of neurofeedback research was a study 
that featured functional magnetic resonance imaging (fMRI) changes as an outcome measure 
(Lévesque, Beauregard, & Mensour, 2006). Based on the evidence that the functioning of the 
anterior cingulate cortex is abnormal for those with ADHD during tasks involving selective 
attention, these researchers investigated whether neurofeedback would effect change in the pre 
and post scans of fifteen unmedicated children performing a Stroop task. Twenty sessions with 
Lubar’s SMR/Theta protocol (enhancing SMR 12-15 hz and inhibiting theta 4-7 hz) over the 
vertex were followed by twenty sessions of theta/beta training (inhibiting theta 4-7 hz and 
enhancing beta 15-18 hz). Although the study had small numbers of participants, the 
neuropsychological (digit span and a continuous performance test) and behavioural measures 
significantly improved and provided solid empirical support for the neurofeedback treatment. The 
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activation of the right anterior cingulate cortex revealed by this research suggested that this form 
of training could effectively normalize brain activity in these patients. Five more children had 
been assigned to a no treatment control group, but the lack of a sham treatment has been a 
criticism of the study. It is however generally recognized that a placebo effect would probably not 
have produced activation in the brain area under investigation. 
   Three recent RCT’s from Germany employed intensive active control groups that involved 
equivalent amounts of time in treatment as the neurofeedback. A well-designed study published 
in the Journal of Child Psychology and Psychiatry (Gevensleben et al., 2009) has been 
considered the most solid methodological study to date since it had a large sample size (94 
participants), as well as a control group that can be considered a credible sham control group. 
Forty-six children randomly assigned to the experimental group were offered either theta/beta or 
slow cortical potential training. Over the course of 36 sessions, they either trained to reduce theta 
activity (4-6 hertz) and increase beta activity (13-20 hertz) or they trained to increase/decrease 
slow cortical potentials aimed to increase central-midline alpha activity. The other children (26) 
received computerised attention skills training designed to improve vigilance and reactivity. 
Parents and teachers were blind as to the particular training the child received. There were 
significant improvements in the experimental group of behaviour rating scales by parents and 
teachers for inattention and hyperactivity/impulsivity even though there were not equivalent 
changes in the EEG. For example, despite reductions in theta activity over the course of the 
treatment, the reductions were not significant. All of the children were directed to think about the 
strategies they were developing and to practise the skills outside of the clinical setting. 
Interestingly, the author has stipulated that these transfer skills are essential to the generalisation 
of the effect of the treatment, and that without them the significant benefit of the training (26% 
improvement in the primary outcome measure) is lessened. 
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   A pilot study conducted in the same year described neurofeedback as a “behavioural technique” 
developed to improve the core symptoms of ADHD by modifying neurophysiologic parameters 
(Holtmann et al., 2009). Thirty-four children with ADHD were randomly assigned to a 
neurofeedback intervention or to a computer brain-training treatment. Parent rating scales and a 
stop signal paradigm (a measure of response inhibition) were the outcome measures. 
Interestingly, the parent rating scales showed no significant difference between the groups, 
whereas the cognitive performance measure found that the neurofeedback group had normalised 
response inhibition. A common criticism of neurofeedback has been that parents can be 
intimidated by the high-tech nature of the treatment and exaggerate any benefits achieved. In this 
study, this purported effect was not apparent. This concern can best be addressed by choosing 
comparison treatments that are equally high-tech in nature. The third German RCT used a 
continuous performance test and a paper-and-pencil short-term selective attention test, as well as 
parent and teacher rating scales, to compare a neurofeedback group to another biofeedback 
modality, electromyography (EMG) for children considered hyperkinetic. This biofeedback was 
considered similar enough to the neurofeedback to control for unspecific effects such as parental 
engagement and motivational effects on the participants. Results indicated that both groups 
showed improvements, particularly on the paper-and-pencil tests, but only the neurofeedback 
group improved significantly in three areas; the commission errors which are a sensitive measure 
of impulsivity and inattention; the parental rating scale for inattention; and the teacher rating 
scale for impulsivity (Bakhshayesh, Hansch, Wychkon, Rezi, & Esser (2011). 
Sham Control in Neurofeedback 
   Sham controlled studies have proven problematic for neurofeedback research. Because of this 
issue, the mainstream community has been hesitant to accept neurofeedback as a treatment option 
except when medication proves undesirable. The specific mechanisms involved in the benefits 
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seen in large numbers of neurofeedback studies cannot be considered actual brain-based 
alterations of neuronal functioning rather than placebo effects or changes due to other non-
specific variables. Because of the limitations in terms of research design, most neurofeedback 
studies are not included in reviews of the evidence-base for the approach. A 2014 review of 
psychosocial treatments for children and adolescents with ADHD reviewed only one study (the 
2009 Gevensleben study) and rated neurofeedback as “possibly efficacious” (Evans, Owens, & 
Bunford, 2014 ). Unfortunately, it is difficult to design an equivalent feedback that is inert and 
that would not be easily recognised by participant and therapist alike. This situation could lead to 
indifference on the part of the subject with a skewing of the results. Neurofeedback as an operant 
conditioning technique does not require effort on the part of the participants, but there must be an 
element of volition or engagement (Collura, 2014). Neurotherapists have argued that 
methodological and ethical limitations prevent them from incorporating a sham treatment group 
to pinpoint the mechanism of efficacy in neurofeedback (Rossiter, 2004a). When one considers 
the significant time commitment involved in such a treatment, it is difficult to rationalize asking 
people to enroll in studies where one of the conditions is a placebo. Children with ADHD are 
often already lagging behind their peers in several aspects of their development. To expose them 
to an inert treatment for a protracted period of time and risk aggravating the lag is problematic. 
   Several attempts have been made to overcome the current limitations of sham treatments, but 
most have been considered inconclusive, whether they showed neurofeedback to be effective or 
not (Gevensleben et al., 2013). The criticisms of these studies have focused primarily on 
methodological limitations such as the use of non-standard protocols, or very small numbers of 
participants (Logemann, Lansbergen, Van Os, Bocker, & Kenemans, 2010; Perreau-Linck, 
Lessard, Lévesque & Beauregard, 2010). A novel sham treatment used in a recent doctoral thesis 
may very well provide a solution for researchers (Moreau, 2012). The two-part study initially 
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used a wait-list condition while fifteen children completed neurofeedback training for ADHD. 
Their recorded brainwaves were then subsequently used as the sham feedback for a control group 
in a second intervention with 31 children. A technician who was blind to the use of the 
substituted brainwaves, and trained in neurofeedback specifically for this experiment, did the 
training with the children. Improvements were identified in both studies on parent-rating scales, 
and for the second study, on neuropsychological measures of working memory and verbal 
comprehension. 
   Currently, there is a joint effort to design and conduct a massive sham-controlled study which it 
is hoped will help identify the specific mechanisms involved (Arnold et al., 2013). For the time 
being, it can be concluded that neurofeedback is a valid psychological treatment based on the 
principal of operant conditioning with as yet unidentified mechanisms of action (Gevensleben et 
al., 2013; Simkin, Thatcher, & Lubar, 2014).  
Neurofeedback and Substance Use Disorders  
   Another main area of research in neurofeedback has been its application in addiction therapies. 
The main type of training in this domain has been the alpha-theta brainwave feedback protocol 
developed by Peniston and Kulkosky (1989) for the treatment of chronic treatment resistant 
alcoholics. Often called “deep states training”, the goal of alpha-theta therapy is to enable the 
person to enter into a profound, liminal state between sleeping and waking and maintain the effect 
for a protracted period of time. In this state, the mind can be directed or conditioned more easily 
because of a purported easing of psychological defence systems (Soutar & Longo, 2011). Gene 
Peniston developed this approach by combining two training techniques, each of which targeted 
specific brainwaves. Alpha training can be used to deepen awareness while at the same time, 
increasing physical relaxation, whereas theta training brings on the border state between sleeping 
and waking. Peniston used this combination as one component of a treatment for alcoholics within 
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a residential program that also utilised visualisations, autogenics and rhythmic breathing alongside   
more traditional therapy. 
   Although numerous studies have confirmed reports that the alpha-theta protocol is an efficacious 
co-treatment for alcohol, its success as a treatment for other abuse substances such as cocaine, 
marijuana and stimulants has been less clear cut (Trudeau, 2005). In an attempt to potentiate alpha-
theta therapy in these populations, the treatment was eventually modified to include protocols 
normally used for other issues. SMR training, in particular, was explored to see whether its 
inclusion could improve treatment outcomes given the success seen in ADHD and epilepsy, as 
well as its reputation to produce calm, insight-oriented improvements in participants (Gruzelier & 
Egner, 2005). The hypothesis was that protocols that included SMR enhancement would be a 
potential adjunct treatment for clients who may have altered their brain functioning through drug 
use (Trudeau, Sokhadze, & Cannon, 2009). 
   One such protocol is the so-called betaSMR protocol, or sensorimotor-beta training, which is 
designed to enhance SMR frequencies (12-15) on the right side of the brain, and higher beta 
frequencies (15-18) on the left side of the brain. A research study with over 1000 participants 
showed that sensorimotor-beta training led to significant improvement in attentiveness, impulse 
control, and response variability on a continuous performance test (Kaiser & Othmer, 2000). In 
this particular study, each side of the brain, at C3 and C4, was treated one after the other. Success 
has also been reported when the enhancement of the different frequencies is done simultaneously - 
a treatment made possible by the development of amplifiers with more than one channel (Putman, 
Othmer, Othmer, & Pollock, 2008). 
   The main adaptation, therefore, to the alpha-theta treatment for addictions with stimulants was to 
include betaSMR training. This is known as the Scott-Kaiser modification of the Peniston Protocol 
(Scott et al., 2005). These researchers tested their modification by training participants from a 
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mixed substance abusing population using a betaSMR protocol until their attention scores on a 
continuous performance test normalised. They reported an average of 13 sessions in order to do so. 
The betaSMR training was then followed up by the alpha-theta protocol as part of a multi-faceted 
treatment programme. In a randomised controlled study of the modified protocol in combination 
with standard therapy, 77% of those in the experimental group were abstinent at 12 months 
compared to 44% of the control group which had received no neurofeedback (Scott et al., 2005). 
The SMR Protocol 
   Although SMR training has been a mainstay of neurofeedback since its elaboration by Sterman 
in the 70’s, there has been a recent resurgence in interest in order to explain why voluntary 
production of the sensory motor rhythm is so effective for a variety of disorders including 
epilepsy, ADHD, Tourettes, fibromyalgia, sleep, memory, and possibly others such as Aspergers 
and mood disorders (Benvenuti, Buodo, Leone & Palomba, 2011; Gruzelier, 2014; Hammer, 
Colbert, Brown, & Ilioi, 2011; Kayiran, Durson, Dursun, Ermutlu, & Karamürsel, 2010; 
Thompson & Thompson, 2009b; Vernon et al., 2003). In fact, SMR training is the fallback 
protocol when an assessment of brainwaves does not reveal a profile associated with specific 
difficulties, or when there are no identifiable areas or hot spots outside of normal functioning 
(Arns et al., 2012b). A study using functional magnetic resonance imaging before and after forty 
SMR enhancement training sessions showed evidence that the neurofeedback had consolidated the 
Default Mode Network in twelve children diagnosed with ADHD (Russell-Chapin et al., 2013). 
The results confirmed the findings of the Lévesque et al. (2006) who had used an SMR/Theta 
training protocol. Arns and Kenemans (2012) have proposed a disturbed vigilance model for the 
impact of SMR work as related to certain subtypes of ADHD. They hypothesize that SMR 
training, as well as slow cortical potential neurofeedback have an impact on the sleep spindle 
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circuitry, thereby stabilizing vigilance. This model ties in nicely with Sterman’s work examining 
the sleep spindle activity of cats. 
   It has always been assumed that it is the enhancement of SMR that produces therapeutic effects. 
As such, it has been proposed that therapeutic benefits can only be truly obtained when there is a 
concomitant increase in scores and that this should be the basis for the measure of effectiveness of 
neurofeedback studies. For SMR enhancement in particular, this is a complex issue. Although the 
goal of most SMR training is generally a significant increase in SMR scores, behavioural 
improvements can occur without it, and vice versa. Several authors have noted that despite 
improvements in targeted behaviours and abilities, and despite within session increases in SMR 
scores, there was no corresponding increase in the SMR score across sessions. This is perhaps 
because increases in SMR can at times be a very slow process. Behaviour changes may pre-cede 
significant amplitude increases as control over the SMR response is developed. Using healthy 
participants, the SMR score was found to rise significantly only at the very last training period 
(Dopplemayer & Weber, 2011). At times, the score has even been found to be lower at the end of a 
training period than at the beginning. Arns et al. (2012b) reported a decreased SMR score after 
more than twenty sessions during which ADHD participants tried to increase their SMR, yet there 
were indications of a normalisation of underlying neural circuitry related to stimulus 
discrimination and attention/memory updating and an improvement in behavioural outcome 
measures., or even to decrease initially and as participants became more skilled, to eventually 
increase. Kleinnijenhuis, Arns, Spronk, Breteler and Duysens (2008) found a relationship between 
the slow cortical potential and SMR whether the subject was working at increasing or decreasing 
SMR. Vachon-Presseau, Achim and Benoit-Lajoie (2009) found that tasks requiring increased 
attention actually lowered SMR. Other researchers noticed that when SMR was increased at Cz 
(while a subject with Tourettes was also trying to decrease theta) SMR decreased at C4 initially, 
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eventually to increase but without exceeding pre-training levels despite significant changes in 
symptoms (Benvenuti et al., 2011). 
   In summary, the changes in SMR amplitude do not appear to always correlate with changes in 
behaviour. Enhancement can be very slow, or can occur in as little as eight sessions (Vernon et al., 
2003). It has been suggested that like slow cortical potential training, it is the improvement in 
control of the elicitation of an SMR bursting response, whether scores increase or decrease, that 
leads to therapeutic change, and that participants develop their own individual strategies for doing 
so (Arns et al., 2012b). There is much to be understood in terms of the mechanism of change in 
SMR neurofeedback, not unlike other therapeutic modalities, such as psychotherapy, that have 
been used prominently for decades. 
 
Research Goals 
   In conclusion, although neurofeedback to address attention problems has already been used 
successfully in the context of substance use disorders (the Scott-Kaiser modification protocol in 
particular) there is little research on neurofeedback in a smoking cessation context for this group of 
patients. Given that they are at increased risk for significant health complications, any potential 
therapy to improve smokers` ability to stop smoking would be very valuable, especially one that 
could be easily incorporated into a clinical practice. Most neurofeedback addiction research has 
included multiple variables (e.g., residential settings; other biofeedbacks; the alpha-theta protocol 
combined with guided visualisation). The investigation of an “attention protocol” such as the 
betaSMR protocol as a potentiator of a known smoking cessation treatment in the context of a 
clinical setting would be useful. Stimulants prescribed for attention problems in addition to 
nicotine replacement therapies have been shown to have an impact on cessation attempts, although 
inconsistent results may be confounded by increased adverse effects of the medication, as well as 
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other less well understood factors. As such, these elements support the exploration of the potential 
efficacy of a betaSMR neurofeedback treatment for individuals with attention deficits who are 
struggling unsuccessfully to quit smoking. Improving attention through a self-regulation 
biofeedback treatment such as the betaSMR protocol may place smokers with ADHD on an equal 
footing with other smokers who benefit from the use of a nicotine replacement therapy to diminish 
their dependence on smoking cigarettes to acquire the nicotine their brain has become accustomed 
to, and to control withdrawal symptoms that undermine their cessation attempts. As the 
neurofeedback works to improve performance on a measure of attention, participants with ADHD 
who are already using an NRT unsuccessfully may find their ability to reduce their smoking may 
improve. 
 Study Objectives 
   The primary objective of this study was to investigate the impact of neurofeedback on a 
conventional smoking cessation treatment for adults with ADHD and nicotine dependence. More 
specifically, the study assessed the effect of a betaSMR treatment protocol on the ability of 
smokers with ADHD to refrain from smoking while using a nicotine patch. The contention put 
forward was that improvement in attention following the neurofeedback treatment would gradually 
help to reduce dependency and withdrawal symptoms and lead to eventual abstinence. 
Hypothesis 
   It was hypothesized that a neurofeedback treatment would significantly improve attention as 
measured by a continuous performance test, in smokers with ADHD who were unable to quit 
despite the use of a nicotine patch, thereby reducing dependency and withdrawal symptoms as 
measured by a scale evaluating six dimensions of withdrawal, to result in a decrease in nicotine 
dependence as measured by a scale derived from the DSM-IV-TR definition of nicotine 
dependence. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Methods
 
 
 
Design 
    A single case experimental design was used to evaluate the effects of the neurofeedback 
treatment (Kazdin, 1978). In order to maximise internal validity, a multiple baseline across 
participants design (MBD) was chosen (Kratochville & Levin, 2010). A single transition from 
baseline to treatment was instituted given the impossibility of negating the effects of the treatment 
in a subsequent withdrawal phase. This design is relevant to practitioners in clinical settings. 
Ethical considerations required a non-concurrent start to each baseline phase. It would have been 
detrimental to the efforts of the participants struggling to quit smoking to require them to wait until 
sufficient participants were recruited in order to start them all concurrently. Furthermore, some 
participants were eager to begin the experimental treatment as they were already unsuccessful with 
the NRT.  It was decided to respect fixed start times rather than use a response-guided introduction 
of the treatment phase. Participants were randomly assigned to different baseline lengths as soon 
as the assessment process was completed. Ultimately, the pre-established baseline lengths of the 
design (12, 10, 8 and 6 days) were not strictly adhered to due to participants changing their 
availabilities to begin treatment. Actual baselines were 20, 10, 8 and 7 days. During that period, 
and for the duration of the treatment, participants continued to use the nicotine patch as prescribed 
to them. The introduction of the treatment in a staggered fashion across the participants was 
intended to minimize the impact of external factors on the results. As such, a causal relationship 
can eventually be established in the targeted behaviour following introduction of the 
neurofeedback treatment. According to Kazdin (1978), confident conclusions can be drawn about 
the treatment effectiveness using an MBD design when at least three participants are used. Four 
participants recruited from a bilingual suburb west of Montreal were enrolled in the study and 
completed the treatment. The treatment phase of the study ended when participants had 
significantly improved a measure of attention that was tracked throughout the study (after 12 and 
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13 sessions of neurofeedback). (For the study timelines see Appendix 1). The initial measure of 
nicotine dependence was repeated ten weeks following the termination of treatment, as well as an 
evaluation of smoking abstinence as this was the ultimate goal of a smoking cessation treatment. 
Screening Measures 
   FTND: The Fagerström Test of Nicotine Dependence. The FTND (see Appendix 2) is the 
most widely known measure of nicotine dependence and is most utilized by researchers. The 
FTND quantifies dependence using six questions that yield a score from 0 to 10 (Heatherton, 
Kozlowski, Frecker &, Fagerström, 1991). It classifies smokers as very low dependence (score 0-
2), low dependence (score 3-4), moderate dependence (score 5), high dependence (score 6-7) and 
very high dependence (score 8-10).  The first question (time to first cigarette in the morning) is 
considered a valid indicator of nicotine dependence. This scale also taps into behaviours associated 
with difficulty maintaining abstinence due to withdrawal symptoms. The internal reliability 
coefficient (Cronbach’s alpha) is 0.68 for the FTND with a test-retest reliability ranging from 0.67 
to 0.87 (Meneses-Gaya, Zuardi, Loureiro, & de Souza Crippa, 2009). As a screening measure to 
identify moderate to heavy nicotine dependence, an FTND score of equal to or greater than > 5 is 
recommended, for which the FTND score and saliva cotinine correlation is 0.45 (Huang, Lin & 
Wang, 2005). In a psychiatric population, convergent validity for total FTND scores correlated 
0.38 with milligrams of nicotine per day (Buckley et al., 2005). The scale was chosen in part 
because participants were potentially French or English and has been adapted and validated in 
French (Etter, Le Houezec, & Perneger, 1999). 
   ASRS v1.1: Adult Self-Report Scale (World Health Organisation). The 6-item questionnaire 
(the first 6 questions of the 18-item scale) was used as a telephone screening tool for the study (see 
Appendix 3). It has been found that the six first questions are most predictive of the disorder 
(Kessler et al., 2007). The 18-item screener (completed with the other assessment scales) was 
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constructed using the DSM-IV-TR symptoms for ADHD. The ASRS v1.1 has a test-retest 
reliability of 0.58 to 0.70 and an internal consistency coefficient of 0.63 to 0.73 (Kessler et al., 
2007). The overall positive predictive value of the ASRS was 0.26 (95% CI: 0.22–0.30), the 
negative predictive value was 0.97 (Van de Glind et al., 2014). The French version of the scale 
was adapted and validated in 2009 (Caci, Oliveri, & Dollet, 2009).  
Evaluation Measures 
   CADDRA ADHD Assessment Toolkit (CAAT) - 3rd edition. The Canadian Attention Deficit 
Disorder Resource Alliance (CADDRA, 2011) is an assessment package for ADHD developed by 
a multidisciplinary team of Canadian experts. The package is made up of guidelines designed to 
help in the diagnosis of ADHD across the lifespan. CAADRA is careful to point out that these 
tools are not diagnostic. They provide important measures of the symptoms that can help identify 
attention disorders but it is the clinical interview that is the basis of a formal diagnosis. The 
following scales and questionnaires from the toolkit (see Appendix 4) were used to obtain 
descriptive information from the participants:  the Weiss Symptom Record (WSR) and the Weiss 
Functional Impairment Rating Scale-Self Report (WFIRS-S) and the Weiss Functional 
Impairment Rating Scale –Parent Report (WFIRS-P) whenever possible. Otherwise, participants 
were asked to complete the Wender Utah Rating Scale (WURS) (Appendix 5) in order to 
establish whether the attention problems dated back to childhood. The WSR is a clinical 
screening questionnaire based on the DSM-IV-TR criteria. It collects information using 18 
subscales about Axis I and Axis II psychiatric disorders in any age group and from any informant. 
The questionnaire was filled out by the participants to evaluate clinical information on possible 
co-morbidities. It is not a psychometrically validated instrument but is a clinical record of the 
DSM-IV-TR criteria for various disorders. The WFIRS-S evaluates the adult’s capacity to 
function in the different areas of daily life and the impact of the behavior. It is a questionnaire 
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with 50 items grouped in various scales that include the family, work, academic skills, self-
concept, life skills, social activities and risky activities, which include inappropriate behaviors 
related to driving, police, drugs and sex. The scores on the items range from 0 to 3. For clinical 
purposes, a mean score >1 on some of the domains (except risky behaviors, which is 0.5) 
indicates a significant dysfunction. The scale has good psychometric properties, with a 
Cronbach’s alpha > 0.9 overall, and subscale domain Cronbach’s alphas ranging from 0.75-0.93 
(Epstein & Weiss, 2012).  
   IVA+Plus: Integrated Visual and Auditory Continuous Performance Test Plus. The 
IVA+Plus (see Appendix 6 for a sample report) is a computerized, cognitive assessment that 
differs from other continuous performance tests in that it was designed to include both auditory 
and visual measures in a standardised and individually administered instrument (Sandford & 
Turner, 2000). Using a mouse, the participant is asked to indicate when hearing or seeing a 
number ‘1’ and to refrain from responding should the stimulus be a number ‘2’. The 17 minute 
test measures errors of commission and errors of omission and begins with a brief practice to 
ensure that the directions are well understood. The main test lasts about 13 minutes during which 
a total of 500 trials lasting approximately 1.5 seconds each are recorded and ends with a cool-
down period. The scores to be tracked in this study will be the Auditory Sustained Attention 
Quotient and the Visual Sustained Attention Quotient. These are global scores resulting from an 
analysis of the following scales: Acuity, Dependability, Elasticity, Reliability, Steadiness and 
Swiftness. They are standard scores and the descriptive categories are: Exceptional 130 and 
above; Superior 120–129; Above Average 110 – 119; Average 90 – 109; Slightly Impaired 85 – 
89; Mildly Impaired 80 – 84; Mildly to Moderately Impaired 76 – 79; Moderately Impaired 72 – 
75; Moderately to Severely Impaired 68 – 71; Severely Impaired 61 – 67; Extremely impaired < 
60. This CPT was part of the initial evaluation of attention in the selection of participants, but 
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also served as an objective weekly measure of the status of attention throughout the study. When 
attention normalised, i.e., when at least one of the scores that were monitored was in the average 
or mildly impaired range, treatment was halted. The test-retest reliability ranges from 0.66 to 0.75 
for inattention scores and 0.37 to 0.41 for hyperactivity/impulsivity scores (a four week interval). 
Reliability and validity was established using a norming sample of individuals from 6 to 70 years 
of age. In a more recent study, the IVA+Plus correctly identified clinician diagnosed ADHD 
children 92.3% of the time (Arble, Kuentzel, & Barnett, 2014). Because of the simultaneous 
assessment within two sensory modalities, this CPT has become popular as a measure for various 
clinical investigations, both pediatric (Tinius, 2003) and adult (Corbett & Constantine, 2006; 
Quinn, 2003).  
Outcome Measures 
   CDS-5/CDS-12: Cigarette Dependence Scale. The CDS-12 (and ultimately its subscale the 
CDS-5) was the primary independent measure of the study (see Appendix 7) and was completed 
daily by the participants (Etter, LeHouezec, & Perneger, 2003). This scale was selected because 
participants were potentially French or English speaking, and this instrument was initially 
developed and validated in French, and then validated in English. The CDS-12 has 12 items that 
measure core constructs of cigarette dependence according to the DSM-IV-TR and the 
International Classification of Disease 10th revision (World Health Organization, 1992). The CDS-
5, considered the short version of the CDS-12, is composed of the first five of the 12 items from 
the CDS-12. Each item yields a score from one to five, e.g., “for you, quitting smoking would be” 
1= very easy, and 5 = impossible. The cumulated CDS-5 scores yield a measure of dependence 
ranging from 5 (low dependence) to 25 (high dependence). For the CDS-12, a score of 25 or less 
indicates a low dependence; between 25 and 44 a moderate dependence and > 44 a strong 
dependence. The average score of the 3009 smokers from France, Switzerland, Belgium and 
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Canada in the original study validating the scale was 44 (Etter et al., 2003). The CDS-12 has good 
psychometric properties with a Cronbach alpha of .084 and a test-retest of 0.83. The instrument’s 
scores are associated with the strength of the urge to smoke during the last quit attempt (R2 > 
0.25), and with saliva cotinine (R2 > 0.17) (Etter et al., 2003). The CDS-5 is slightly more 
correlated with cotinine levels in smokers than the CDS-12 (Sato, Sato, Nozawa, & Sugimura, 
2012). 
   CWS-21: Cigarette Withdrawal Scale. The daily measure of withdrawal symptoms was 
tracked by the CWS-21 (see Appendix 8), a 21-item self-administered scale that evaluates the 
following six dimensions of a withdrawal syndrome: depression/anxiety; craving; irritability; 
appetite/weight-gain; insomnias; concentration problems. Each item, e.g. “I would like to hold a 
cigarette between my fingers”, generates a score from one to five reflecting 1 = totally disagree, or 
5 = fully agree. The first three dimensions (depression/anxiety; craving; irritability) give scores 
from 5 to 20 each. The last three (appetite; insomnia; concentration) give scores from 3 to 15 each. 
The total possible score ranges therefore from 24 to 105. This scale was designed specifically with 
smoking and smoking cessation research in mind and reflects the symptoms of the DSM-IV-TR 
and ICD-10. It was developed and validated initially in French (Etter, 2005), then validated in 
English (Etter & Hughes, 2006). Internal consistency measures (Cronbach’s alpha) are between 
0.83 and 0.96 and the test-retest ranges from 0.60 to 0.71. The predictive validity of the craving 
subscale of the CWS-21, reflecting relapse on day 14 following a quit attempt, (area under ROC 
curve) = 0.63 (.55-.071) with a CI of 95% CI (Etter & Hughes, 2006). 
Participants 
   Six participants, all women residing in the region of the West Island of Montreal, were recruited 
for the study, but only four agreed to participate following the assessment because scheduling 
difficulties (VB, CR, JW, and MT).  Each was bilingual, but all identified English as their mother 
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tongue. Two of the participants had previously been diagnosed with ADHD; one as a teenager in 
the ninth grade by a local psychologist, and the other as an adult in her thirties by a psychiatrist 
well-known for her work with ADHD. A third subject was the mother of two children diagnosed 
with ADHD who felt she had similar issues. Finally, the fourth participant was a nurse in one of 
the medical offices approached for recruitment who, upon completing the screening instrument 
herself, felt she had a likely explanation for her difficulties in quitting smoking after many years of 
trying on and off the patch. Two of the participants (MT and JW) were normally heavy smokers 
when not trying to quit, smoking more than 30 cigarettes a day, whereas the other two smoked 
moderately, from 15 to 25 cigarettes per day. At the time of recruitment, all of them had reduced 
their smoking by using a patch but had resumed smoking daily although to lesser amounts. 
Because of their continued smoking, each one planned on continuing the patch for a time. As 
participants were recruited, they were assigned to a baseline length and began the intervention in 
the following order; CR, JW, VB and MT. The treatment phase of the study spanned the final four 
months of 2012 and the first two months of 2013. A brief description of each participant, their 
initial screening and attention scores, along with their motivation for joining the study, ensues. 
   Participant A (VB). Participant A was a 25 year old who worked as a hairdresser. She had been 
diagnosed with ADHD, predominantly inattentive type by a psychologist in Grade 9. Her initial 
scores on the screening instruments were: FTND = 5 or moderately dependent; ASRS-6 = five 
items endorsed with sufficient severity. At the time of the assessment, her CPT scores placed her 
in the extremely impaired range (IVA+Plus = 12 for sustained auditory attention and 14 for 
sustained visual attention). Her WSR self-report results (ADHD section) were three on nine 
symptoms for inattention and four on nine symptoms for hyperactivity/impulsivity). Other 
symptoms endorsed on the WSR were an inability to relax, sleeping difficulties and past learning 
difficulties. Other than smoking (endorsed as very much a problem), her WFIRS-P report 
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confirmed long-standing issues with the family, school, sleep and smoking. (VB never handed in 
her own WFIRS-S or ASRS-18 forms, promising repeatedly to bring them in, but always 
forgetting to do so). She had tried many times to quit smoking and found the habit repugnant, but 
although she could stop for a brief period, she would inevitably return to cigarettes. She had 
become so discouraged that she reported she would often go several weeks without using the patch 
until she became motivated enough to re-attempt to quit and would put it on and try again. This 
was a long standing pattern on her part. She also reported that although she used the lowest dose 
possible (7 mg), she would frequently develop more sleep problems on the patch. When she was in 
high school she sought help in order to decide what to do with her future as she anticipated having 
problems with higher education. At this point she was evaluated and diagnosed. Medication was 
recommended, but she reports that she refused at that time because of a tendency to be nervous. 
She still did not want to consider it. When she was recruited for the study, she was unhappy at 
work as she found the hours long, the income unreliable and the relationship with her employer 
was tense. Her attempts to quit smoking did not improve her circumstances as she felt it often 
affected her mood. Her parents helped her financially although she lived on her own. Near the end 
of the treatment, she had a falling out with her boss and she decided to look for work elsewhere. 
Interestingly, although she smoked less than any other participant, she reported her addiction as 
very high on the outcome variables. 
   Participant B (CR). CR (50 years of age) worked part-time as a research coordinator in a 
medical office. She had no diagnosis of ADHD. She joined the study after completing the ASRS-
18 and found to her surprise that she responded yes to a majority of the items (four on the initial 
six and 12 in total on the 18 item scale). Her initial FTND score was in the moderate dependence 
range (5). The IVA+Plus scores were 69 (moderate to severely impaired) for both the sustained 
auditory and visual attention scales. Her WSR self-report results (ADHD subscale) were six on 
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nine symptoms for inattention and zero on nine symptoms for hyperactivity/impulsivity. Other 
items endorsed were feelings of guilt, self-blame and indecisiveness (depression symptoms). Her 
WFIRS-S scale indicated she struggled with smoking primarily, followed by self-concept, and 
family relations (for which she reported she had consulted with a psychologist). The WFIRS-P 
confirmed some early difficulties with grades, being bullied by her brothers and sister, but she was 
a quiet child and did not attract attention. It was as a teenager that she struggled most with 
motivation and staying in school. Despite inconsistent grades, she was accepted to a university 
program out of province, only to drop out because she could not keep up with the workload. Some 
time afterwards, she became a single mother and returned to CEGEP to study nursing, determined 
to establish a career that would enable her to care for her son. She never married and felt that the 
financial and emotional burden of single-parenting explained her inability to stop smoking despite 
using a patch. She had also never been able to quit smoking definitively despite the fact that as a 
nurse, she knew she had to. She was on the lightest dose of the patch (7 mg) when she began the 
study.  
   Participant C (JW). The third participant (50 years of age) was recruited by Participant B who 
worked intermittently as a research coordinator in a medical practice. She also did not have a 
diagnosis of ADHD. Her FTND score was eight (very highly dependent). She marked four of six 
items on the ASRS-6 as significant and her IVA+Plus scores were 66 for auditory sustained 
attention and 64 for visual sustained attention (both in the severely impaired range). On the WSR 
(ADHD subscale) she reported six symptoms for inattention and one symptom for 
hyperactivity/impulsivity. On the WFIRS-S scale, smoking was signalled as a major issue, as well 
as items in the life skills subscale relating to keeping up with household chores, avoiding exercise, 
problems managing money, and problems getting to bed. The WURS confirmed long standing 
issues with school (not achieving up to potential), stubbornness, restlessness and distractibility, 
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disorganisation and impulsivity. JW was normally a very heavy smoker, more than 30 cigarettes 
per day, and at one point in her life she had smoked up to two packs per day. She had tried over ten 
times to quit smoking using various methods but was never successful. She worked as a 
bookkeeper, was married for over twenty years and had two adult children, both of whom had been 
diagnosed as children with ADHD. Her mother had abandoned the family when she was a child 
and she and her brother had been adopted by another family. Although she reports having been a 
handful as an adolescent, the circumstances were such that she was never referred for an 
evaluation. When she was recruited for the study, she was proud of what she had accomplished for 
herself and her family, but was unhappy that she could not quit smoking. She had been prescribed 
starting a cessation program with the highest dosage of nicotine patch (24mg).   
   Participant D (MT). This participant (44) had been diagnosed with ADHD by a well-known 
ADHD researcher and psychiatrist as an adult in her thirties. She was highly dependent when she 
joined the study (FTND = 7) although in early adulthood she had smoked more heavily. Her 
ASRS-6 and ASRS-18 scores were both very elevated (6/6 and 18/18). Her CPT scores were 77 
for auditory sustained attention (mildly impaired range) and 90 for visual sustained attention 
(average range). On the WSR (ADHD subscale) she listed 7/9 inattentive symptoms, and 5/9 
hyperactivity/impulsivity symptoms. She also endorsed several anxiety symptoms, but when 
queried, she said they would come and go depending on the severity of the family’s financial 
stressors. The WFIRS-S indicated family problems, problems being late, life skills problems 
(managing money and getting ready to leave the house), and self-concept difficulties such as 
frustration and discouragement. She felt some of her stress and frustration could be alleviated if 
she could give up smoking. The WFIRS-P scale confirmed family impairment, school issues, life-
skills deficits and risky behaviours as a child and adolescent. At the time of her diagnosis 10 years 
prior, she had an alcohol problem and was unwilling to take medication. She joined AA and 
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stopped drinking, but was never able to quit smoking entirely, (although she did manage to stop 
smoking during her pregnancy). She worked as a dog groomer and had been married five years to 
a partner with five children of his own. They lived in the country and she described her situation as 
chronically stressful given the familial and financial problems they experienced. Her mother was a 
significant source of stability, helping her in the care of her biological child, sharing custody so he 
could attend school in town. She was using the medium dose patch (14 mg). 
Procedures 
   Participants were recruited by letters sent to medical offices and employee assistance programs 
in the West Island of Montreal. Given the bilingual characteristics of this area, all of the materials 
used in the study were prepared in both French and English, and the outcome measures were 
carefully chosen to be applicable to both languages. The letters presented the study and explained 
that the proposed treatment would supplement the use of a nicotine replacement therapy (NRT) for 
patients with ADHD who were struggling nonetheless to quit smoking. They were simply handed 
to interested individuals who then contacted the researcher. An initial telephone screening of 
nicotine dependence was performed using the Fagerström Test of Nicotine Dependence (FTND) 
(> 5), and attention problems were likewise screened using the ASRS v1.1 (at least four responses 
of sufficient severity to the first six questions). Additional inclusion factors were: being 18 years 
of age or older; being available for treatment; being able to freely provide informed consent to the 
study; and following an assessment, showing a sufficient number of ADHD symptoms as well as 
impairment in childhood (not due to other conditions) to potentially qualify for a diagnosis of 
ADHD. Seven individuals who met the screening criteria were invited to a first appointment at the 
investigator’s office in Pointe Claire. All the potential participants were told they would be 
assessed for ADHD symptoms. None expressed interest in a formal diagnosis as their primary 
concern was to improve smoking cessation. A consent form that explained the treatment in detail, 
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including potential risks and benefits, was reviewed with them and they were given information 
concerning the treatment. Six participants accepted to proceed with the evaluation portion of the 
study and signed the consent form. Each participant was further evaluated for adult ADHD 
symptoms using the CADDRA Assessment Toolkit (The Canadian Attention Deficit Hyperactivity 
Disorder Resource Alliance - CAAT; the Wender Utah Rating Scale; the IVA+Plus (CPT). The 
CAAT was chosen because it is a comprehensive toolkit that includes a number of scales that 
cover the areas recommended for evaluation in adult clients with attention difficulties (Epstein & 
Weiss, 2012). One potential participant withdrew at this stage due to uncertainty about quitting 
smoking. During a second appointment, each participant underwent a quantitative 
electroencephalogram. Of the five participants who completed this stage of the process, only four 
accepted to proceed with the treatment phase of the study. (The participant who withdrew at this 
point cited time constraints as her reason for leaving.) Two of the participants presented with 
formal diagnoses of ADHD according to the DSM-IV-TR; one had been diagnosed with ADHD- 
combined type and the other ADHD, predominantly inattentive type. The other two participants 
were not interested in obtaining a more formal diagnosis as they were both well established in their 
careers, but they understood their inclusion was based on exhibiting sufficient symptoms to 
potentially qualify for a diagnosis. Exclusion criteria included: current pharmacological treatment 
for ADHD; a neurological or diagnosed psychiatric condition; drug addiction; an excess, according 
to the quantitative electroencephalogram (qEEG), of beta waves in the area where they were to be 
enhanced; and previous neurofeedback treatment.  
   The first participant was given the choice of choosing the first baseline length. Afterwards, 
additional participants were assigned to a baseline. Participants were provided with the scales for 
the daily measures (CDS-12 and CWS-21) and given an appointment for their first neurofeedback 
treatment. They were instructed to begin the monitoring using the scales on the prescribed day 
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preceding the start of the intervention phase. One participant (VB) began the monitoring for the 
baseline phase later than intended although she had been the participant given the choice of 
baseline since she was the first participant recruited. She also put off beginning the treatment phase 
for a variety of minor reasons (e.g., having to work late and missing the appointment, forgetting to 
show up, etc.). As such, her baseline phase was extended from 12 to 20 days. Another participant 
(MT) delayed the start of the treatment by one day so her baseline phase was extended from six 
days to seven. The other two participants, CR and JW began the treatment phase as established and 
their baselines were eight and ten days as planned. (IVA+Plus measures were scheduled following 
every 3rd treatment although several were missed by participants (see Appendix 9). Ten weeks 
following the last treatment, the FTND was reprised and an evaluation of smoking abstinence was 
done. (See Appendices 10 and 11 for the consent form and the recruitment letter.) 
Ethical Considerations 
    Given that neurofeedback is not widely known as a therapeutic intervention, each participant 
was provided with a detailed description of the treatment and was shown the equipment to be used 
during the first meeting with the investigator (see Appendix 12). The main purpose of the qEEG 
was to prevent having participants for whom the proposed protocol might be iatrogenic, i.e. those 
who would already have an excess of SMR waves, when compared to a normative database, at C3 
and/or C4. The results of the qEEGs were verified by an expert in qEEG analysis, Dr. Johanne 
Lévesque. The reports to date from neurofeedback practitioners suggest that undesirable side-
effects are rare and when they occur, they disappear quickly (Sherlin et al., 2010). The main 
recommendation from leaders of the field is to ensure that a qEEG is done in order to minimize the 
risk of an ineffectual treatment (Hammond & Kirk, 2007). In addition, the design of the protocol 
necessarily took into consideration the need of participants to get on with the proposed treatment. 
Finding participants who met the inclusion criteria was not as rapid as anticipated and ultimately a 
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significant period of time elapsed between each successful recruitment. As such, a non-concurrent 
multiple baseline design was used so that participants did not have to wait unduly before beginning 
the neurofeedback. 
Treatment 
   The betaSMR protocol used for this study is based on the attention protocol used in the Scott-
Kaiser modification of the Peniston protocol, inhibiting 4-9 hz activity at C3/4-7 hz at C4, and 
enhancing 15-18 hz at C3/12-15 hz at C4. This protocol was developed and used extensively by 
the pioneer neurotherapists Susan and Siegfried Othmer who promoted bi-hemispheric 
applications of neurofeedback (Kaiser & Othmer, 2000). The participants for this study were asked 
to attend one hour training sessions three times per week at the office in Pointe Claire. Care was 
taken to schedule sessions during the same period of the day in order to ensure comparable training 
results during the study. The initial part of the hour was used to attach electrodes to the scalp at C3 
and C4 using a mild skin preparation product (Nuprep) and Ten20 conductive paste. A reference 
electrode and a ground electrode on each earlobe were also secured. The electrodes were then 
plugged into a Procomp Infiniti amplifier from Thought Technology. The amplified signal from 
the brain was then transmitted to a computer which, using the Biograph Infiniti program (v.5.1.2) 
from Thought Technology, processed the signal and provided feedback to the user on the 
fluctuations occurring in their brainwaves. Feedback was both auditory and visual. In this case, 
participants chose from a selection of short audio visual interleave files and music. When they met 
the criteria established by the protocol and produced the desired brainwaves, the visual file 
advanced and music played. If the selected brainwave patterns were not present, the visual file 
stopped and the auditory feedback stopped as well. 
   The participants were provided twenty minutes of two-channel simultaneous bi-hemispheric 
biofeedback per session (4 x 5 minute training periods with breaks in between). They were 
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instructed to simply observe the feedback initially in order to engage without exerting undue 
effort. Eventually, they were told to see if they could learn to gradually change the feedback at will 
by associating changes in the signal with alterations in their breathing, attitudes, and thoughts.  In 
this way a person can experiment with different ways to regulate the electrical activity of their 
brain. By concentrating to inhibit excessive slow waves and augment the desired fast waves, 
attention is trained to improve. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results
 
 
 
  This study is the first to consider the efficacy of neurofeedback as a treatment to manage 
withdrawal symptoms and reduce cigarette dependence through its effects on attention in 
individuals with ADHD. Single subject analysis is beneficial under such circumstances because it 
provides a closer examination of individual performance, essential for evaluating potential changes 
in each subject. Each participant serves as their own control, allowing for a close inspection of any 
change from the baseline to the treatment phase. The treatment phase ended when each participant 
had improved their IVA+Plus sustained attention scores to the average level (See Appendix 9). 
MT began the treatment with one of her IVA+Plus scores already in the average, but it was 
decided to try to achieve average scores in both modalities. One participant (JW) did not reach that 
goal but having completed 12 sessions of neurofeedback and having substantially improved her 
attention scores, her data was included in the analysis. Finally, VB only managed to meet the goal 
for her sustained auditory attention, although her sustained visual attention improved significantly 
as well. 
   The data points for the CDS-12 representing the two phases for each participant were plotted into 
a series of graphs which were then inspected to discern changes in level, trend or slope and 
variability as a result of the intervention. Because of a high level of variability in some of the data 
points, a new series of graphs was generated using the CDS-5. The Single Case Visual Analysis 
(SCVA) package developed by Bulté and Onghena (2012) was used to generate the graphs, which 
were then made equivalent in terms of scale to provide for visual comparability. The SCVA, is 
available at the developers’ website, ppw.kuleuven.be/english/research/mesrg and was developed 
to aid in the visual analysis of single case data through the utilisation of central location and trend 
lines. Parker and Vannest (2012) recommend that visual inspection precede further analysis in 
order to enable the investigator to make valid decisions concerning the data to be analysed and the 
statistical method to choose to complete the analysis. 
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Visual Analysis 
   The changes in the mean from the baseline to the intervention phase in the graphs for the CDS-5 
appear to suggest a positive treatment effect for three of the four participants (VB, RC, and JW), 
indicating decreased dependency as measured by the CDS-5 (see Figure 1). For MT, there was a 
slight increase in the mean from the baseline phase to the intervention phase. A horizontal 
  
Figure 1. CDS-5 Mean 
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reference line is included by the SCVA package to assist in the visual inspection of the measure of 
central location. Upon visual inspection of the CDS-5 data points, it appears that the baseline data 
were not stable for all of the participants. Although it is preferable that baselines be stable for 
analysis of multiple baseline studies, it is not always possible in a clinical setting. Robust linear 
trend lines were generated to further assist the visual analysis in this case (see Figure 2).  
 
Figure 2. CDS-5 Trend 
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All but one of the participants (JW) had decreasing trends in the desired direction of the treatment 
effect in the early part of the baseline, followed by an increase (VB and MT) or a stabilisation 
(RC) of the trend in the latter half of the baseline. The heaviest smoker (JW) exhibited an 
increasing trend in the opposite direction of the treatment effect from the outset during the baseline 
phase. Baseline trends in the opposite direction of the desired treatment effect do not invalidate 
conclusions of a positive outcome should there be one. 
   The graphs depicting the intervention phases of the study also show a divergence between JW’s 
results and those of the remaining three participants. Her trend line does not decrease during the 
intervention phase, although it stabilises in the second portion of the intervention. It is important to 
note however that she showed the greatest step diminution of dependence at the beginning of the 
treatment, as well as a shift in the slope of the trend line during the intervention phase as compared 
to the baseline. Although her trend line in the intervention phase is initially increasing, it 
eventually stabilises as a flat line. Given that neurofeedback is a gradual process, other factors are 
likely responsible for the step change, but the eventual flattening of the slope at a lower level than 
during the baseline can be considered a treatment effect. 
   The other three participants (VB, RC and MT) all show overall decreasing trends in the 
intervention phase. Participant VB had a decreasing trendline beginning several days into the 
treatment. This is consistent with the purported effects of neurofeedback which, unlike medication, 
produces subtle and gradual changes in neuronal networks over time. Two participants (RC and 
MT) did not show a diminishing trend at the outset of the treatment, but both exhibit decreasing 
trendlines in the later days of the intervention phase. They also had the greatest variability in terms 
of their measures of dependence. The overall step change for RC is apparent, but it is not so for 
MT, visible in the slight increase in her mean scores from the baseline to the intervention phase. 
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    Visual inspection of the CWS-21 data which measures withdrawal symptoms as an aggregate, 
showed the following results. Differences in level between the phases appear to be minor for all 
participants but MT (who had a larger decrease in overall withdrawal symptoms), although VB 
also exhibited a decrease (see Figure 3). (Recall that MT was the only participant who showed a 
minor increase in her dependency scores as measured by the CDS-5).  
 
Figure 3. CWS-21 Mean 
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As for trend (see Figure 4), both JW and MT reported overall decreases in withdrawal symptoms 
during the baseline phases. These trends were reversed (for MT the reversal began in the latter part 
of the baseline) and became an increasing trend which continued during the initial part of the 
treatment phase, only to once again reverse to indicate a decrease in withdrawal symptoms in the 
latter part of the treatment phase. (Both JW and MT were much heavier smokers than VB and RC.)  
 
Figure 4.  CWS-21Trend 
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 Participant RC had a temporary increase in withdrawal symptoms when the neurofeedback 
treatment was initiated. There was however no appreciable difference from the baseline phase to 
the latter part of the treatment phase in RC’s CWS-21 data. VB’s trend line graph was more 
difficult to interpret visually. She reported increases in withdrawal symptoms during the baseline, 
but the variability of the data points in the neurofeedback phase made it unclear as to whether there 
was an overall decrease. 
  It is helpful in situations where the visual analysis is ambiguous to have access to statistical 
methods to interpret the data. The Tau-U analysis that follows quantifies the tendencies described 
above. It is especially useful in cases, as this one, when the data is highly variable, and the baseline 
is not stable and so was the ideal choice for further analysis of the results/ 
 Tau-U Analysis 
      The Tau-U is a non-parametric method that can be used to measure the effectiveness of 
treatment by considering the percentage of data points during the intervention phase that do not 
overlap (PND) with the baseline data points, an idea similar to that of an ROC analysis (Parker, 
Vannest, Davis, & Sauber, 2011). Normally, PND analysis, which is insensitive to trend, is not 
useful when there is an undesirable trend in the baseline phase. For two participants (RC and VB), 
there appears to be somewhat of a trend (albeit one that reversed or stabilised) matching the 
direction of the desired treatment effect for the CDS-5.The other two participants (JW and MT) 
also exhibit trends in the baseline but in the opposite direction of the desired treatment effect, 
which is less of a challenge to the interpretation of a positive treatment effects. For the CWS-21, 
undesirable baseline trends appear in the data for JW and MT. In order to address these issues, this 
study used the Tau-U method to analyse the data. Named after its parents Kendall’s Tau and 
Mann-Whitney U, Tau-U can control for a baseline trend, resulting in an index which interprets 
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the percent of data that improve over time in any profile, not only in a straight line (Parker & 
Vannest, 2009 ). The method also provides a p-value and Z scores (see Table 1). 
 
Table 1  Results of the CDS-5 and CWS-21 Tau-U Analyses for Baseline Trend 
______________________________________________________________________________  
Participants   Baseline     Baseline  
Tau-U  CDS-5     Tau-U  CWS-21     
______________________________________________________________________________  
VB   -.0789      .3263  
RC   -.7111     .11  
JW     .3571     -.50   
MT   -.381     -.4286 
 
(Tau-U > 40% indicates a significant trend) 
 
   The first step of the statistical analysis was to assess whether the undesirable baseline trends 
were significant. To establish which baselines required an adjustment, a web-based Tau-U 
calculator was used (Vannest, Parker, & Gonen, 2011). Parker has recommended that Phase A 
datasets with > .40 should be selected for baseline control (Parker et al., 2011). Only one of the 
baselines (RC = 71%) exceeded .40 for the CDS-5 data. For the CWS, two deteriorating baselines 
were identified, JW and MT (Table 1). For JW, the Tau-U was 50%, and for MT it was 42%. 
    The calculator was then used to compare each baseline phase to its corresponding intervention 
phase to provide an individual effect size for the CDS-5 (after correction of the baseline for 
Participant RC). The results are summarized in Table 2 which includes Z scores and p-values.   
Three participants registered decreases in dependency as measured by the CD-5 (VB = -74%, 
RC= -63%; JW = -72%). The only participant not experiencing at least a moderate treatment 
effect as measured by the CDS-5 was MT (-8%). 
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Table 2   Comparison Results of the Tau-U Analyses for CDS-5 (Phase A vs Phase B) 
______________________________________________________________________________  
Participants       A (baseline) versus B         
Tau-U      p-value  Z-score   
   
______________________________________________________________________________  
VB   -.7361     .000    -4.5314  
RC   -.6325* (.71)  .0022* (.0005) -3.0681* (-3.46) 
JW    -.7232     .0021     -3.0821   
MT   -.0779     .7487      0.32040  
 
 
(Tau-U > 40% indicates a significant trend) 
*indicates a comparison with a corrected baseline 
 (Italics indicate the Tau-U analysis with the alternate baseline results for those participants with 
baseline trends that are significant.)  
 
Individual effect sizes were then grouped to provide an overall effect size for the study. A 
weighted average of all four participants was found to be Tau-U -.5346 with an overall Z score of -
5.9614, a confidence interval of -.3587 to -.7106 at 90% and a p-value of 0. 
   The Tau-U analysis of the aggregate CWS-21 scores was conducted in the same fashion. The 
baselines for JW and MT were corrected (see Table 1), then phase A was compared to phase B for 
each of the participants (see Table 3).  
 
Table 3   Comparison Results of the Tau-U Analyses for CWS-21 (Phase A vs Phase B) 
______________________________________________________________________________  
Participants      A (baseline) versus B         
Tau-U      p-value  Z-score   
   
______________________________________________________________________________  
VB   -.444      .0071   -2.6932  
CR   -.0525    .799     -0.2547 
JW     .0759*(.0134) .7464* (.9545)  0.3234*(.0571) 
MT   -.71* (-.7489)  .0035* (.0021) -2.9188* (-3.079) 
 
 
(Tau-U > 40% indicates a significant trend) 
*indicates a comparison with a corrected baseline 
(Italics indicate the Tau-U analysis with the alternate baseline results for those participants with 
baseline trends that are significant.) 
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A very modest diminution of withdrawal symptoms was recorded for VB (-44%), and a more 
significant improvement in symptoms occurred for MT (-71%). The CWS-21 weighted average 
was found to be Tau-U -.2797 with an overall Z score of -2.611, p-value = .0090, and a confidence 
interval of -.1035 to -.4559 at 90%.  
   The CWS-21 was composed of six subscales of symptoms: depression-anxiety; craving; 
irritability-impatience; difficulty concentrating; appetite-weight; insomnia. Each baseline was 
verified for trend followed by a comparison of Phase A to Phase B (see Table 4). In terms of the 
baseline trends, VB showed a modest increase in depressive symptoms during the baseline (45%). 
JW and MT had the same increase in depressive symptoms during the baseline (52%). MT also 
had significant decreases in craving and irritability during the baseline phase, whereas JW had an 
overall decrease in sleeping problems (48%).  
   After the baseline correction, the comparison of the baseline phase to the neurofeedback 
intervention phase for the CWS-21 subscales revealed no consistent patterns but for one 
participant. Despite no real change in her CDS-5 scores, the CWS subscales for MT showed 
significant decreases in certain withdrawal symptoms (craving = -72%; concentration = -85%; 
appetite = -79%). Only craving appeared to respond to the treatment for more than one participant 
(VB and MT). Both of these participants had higher levels of ADHD symptoms. The only other 
change was a decrease in the depression-anxiety scale for VB. The participants with a lesser 
number of reported ADHD symptoms (CR and JW) had no real change in terms of their 
withdrawal symptoms, although JW (the heaviest smoker) did show a tendency to report slightly 
more symptoms. No participant however exhibited any increase of significance in their withdrawal 
symptoms as measured by this scale. 
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Table 4  Results of the Tau-U Analyses for CWS-21 Subscales (Baseline and Comparison) 
______________________________________________________________________________ 
Subscale   A (baseline)  A versus B        
    Tau-U     Tau-U  p-value Z-score 
       
 
Depression-anxiety     
 VB    .4474  -.4543* .0054*  -2.7819* 
 CR    .1778   .32  .1206    1.5522 
 JW   -.5238   .2092* .3979*    0.8454* 
 MT   -.5238  -.2424* .3189*    - .9967* 
Craving 
VB    .2053  -.5443  .0009   -3.331  
 CR    .0667  -.185  .3695   -0.8974 
 JW    .0476   .2806  .2568    1.1341 
 MT   -.8947  -.7229* .003*   -2.9722*  
 
Irritability-impatience 
VB     .0737  -.02   .9025   -0.1225 
 CR   -.2444  -.13   .5283   -0.6306 
 JW   -.1905   .0714   .7728     0 .2887  
 MT   -.5714  -.3506* .1494*   -1.441* 
 
Difficulty concentrating 
VB   -.1105   .03  .8542    0.1837 
 CR   -.0222    0  1    0   
 JW   -.1429   .1378  .5567    0.5777 
 MT   -.1481  -.8462  .0007  -3.3908  
 
Appetite-weight gain 
VB     .2579   .05  .7621   0.3028 
 CR   -.1556  -.3532  .0991   -1.6492 
 JW     0   .1786  .4705  -0.7217 
 MT   -.0952  -.7922  .0011  -3.257   
 
Insomnia      
VB     .0684  -.16  .3272   -0.9798   
 CR    .2444  -.12  .5605   -0.5821  
 JW   -.4762   .148*  .5499*    0.598* 
 MT    .1429   .1039  .6693    0.4271   
 
*indicates a comparison with a corrected baseline  
  Bolded figures indicate significant trends 
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   To evaluate abstinence, the FDA recommends a four week period of complete abstinence to 
establish the efficacy of a smoking cessation treatment (Hughes et al., 2003). Only one participant, 
CR, achieved such a level of abstinence at the time of the follow-up. Two others continued to 
smoke albeit fewer cigarettes per day than prior to the study (VB and RM) and with a reduced 
dependency as measured by the FTND. One participant did not respond to the subsequent follow-
up (JW). The ten week follow-up with the FTND (which was originally required to be > 5 
indicating moderate or more heavy dependence) was as follows: VB= 2; CR= 0; MT= 3 indicated 
a change to very low, zero and low dependence. (For original FTND scores, see Appendix 8). The 
significant change in the final FTND scores corroborates the trend of the changes in the CDS-5 
reports.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion
 
 
 
    Neurofeedback is learning – learning that is based on operant conditioning principles using a 
biofeedback to become aware of brainwaves that normally are not accessible, and therefore not 
usually amenable, to being shaped purposefully (Arns, Heinrich & Strehl, 2013). Like most 
shaping, this is a gradual process, requiring many repetitions before producing more enduring 
change. “Each time the designated event occurs, the instrumentation provides a signal indicating 
this to the trainee. If the signal is perceived as desirable, then the brain will spontaneously learn to 
achieve the state that leads to the signal, over a long number of trials.” (Collura, 2014, p. 16). 
Although some sensitive individuals can very quickly become aware of what is happening, 
evidence of a shift is usually apparent only after a delay. As in all learning processes, the time 
required is a very individual matter and can vary to some extent, but clinical reports reveal that 
betaSMR protocols on average show some results in as little as eight sessions (Vernon et al., 
2003) although it can take many more to anchor the new learning. Scott et al. (2005) reported an 
average of 13 sessions in the original Scott-Kaiser study before normalisation of attention scores 
in their study, composed of individuals in a treatment program for mixed substance abuse. 
Similarly, one would expect that it is not when the treatment was introduced in this study that 
benefits would appear.  
   Three of the participants (CR, VB & MT) had decreasing dependency score trends at the outset 
of the study during the initial portion of the pre-intervention phase (Phase A), whereas one 
participant (JW) appeared to increase her dependency during the baseline phase. Normally, a 
decreasing baseline would present a challenge to any conclusion that there was a treatment effect. 
It was possible with the use of the Tau-U analysis, to account for the decreasing trends across the 
baseline when taken as a whole and nonetheless conclude with confidence that there were 
moderate effects at play in this study that supported the hypothesis. A closer analysis of the trends 
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within each phase of each case study suggests even stronger support that neurofeedback 
diminished dependence on nicotine for the participants trying to quit smoking. 
   Examining the initial and latter sections of each single case (see the regression trend lines in 
Figure 2) reveals that the three decreasing trends were either reversed or flattened just prior to the 
introduction of the treatment during Phase B. Whatever factors produced the initial decrease in the 
dependence scores appeared to no longer exert influence on the scores as time went on. Then, 
following the start of the neurofeedback training (Phase B), two of the participants (CR & JW) 
exhibited increasing trends in terms of their dependency scores for the first half of the intervention. 
The other two (VB & MT) had either a decreasing trend, (which in the case of VB was a reversal 
of the end of the baseline trend), or a flat trend (MT). Again, an examination of the regression 
trend lines in the latter half of the intervention phase would suggest that all the participants were 
ultimately responding to the intervention. Three participants (CR, VB & MT) showed decreasing 
trends in terms of their dependency scores as measured by the CDS-5 and one subject (JW) 
showed a flat trend at a lower level of dependency than during the baseline phase. As stated, 
neurofeedback should exert a gradual influence on behaviour. The fact that all of the participants 
showed decreasing or lower dependency trends in the latter half of the intervention phase would 
suggest that these results were potentially due to the betaSMR training they obtained. 
     As in previous research looking at nicotine dependency in this particular population, the 
combined results, including the withdrawal subscales, point to the complex interplay of 
psychological and physiological factors that can affect smoking behaviour and perceptions of 
dependency on the part of the participants. An examination of each single case individually will 
exhibit in greater detail how some of these additional elements (such as severity of dependence, 
hyperactivity/impulsivity symptoms, psychological and psychosocial factors, and the choice of a 
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quit date) may have had an impact on the results. Potential explanations looking at the mechanisms 
underlying these elements will ensue. 
Self-Efficacy, Severity of ADHD and Nicotine Dependence within the Single Cases 
   Participant A (VB) was the first participant to join the study. Initially, fixed baseline lengths had 
been worked into the design of the study in order to randomise participants to a particular baseline 
and thereby benefit from more traditional statistical methods of analysis. VB as the first participant 
was given the choice of the first baseline length, and all other participants were to be randomly 
allotted to their baselines as they subsequently joined the study. This plan was revised when VB 
instituted several delays to the start of Phase A. She ultimately began only after two other 
participants had already started. This was the first clue that although she had stated she was 
determined to continue her efforts to quit smoking when recruited, VB’s resolve perhaps wavered. 
She might have viewed the start of Phase A as a potential new quit date and at the last instance was 
hesitant to commit. The willingness to quit is regarded as insufficient as people often fail to act on 
their intentions (de Vries, Eggers & Bolman, 2013). A quit date signals a shift from an intention or 
willingness to quit to the enactment of a plan to quit. It can therefore have a significant impact on 
behaviour change in smoking cessation. Once VB had set a quit date (the decision to begin 
completing the scales), she began to reduce her smoking even though nothing had as yet changed. 
This is one possible explanation for the descending trend lines in the CDS-5 during the baseline 
phases of the study, not only for VB, but for two other participants as well (CR and MT). 
(Although the study design called for a target date to begin each phase, these dates were never 
intended as potential quit dates given that all of the participants were already involved in a 
smoking cessation treatment with a nicotine patch, albeit a non-successful one.) 
   Even after having started Phase A, VB then delayed the beginning of the treatment resulting in a 
longer baseline phase then initially intended. She was very unsure of her capacity to quit even with 
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the added treatment. This could be interpreted as a sign of a lack of self-efficacy. A lack of 
confidence in her ability to reduce her dependence is suggested by her consistently high ratings on 
the first question of the CDS-12, “rate your level of addiction to cigarettes” during both phases of 
the study. She gave herself the highest possible score (5 = extremely addicted) regardless of any 
other changes that occurred. For example, VB eventually smoked fewer cigarettes per day than 
anyone else and began reporting a significant delay the first cigarette of the day (strong indicators 
of weakening physiological dependency). High self-efficacy and self-confidence in one’s ability to 
quit predict actual quitting (Etter, Bergman, Humair, & Pernegger, 2000).  
   Another possible explanation for the descending baseline trend is the impact of the self-
monitoring inherent in the completion of the scales. A daily measure of their smoking behaviour 
and the impact on their well-being and health may have produced a renewal of their efforts to quit 
and possibly even a more consistent use of the patch during this period. (Not all of the participants 
appeared to have viewed the start of Phase A as a “new” quit date. JW actually increased the 
number of daily cigarettes smoked right up to the start of the intervention phase resulting in a 
steady increase in dependency scores, followed by a significant step change the day the 
intervention began.)  
   VB was one of the two participants who entered the study with an established diagnosis of 
ADHD and she reported more hyperactive/impulsive symptoms as well (see Appendix 8). Her 
initial IVA+Plus scores were unusually low but may have been influenced by excessive caution on 
her part when responding to the prompts during the first trial of the CPT (she said she was worried 
about not doing well). The opening evaluation in the study revealed she was plagued from time to 
time with insomnia, anxiety and mood swings, and had struggled with possible learning 
difficulties, which is par for the course for some individuals with ADHD. At the start of the 
baseline phase, her depression/anxiety scores on the withdrawal scale increased, then, as the 
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treatment was initiated, the trend reversed and they decreased significantly albeit moderately  -
despite leaving her job just near the end of the treatment due to increased conflict with her boss. 
Depressive symptoms have also been linked both with ADHD status and with smoking relapse, 
both prior to and following a cessation attempt (Etter, 2005). The question which must remain 
unanswered is whether or not VB struggled with these issues in the period just prior to joining the 
study and what impact (or not) her participation in the treatment had on her self-efficacy and 
depressive mood, and eventually on her capacity to become abstinent. 
   Participant B (CR), by contrast, was very motivated to begin as quickly as possible. In her case, 
the baseline was shortened in order to respect her schedule. While doing the neuropsychological 
tests that accompanied the initial assessment, CR exhibited confidence during several of them.  
Interestingly, although her attention scores as measured by the IVA+ Plus improved throughout, 
she did not report any change in her concentration level (as measured by a self-report subscale of 
the CWS-21) from the baseline phase to the treatment phase (in contrast to her assessment and to 
her CPT scores). Perhaps this discrepancy is explained by the fact that this participant was the only 
one to report using mnemonic strategies when evaluated with the Brown Peterson Trigram. Such 
techniques reveal her efforts to overcome her childhood and adolescent difficulties in attention.  
In addition, she revealed that she had pursued psychotherapy on several occasions to help her work 
on her emotional and family problems. So although CR was the participant with the greatest 
number of reported co-morbid symptoms at the outset of the study, she had achieved professional 
stability and was confident in her skills and competency as a nurse. She was also the participant 
who had the least reported ADHD hyperactivity/impulsivity symptoms and the lowest levels of 
nicotine dependency. Severity of dependence and level of ADHD symptoms have been shown to 
have an impact on smoking cessation. It was found that participants with ADHD-Inattentive 
subtype were more likely to achieve abstinence with a placebo than with medication as an adjunct 
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treatment to the nicotine patch (Covey et al., 2011). CR was the only participant to report having 
successfully quit smoking at the 10-week follow-up after terminating treatment.  
   MT not only reported a higher level of dependence initially (FTND = 7), she also indicated the 
most ADHD symptoms on the ASRS-18 (18 of 18) and a number of current stressors on the 
functional assessment. Consistent with the findings of persistence of ADHD symptoms into 
adulthood, there was significant impairment throughout her life span. Severity of ADHD 
symptoms has been shown in similar studies such as this one to alter the efficacy of the treatment. 
When smokers were treated with OROS methylphenidate and a nicotine patch, only those with 
more severe symptoms of ADHD eventually benefitted from the treatment (Nunes et al., 2013). 
Smokers with less symptoms of ADHD were actually hindered by the medication in their attempts 
to quit in this analysis. MT finished the study with a significant improvement in both her CDS-5 
scores and the final FTND score, which corresponds with the findings reported above concerning 
heavier ADHD symptoms. In this study however, even participants with less ADHD symptoms 
found the treatment beneficial.  
  When recruited, MT had been using the patch inconsistently (due to financial strain). In order to 
participate in the study, she committed to stabilizing her patch usage while enrolled, but it is 
possible her use of the patch prior to the start of the study had an impact on her cigarette use and 
withdrawal symptoms during the study, even though the treatment was not totally new to her. The 
decreasing trend in terms of withdrawal symptoms eventually stabilized and even increased briefly 
as the study progressed, eventually decreasing again with no change in patch usage. It should be 
mentioned that this participant was experiencing the greatest level of psychosocial stress during 
the study. She had been waiting several months for an operation for carpal tunnel syndrome. She 
was called halfway through the intervention phase, and although she did not miss any training 
because the operation was an outpatient intervention, she had to book off work. This caused the 
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family significant financial pressure. Then, upon her return to work, MT was told her position was 
to be abolished at the end of the season. It is very possible that these additional stressors stymied 
her eventual abstinence although as can be seen in a visual inspection of the trends, she ultimately 
did appear to benefit from the treatment (in addition to her own verbal report) before meeting the 
stop condition for the study (normalisation of IVA+Plus score).  
    The other heavy smoker of the participants, JW, did not meet the condition for stopping the 
treatment and although she dropped out of the study before meeting the stop criteria, there was 
sufficient data to include her in the analysis. In her case, the decreasing withdrawal symptoms 
during the baseline phase appear to be related to an increase in smoking prior to Phase B (see 
CDS-5 results in Table 3 for this participant). As previously mentioned, once the treatment began, 
there was a significant step change in her dependency scores which were not likely due to the 
neurofeedback treatment given the gradual effect of the training, although the stabilisation of her 
scores in the latter half of the intervention phase could most likely be attributed to the effects of the 
betaSMR protocol. JW’s sustained attention scores never normalised, but they improved 
dramatically from 66 to 73 (standard scores) for sustained auditory attention, and from 64 to 83 for 
sustained visual attention. It is perhaps noteworthy that although JW did not report current 
hyperactive/impulsive symptoms during the intake process, she did report having such difficulties 
as a teenager. The higher levels of symptoms earlier on in life may have ultimately contributed to a 
higher level of dependency on nicotine for this participant. It should also be mentioned that JW 
suffered from bouts of arthritis pain and had several episodes during the study. This may also have 
been a factor in her significant dependency on nicotine. 
Craving and Hyperactivity/Impulsivity versus Attention 
   In terms of the withdrawal symptoms that were examined, there were no replications of 
significant changes across all the participants for the six subcategories included. The only potential 
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pattern of note was the significant reduction in craving for the two participants (VB = -54%; MT = 
-72%) who entered the study with higher levels of ADHD hyperactivity/impulsivity symptoms. 
Craving is a particularly important aspect of the withdrawal syndrome as cigarette craving can 
significantly contribute to relapse during cessation attempt, particularly for clients with ADHD 
(Canterbury et al., 2013; Etter, 2005). Although some investigations have suggested medication 
for ADHD can reduce craving in a smoking cessation context, further analysis has revealed that 
there is an overlap between ADHD symptoms and withdrawal symptoms. Once ADHD symptoms 
are controlled for, only craving as a withdrawal symptom is not reduced by medication (Berlin et 
al., 2011). For individuals with more pernicious ADHD for whom cigarette cessation can be more 
of a challenge that other people, a treatment that addresses their craving while decreasing ADHD 
symptoms could be especially helpful. MT, who was the participant with the greatest impact of 
ADHD symptoms on her functioning by far, seemed to benefit the greatest from the treatment in 
terms of the impact on withdrawal symptoms (see Table 4). Finally, there is some evidence 
showing that women with ADHD in particular experience an increase in craving with abstinence 
(McClernon et al., 2011). 
   A possible explanation for the effect on craving of the treatment used in this study, especially for 
those with higher scores on the ASRS-18 scale, comes from recent work with real-time fMRI 
(rtfMRI) neurofeedback and smoking. These investigations use the blood oxygenation level-
dependent (BOLD) response to modulate neural activity fed back to them by the rftMRI (Hartwell 
et al., 2013). It was found that when non-ADHD smokers were exposed to videos designed to elicit 
craving, they exhibited an increase in brain areas associated with attention and motor planning 
(Smolka et al, 2006), as well as a decrease in deactivation of part of the default-mode network 
(Claus et al., 2013). The authors concluded that these smokers had an attentional bias toward 
smoking cues and were potentially more engaged in a self-referential process that monitored 
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somatic sensations intensifying craving, triggering an automated response to cigarettes by an 
increased engagement of sensorimotor and motor preparation circuits. Others have speculated that 
this relationship is amplified in individuals with ADHD, explaining that as the severity of 
symptoms increases, craving is intensified (McClernon, 2009). Although the betaSMR protocol 
has often been shown as more effective in improving attention, with lesser effects on hyperactivity, 
theoretically it acts upon the sensorimotor cortex therefore it should have an impact on adult 
hyperactivity/impulsivity symptoms that are ultimately modified as attentional biases are 
modulated. This research is especially relevant given that the betaSMR neurofeedback protocol 
utilised in this study has been shown to act upon the default mode network in participants with 
ADHD (Russell-Chapin et al., 2013). 
Role of the NRT 
   The literature on neurofeedback and substance use disorders unequivocally states that 
neurofeedback is not a stand-alone treatment for addiction (Sokhadze, Cannon & Trudeau, 2008). 
Of course, most of this work has been done on populations with primary addictions other than 
cigarettes, and therefore involves co-morbidities such as depression and conduct disorder or 
personality disorders that are not necessarily implicated in cigarette smoking. The brain and EEG 
alterations that result from the use of substances such as cocaine and alcohol further complicate 
neurofeedback applications with these disorders. But it is known that smokers also have alterations 
in the brain such as reduced gray matter volume in pre-frontal cortical areas and different 
distributions of nicotinic receptors (McClernon, 2009). Pre-existing ADHD symptoms that are 
often associated with stimulant preference in choice of drug might further predict that 
neurofeedback alone would be ineffective in dealing with the dependence and withdrawal 
syndrome as well as the underlying condition. These considerations led to the choice to offer 
neurofeedback as an additional intervention to people already using nicotine replacement treatment 
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unsuccessfully rather than offer neurofeedback alone. That being said, the additional variable of 
nicotine delivered by a patch would have inevitably had an impact on the dependence and 
withdrawal symptoms being observed.   
   Studies that have tracked withdrawal symptoms in general populations who successfully quit 
smoking reveal a peak within a few days of abstinence, followed by an eventual decrease of 
withdrawal symptoms (Dawkins, Powell, Pickering, Powell, & West, 2009). A disruption in 
concentration and other factors within the CWS-21 was therefore to be expected as dependency 
scores decreased. There is a great deal of research confirming the disruption of attention in ADHD 
(and non-ADHD) smokers when they refrain from smoking (McClernon & Kollins, 2008). This 
was not observed consistently in the self-reported data across the participants. The presence of the 
NRT most likely played a role in cushioning participants from a worsening of some withdrawal 
symptoms, even as dependency scores diminished, but one would have expected greater 
difficulties for the heavier smokers, as well as for those with more severe ADHD symptoms. In 
addition, although the measure of sustained attention eventually increased for all of the participants 
in this study, (even partially normalising for three of the participants), there was no consistent 
pattern that was discernible as treatment progressed (see Appendix 9), particularly for the heaviest 
smokers (JW & MT). It appears that attention as measured by the sustained attention index of the 
IVA+Plus was affected by something other than the intervention. (A practice effect would have 
produced consistently increasing scores as well.) There is even some indication that an excess of 
nicotine can interfere with this form of attention. Did the NRT become excessive as the nicotine 
intake through smoking decreased and as the neurofeedback treatment became effective? One 
study reported that individuals with ADHD with higher levels of attentiveness showed a nicotine-
induced decrement on measures of sustained attention (Poltavski & Petros, 2006).   
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   Of course, the aim of the study was not to correlate discrete changes in attention with the 
moment to moment changes in nicotine dependence. Such an objective would have required very 
sophisticated measures of both nicotine and attention as well as very tight controls of the intake of 
nicotine, something that was not included in the design of this small study which left the usage of 
the patch in the hands of the participants and their medical practitioners (although no changes were 
reported for the duration of the treatment). The measure of attention was used primarily to identify 
a termination point for the treatment. The NRT was necessary as an adjunct treatment for ethical 
reasons, but it remains as a confounding element in the interpretation of the observed results. 
   Ultimately, the purpose of this project was to explore the usefulness of neurofeedback in a 
smoking cessation context for clinical work. To that end, this study suggests that neurofeedback 
could potentially reduce tobacco usage in a vulnerable population. Futhermore, the non-
exacerbation of potential side-effects is a significant benefit. The main drawback is the time 
commitment that is required to achieve lasting results. This difficulty can be attenuated in several 
ways. Although the design and supervision of the training should be carried out by a licensed 
practitioner, the actual training is a relatively straightforward procedure and can be taught to 
family members or the trainee themselves in order that they continue supervised training at home. 
Neurofeedback can also be combined with any number of treatments such as medication, hypnosis, 
psychoeducation and psychotherapy (Soutar & Longo, 2011).  
Limitations  
   Although single case research is gaining ground in terms of its usefulness in clinical settings, 
especially as analysis methods are refined, results must nonetheless be interpreted with caution 
and generalizing to other settings should be avoided.  In addition, the assumption that the people 
recruited were sufficiently alike in order to compare treatment effects across participants was 
especially not clear in this case given the heterogeneity of the clinical presentations of ADHD, a 
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difficulty inherent to ADHD research. Participants had varying levels of inattention and 
impulsivity. The measures of smoking dependence also produced unexpected variability within 
both phases, although variability was decreased with the use of the CDS-5. It would have been 
preferable that the baselines of Phase A be more stable before the introduction of the treatment 
although the utilisation of the Tau-U permitted that factor to be diminished. The Tau-U is, 
however, a relatively new method of analysing single case research and it remains to be seen if 
the method for controlling baseline trend will be accepted and if the effect sizes it produces will 
be in line with the effect sizes of other more established statistical methods. 
   There are several EEG profiles that are associated with the strengths and deficits of ADHD. It 
appears therefore unlikely that a single standard neurofeedback protocol, even SMR training, 
would be the ideal approach to addressing underlying brain anomalies in order to improve target 
behaviours. Although for research purposes, standardised protocols are used to provide more 
control of variables within a study, studies that have matched the brain profile to the 
neurofeedback protocol appear to have had greater success with larger effect sizes reported 
(Monastra et al., 2002; Arns et al., 2012b). This study did assess participants with a 19-channel 
qEEG, but only to ensure that there were no focal anomalies or contraindications to the protocol 
being used. In addition, participants were not reassessed at the end of the study. The importance 
of the qEEG is growing steadily, not only in the field of neurofeedback but in neuropsychology 
and neurology as well. Future work should consider using the qEEG to guide protocol choice, as 
well as to provide pre-and post measures.  
   Participants were asked to follow medical advice as to the use of the NRT for the duration of 
the study. Subsequent inquiries that include an NRT should consider tracking possible changes in 
the use of the product just prior to the start of the study, as well as after the end of the treatment 
phase. In this case, participants did not signal any change during the active portion of the study, 
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but there were perhaps changes just before or after that may have affected outcomes. 
Furthermore, it would be useful to investigate the impact of neurofeedback on nicotine 
dependence and attention in smokers with ADHD who are not actively trying to quit and 
therefore not receiving smoking cessation treatment at all, thereby avoiding the confounding 
factor of the NRT. 
   Self-reports were the basis of the outcome measures. The validity of self-report outcome 
measures in smoking studies has frequently been questioned and although they have for the most 
part been found to be fairly accurate, the recommendation ultimately is to include a physiological 
measure to corroborate self-reports of changes in smoking behaviour (Patrick et al., 1994). 
Although the cost of such a tool was beyond the scope of this study, it would be an additional 
means to verify outcomes in future research. Such a tool would have allowed a verification of 
compliance of the use of the NRT.  
   It was not always possible to have the volunteer participants stay for the extra half hour to 
complete the IVA+Plus following their last weekly training session. On several occasions, the 
CPT measure was not obtained. On one occasion, the data was lost when the trainee inadvertently 
exited the program. Despite the fact that attention was not one of the dependent variables in this 
small study, it would have been useful to find better measures of attention or perhaps a measure 
of a broader deficit such as executive functioning to deepen the understanding of the impact of 
the neurofeedback training. Executive functioning issues were evident in the difficulties that 
occurred as pertains to scheduling and symptom reporting by the participants. Three sessions per 
week were requested of those who were recruited in the belief that they would benefit more from 
more frequent training, but on occasion participants showed up only once or twice per week. 
Given the significant demands of the assessment, training and monitoring of participants, twice 
weekly sessions would have perhaps produced more consistent data collection. Although 
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anecdotal evidence indicates that twice weekly training is sufficient for relieving problems of 
attention, most addiction studies are done in an intensive fashion, often daily. This aspect of the 
question would warrant further exploration. 
   Normally, many more sessions are required to produce and maintain improvements in 
behaviour with neurofeedback. Like the Scott- Kaiser study, measure of sustained attention 
improved quickly in this study (12-13 sessions). The assumption was that an improvement in 
attention would provide sufficient buffering or protection from withdrawal symptoms in order to 
enable the participants to reduce their smoking. Although the follow-up to the treatment was 
relatively short-term, it is unlikely that if participants were still smoking (albeit less) at the end of 
the treatment, that they would achieve abstinence without further support. It would be interesting 
to investigate the impact of a longer term betaSMR treatment on smoking cessation, or even the 
use of an alpha-theta protocol as a follow-up the betaSMR program, as was done in the Scott-
Kaiser study. “The efficacy of alpha-theta EEG biofeedback may lie in its ability to allow 
participants to better tolerate stress, anxiety, and anxiety-eliciting situations, which are 
particularly evident during the initial phases of recovery. This protocol was shown to 
significantly lower 13 of the scales of the Millon Clinical Multiaxial Inventory (MCMI)...” (Scott 
et al., 2005, p. 455). This approach may prove invaluable and even necessary in resolving the 
problems encountered with unexpected stressors and self-efficacy questions. Individuals with 
ADHD are often plagued by difficulties with self-esteem and depression to a greater degree than 
the norm. Including more in-depth measures of these factors in the pre and post assessments 
would improve understanding of the impact of each protocol on participants.  
   Finally, all the participants were white women. It has been accepted for some time that there are 
gender differences in the way ADHD manifests in women and men (more anxiety, more 
inattention, possibly more executive functioning issues). More evidence is also accumulating 
91 
 
 
underlining how gender differences alter nicotine dependence and withdrawal symptoms as well 
(McClernon et al., 2011). Given the research that indicates important differences in how race and 
gender affect outcomes, the generalisability of the results is therefore limited. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions
 
 
 
   Addictions have long been a particular focus of biofeedback practitioners because of the non-
intrusive nature of these techniques. Side-effects are rare and short-lived if any. Clients who are 
already struggling to regain control of their substance use are good candidates for approaches 
that do not add to their physiological burden. The focus on self-regulation in biofeedbacks is 
inherently therapeutic for what ails them. Neurofeedback has a good track record in the treatment 
of alcohol and stimulant abuse. “Taken together, while current pharmacological treatments 
control behavioral symptoms for many individuals, there remains a significant need for new 
treatment strategies in ADHD, including treatments aimed at cognitive dysfunction and emotion 
dysregulation as these are not adequately treated with existing pharmacotherapies” (Potter et al., 
2014, p. 1105). 
   There is an established relationship between attention problems and the abuse of stimulants such 
as cocaine and nicotine. People with ADHD often develop more severe addictions with these 
substances and have a more difficult time abstaining. Treatment options that potentially increase 
the side-effects suffered by this group do not contribute to better cessation outcomes. BetaSMR 
neurofeedback training has been used since the early days of neurofeedback to help individuals 
better regulate their attention. It has also been used in the past to ‘prime’ stimulant abusing 
patients prior to another neurofeedback intervention and was found to significantly contribute to 
their eventual freedom from addiction. It is therefore a good fit in the toolkit of practitioners 
looking to provide adjunct therapies to those clients who want to quit smoking. 
   In this multiple-baseline across participants study, four smokers with attention problems who 
were already using nicotine patches in unsuccessful attempts to quit smoking were provided with 
betaSMR neurofeedback training for thirteen sessions. It was hypothesized that improvement in 
their ADHD symptom status would also improve their chances at smoking cessation. Although 
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abstinence was achieved by only one participant, results were positive for three of the four 
participants who decreased significantly, if moderately, their nicotine dependency as measured by 
the CDS-5 and for whom there were no increases in withdrawal symptoms as measured by the 
CSW-21. Although the fourth participant did not decrease her dependency scores in the 
comparison of Phase A to Phase B of this study, she did report a reduction in number of cigarettes 
smoked. Finally, all the participants showed eventual significant improvements in sustained 
attention scores.  
   Neurofeedback as a treatment is based upon operant conditioning principles (Gunkelman & 
Johnstone, 2005).  The EEG can be characterised as behaviour. Although highly technological in 
nature, the fundamentals of neurofeedback are based in the grassroots of clinical psychological 
practise. Clinical psychologists and their clients could potentially benefit enormously from this 
brain-based modality as part of a multi-modal approach to treatment, yet it remains largely 
unknown or misunderstood. Although this paper focussed on adult smokers with ADHD, there is 
emerging research on the use of neurofeedback for many other mental health disorders as well. 
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STUDY TIMELINES:    
 
 
 
 
 
 
 
 
Non-concurrent baselines 
 
Daily measures 
VB baseline = 20 days  treatment starts on day 21 ends on day 56 
CR baseline = 10 days  treatment starts on day 11 ends on day 50   
JW baseline = 8 days  treatment starts on day 9 ends on day 36 
MT baseline = 7 days  treatment starts on day 8 ends on day 40 
 
 
 
 
 
 
 
 
  
 
VB  i b b b b b b b b b b b b b b b b b b b b /n t n t t t t n t n t n t t n t n t t t t n t n t t n t n t n t t t t n 
CR i b b b b b b b b b b /n t n t n t t n t n t t t t t n t t n t t t n t t n t t t t n t n t t n t t t n 
JW i b b b b b b b b/ n t n t t n t n t n t n t t n t n t t n t t n t n t t n 
MT i b b b b b b b/ n t n t n t t n t n t n t t t t t t n t n t t n t n t t n t n t n 
 
i = first cpt; b = day of baseline phase; / = start of treatment phase and t= day of treatment phase; n = day of neurofeedback 
treatment; n = day of neurofeedback treatment and cpt measure 
 
CDS and CWS measures every day during both phases 
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Fagerström Test for Nicotine Dependence (FTND) 
 
Question Answers Points 
1. How soon after you 
wake up do you smoke 
your first cigarette? 
Within 5 minutes  3  
                                               6-30 mins                         2  
                                             31-60 mins                         1  
                                               > 60 mins                         0 
 
2. Do you find it difficult to 
refrain from smoking in 
places where it is 
forbidden, e.g., in church, 
at the library, in the 
cinema, at work, etc.? 
       Yes  1  
                                                        No                                                0 
 
3. Which cigarette would 
you most hate to give up? 
The first one in the 
morning 
  1  
                                                     Any other                                                0 
 
4. How many 
cigarettes/day do you 
smoke? 
     10 or less                       0  
                                           11-20                         1  
                                            21-30                         2  
                                             31 or more                         3 
 
5. Do you smoke more 
frequently during the first 
hours after waking than 
during the rest of the day? 
      Yes  1  
                                            No                        0 
 
6. Do you smoke if you are 
so ill that you are in bed 
most of the day? 
       Yes                       1  
                                              No                        0 
 
 
©Permission to use this scale for purposes other than research must be obtained from 
K.O. Fagerström. 
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Adult Self-Report Scale Screener (ASRS v 1.1) 
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CADDRA ADHD Assessment Toolkit (CAAT) 
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Wender Utah Rating Scale 
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IVA+Plus Sample Report 
 
 
 
 
 
 
 
 
 
 
 
 
 
136 
 
 
 
 
 
 
 
 
 
 
 
137 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 7 
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The Cigarette Dependence Scale, English-language version    DATE__________________ 
                
 
  Questions       Response options Coding 
 
1. Please rate your addiction to cigarettes on a    ___Addiction  0-20 = 1 
scale of 0 to 100:         21-40 = 2  
-I am NOT addicted to cigarettes at all =     0    41-60 = 3 
-I am extremely addicted to cigarettes  = 100    61-80     = 4 
          81-100 = 5 
       2. On average, how many cigarettes do you smoke  ___Cigarettes/day 0-5         = 1  
 per day?          6-10       = 2 
           11-20     = 3 
           21-29 = 4 
           30+        = 5 
3. Usually, how soon after waking up do you smoke your ___Minutes  0-5         = 5 
first cigarette?         6-15       = 4 
          16-30     = 3 
          31-60 = 2 
          61+ = 1 
 
4. For you, quitting smoking for good would be:    Impossible  = 5 
Very difficult = 4 
Fairly difficult  = 3 
Fairly easy  = 2 
Very easy             = 1 
 
Please indicate whether you agree with each of the following statements: 
5.  After a few hours without smoking I feel an irresistible urge to smoke.  
Totally disagree = 1/Somewhat disagree = 2/ Neither agree nor disagree = 3/Somewhat agree = 4/Fully agree = 5 
 
6. The idea of not having any cigarettes causes me stress. 
Totally disagree = 1/Somewhat disagree = 2/ Neither agree nor disagree = 3/Somewhat agree = 4/Fully agree = 5 
   
7. Before going out I make sure that I always have cigarettes with me. 
Totally disagree = 1/Somewhat disagree = 2/ Neither agree nor disagree = 3/Somewhat agree = 4/Fully agree = 5 
        
8. I am a prisoner of cigarettes. 
Totally disagree = 1/Somewhat disagree = 2/ Neither agree nor disagree = 3/Somewhat agree = 4/Fully agree = 5 
      
9. I smoke too much. 
Totally disagree = 1/Somewhat disagree = 2/ Neither agree nor disagree = 3/Somewhat agree = 4/Fully agree = 5 
       
10. Sometimes I drop everything to go out and buy cigarettes. 
Totally disagree = 1/Somewhat disagree = 2/ Neither agree nor disagree = 3/Somewhat agree = 4/Fully agree = 5 
 
11. I smoke all the time. 
Totally disagree = 1/Somewhat disagree = 2/ Neither agree nor disagree = 3/Somewhat agree = 4/Fully agree = 5 
 
12. I smoke despite the risks to my health. 
Totally disagree = 1/Somewhat disagree = 2/ Neither agree nor disagree = 3/Somewhat agree = 4/Fully agree = 5 
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141 
 
 
Cigarette Withdrawal Scale (CWS-21)    Date : 
 
      Response options 
totally disagree =1 
mostly disagree =2 
more or less agree =3 
mostly agree  =4 
totally agree  =5 
 
 1. I feel depressed          2. My morale is low 3. I feel worried  4. I feel anxious 5. The only thing I can think about is smoking a cigarette 6. I miss cigarettes terribly  7. I feel an irresistible need to smoke  8. I would like to hold a cigarette between my fingers 9. I am irritable  10. I get angry easily  11. I have no patience  12. I feel nervous 13. I find it difficult to think clearly  14. I find it hard to concentrate  15. I find it hard to focus on the task at hand  16. I am eating more than usual  17. My appetite has increased  18. I have put on weight recently  19. I have difficulty sleeping 20. I wake up often during the night  21. I have trouble falling asleep at night  
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IVA+Plus Results 
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  VB     
 Day   Evaluation     28*          35             44             51*         56 
RC-Quotient 31 - 76 70   -   63 
RC-Auditory 55 - 84 68 - 66 
RC-Visual 35 - 78 86 - 76 
Att-Quotient 33 - 41 64 - 81 
Att-Auditory 68 - 48 63 - 97 
Att-Visual 8 - 48 74 - 67 
Sus-Att-Aud 12 - 38 43 - 95 
Sus-Att-Vis 14 - 50 49 - 61 
 
  CR 
Day  Evaluation         15            26             33            41           50      
RC-Quotient 49 35 30 44 28 55 
RC-Auditory 62 45 32 57 40 78 
RC-Visual 47 39 43 42 32 38 
Att-Quotient 83 106 105 96 95 108 
Att-Auditory 92 107 103 104 92 105 
Att-Visual 77 104 106 89 98 110 
Sus-Att-Aud 69 69 72 75 74 107 
Sus-Att-Vis 69 79 88 61 109 111 
 
  JW 
Day  Evaluation    14          20           28*      31          36        
RC-Quotient 13 # 31 - 62 98 
RC-Auditory 24 # 38 - 67 108 
RC-Visual 21 # 38 - 66 76 
Att-Quotient 71 # 87 - 68 81 
Att-Auditory 74 # 86 - 78 83 
Att-Visual 72 # 88 - 63 81 
Sus-Att-Aud 66 # 94 - 66 73 
Sus-Att-Vis 64 # 77 - 50 83 
 
MT 
  
 
   Day  Evaluation     12            19             31            40 
RC-Quotient 112 84 103 97 105 
RC-Auditory 130 117 101 118 109 
RC-Visual 124 100 103 109 108 
Att-Quotient 86 41 67 70 109 
Att-Auditory 82 23 48 51 81 
Att-Visual 82 24 52 55 93 
Sus-Att-Aud 77 @ 37 22 112 
Sus-Att-Vis 90 @ 20 33 90 
           (*apt.missed), (@ =invalid), ( # = data lost) 
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FORMULAIRE D’INFORMATION ET DE CONSENTEMENT 
 
Vous êtes invité(e) à participer à un projet de recherche. Le présent document vous renseigne sur 
les modalités de ce projet de recherche. S’il y a des mots ou des paragraphes que vous ne 
comprenez pas, n’hésitez pas à poser des questions. Pour participer à ce projet de recherche, vous 
devrez signer le consentement à la fin de ce document et nous vous en remettrons une copie 
signée et datée. 
 
Titre du projet 
 
Traiter la dépendance à la nicotine par le neurofeedback chez des adultes ayant un trouble 
déficitaire de l’attention avec hyperactivité. 
 
Personnes responsables du projet 
 
Chercheure principale : Suzanne Lamontagne est psychologue en pratique privée et étudiante au 
doctorat en psychologie à l’Université de Sherbrooke. On peut la rejoindre par courriel à …Le 
présent projet de recherche s’inscrit dans le cadre de sa thèse de doctorat en psychologie 
clinique.  
Ce projet est réalisé sous la direction de Dre Dominique Lorrain, professeure titulaire au 
Département de psychologie de l’Université de Sherbrooke et directrice du Laboratoire de 
vigilance au Centre de recherche sur le vieillissement du Centre de santé et de services sociaux – 
Institut universitaire de gériatrie de Sherbrooke . On peut la rejoindre par courriel à … 
 
Objectifs du projet 
 
L’étude consiste à évaluer l’impact d’un entraînement en neurofeedback chez des adultes atteints 
d’un TDA/H et qui, malgré l’utilisation d’un timbre de nicotine, n’arrivent toujours pas à cesser 
de fumer. Ce traitement non invasif utilise l’activité du cerveau comme rétroaction pour aider à 
développer un meilleur contrôle attentionnel.  
 
Raison et nature de la participation 
 
Dans le cadre de ce projet, nous procéderons à une évaluation des symptômes typiquement 
associés au TDA/H.  Cette évaluation se fera en deux parties. La première partie sera une 
rencontre d’environ trois heures, Des pauses vous seront proposées afin d’éviter la fatigue. Au 
cours de cette rencontre vous passerez des tests cognitifs qui nous permettront de mieux 
connaître votre profil attentionnel. Je vous remettrai également des questionnaires que vous 
pourrez compléter à la maison et qui nous permettrons d’évaluer la présence de problèmes qui 
sont fréquemment retrouvés dans le TDA/H. Il y aura à la fin de cette rencontre une 
démonstration d’un entraînement en neurofeedback.   
La deuxième partie de l’évaluation sera une rencontre d’environ une heure et demie au cours de 
laquelle nous ferons une évaluation de votre activité cérébrale. Pour ce faire, nous placerons des 
électrodes (petits disques de métal maintenues en place par une pâte adhésive) à deux endroits 
sur votre tête ainsi que sur les lobes d’oreilles. Nous pourrons ainsi enregistrer l’activité 
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électrique de votre cerveau et déterminer les ondes cérébrales  sur lesquelles nous travaillerons 
pour tenter d’améliorer vos capacités attentionnelles. 
 
Vous serez ensuite invité à participer à une série de 10 à 20 séances de neurofeedback à raison de 
trois (3) fois par semaine. À chaque séance d’entrainement, nous installerons sur votre tête les 
électrodes de la même manière qu’au cours de l’évaluation.  
 
Pendant la période d’entraînement, vous aurez à compléter quotidiennement deux petits 
questionnaires sur vos symptômes de sevrage et votre utilisation de la cigarette. Il y aura 
également la passation d’test d’attention sur ordinateur à chaque semaine pour mesurer des 
changements potentiels. Les traitements prendront fin après 20 rencontres ou avant si cette 
mesure indique que votre attention s’est améliorée. Dix semaines après le dernier traitement, 
vous serez recontacté par téléphone pour évaluer votre abstinence par rapport à la cigarette. 
L’évaluation ainsi que l’ensemble des traitements seront gratuits. 
 
Toutes les rencontres auront lieu dans la ville de Pointe Claire. 
 
Avantages pouvant découler de la participation  
 
Votre participation à ce projet de recherche vous apportera l’avantage d’une évaluation pour le 
TDA/H et d’un traitement qui pourrait potentiellement aider à améliorer vos capacités 
attentionnelles. À cela s’ajoute le fait que cette étude contribuera à l’avancement des 
connaissances concernant le TDA/H et le tabagisme. 
 
Inconvénients et risques pouvant découler de la participation  
 
Votre participation à la recherche vous demandera une implication importante pour 
l’entraînement en neurofeedback. Pour atténuer les inconvénients de cette implication, des 
rendez-vous seront possibles jour ou soir, en semaine et en fin de semaine. Si pendant 
l’entraînement ou l’analyse de l’activité cérébrale vous vivez de l’inconfort ou de la fatigue, ceci 
devrait être que passager et vous pourrez demander de prendre une pause. À la connaissance de 
la chercheuse, il n’y a aucun risque associé à la participation, incluant l’usage des électrodes 
pour enregistrer l’activité cérébrale. L’utilisation d’une pâte adhésive pour la pose des électrodes 
peut toutefois légèrement défaire votre coiffure. 
 
Droit de retrait sans préjudice de la participation  
 
Il est entendu que votre participation à ce projet de recherche est tout à fait volontaire et que vous 
restez libre, à tout moment, de mettre fin à votre participation sans avoir à motiver votre décision 
ni à subir de préjudice de quelque nature que ce soit. 
 
Advenant que vous vous retiriez de l’étude, demandez-vous que les tests, les 
enregistrements de votre EEG et les documents vous concernant soient détruits? 
Oui    Non   
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Il vous sera toujours possible de revenir sur votre décision. Le cas échéant, la chercheuse vous 
demandera explicitement si vous désirez la modifier. 
 
 
Confidentialité, partage, surveillance et publications 
 
Durant votre participation à ce projet de recherche, la chercheuse responsable recueillera et 
consignera dans un dossier de recherche les renseignements vous concernant.  Seuls les 
renseignements nécessaires à la bonne conduite du projet de recherche seront recueillis.  Ils 
peuvent comprendre les informations suivantes : nom, sexe, date de naissance, les résultats de 
l’évaluation cognitive, les résultats de l’entraînement en neurofeedback ainsi que les autres 
mesures exigées lors de ce projet. 
 
Tous les renseignements recueillis au cours du projet de recherche demeureront strictement 
confidentiels dans les limites prévues par la loi. Afin de préserver votre identité et la 
confidentialité de ces renseignements, vous ne serez identifié(e) que par un numéro de code. La 
clé du code reliant votre nom à votre dossier de recherche sera conservé par la chercheuse 
responsable du projet de recherche. 
 
La chercheuse principale de l’étude utilisera les données à des fins de recherche dans le but de 
répondre aux objectifs scientifiques du projet de recherche décrits dans ce formulaire 
d’information et de consentement. 
 
Les données du projet de recherche pourront être publiées dans des revues scientifiques ou 
partagées avec d’autres personnes lors de discussions scientifiques. Aucune publication ou 
communication scientifique ne renfermera d’information permettant de vous identifier. Les 
données recueillies seront conservées, sous clé, pour une période n’excédant pas 5 ans après la 
fin de la collecte des données. Après cette période, les données seront détruites.  
 
À des fins de surveillance et de contrôle, votre dossier de recherche pourrait être consulté par une 
personne mandatée par le Comité d’éthique de la recherche Lettres et sciences humaines, ou par 
des organismes gouvernementaux mandatés par la loi. Toutes ces personnes et ces organismes 
adhèrent à une politique de confidentialité. 
 
Résultats de la recherche et publication  
 
Vous serez informé des résultats de la recherche et des publications qui en découleront, le cas 
échéant. Nous préserverons l’anonymat des personnes ayant participé à l’étude. 
 
Surveillance des aspects éthiques et identification du président du Comité d’éthique de la 
recherche Lettres et sciences humaines 
 
Le Comité d’éthique de la recherche Lettres et sciences humaines a approuvé ce projet de 
recherche et en assure le suivi. De plus, il approuvera au préalable toute révision et toute 
modification apportée au formulaire d’information et de consentement, ainsi qu’au protocole de 
recherche. 
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Vous pouvez parler de tout problème éthique concernant les conditions dans lesquelles se 
déroule votre participation à ce projet avec la responsable du projet ou expliquer vos 
préoccupations, président par intérim du Comité d’éthique de la recherche Lettres et sciences 
humaines, en communiquant par l’intermédiaire de son secrétariat au numéro suivant : 
 
Consentement libre et éclairé 
 
Je, ________________________________________________ (nom en caractères 
d'imprimerie), déclare avoir lu et/ou compris le présent formulaire et j’en ai reçu un exemplaire. 
Je comprends la nature et le motif de ma participation au projet. J’ai eu l’occasion de poser des 
questions auxquelles on a répondu, à ma satisfaction. 
Par la présente, j’accepte librement de participer au projet. 
 
Signature de la participante ou du participant : _____________________________ 
 
Fait à _________________________ , le _____________201_. 
 
 
Déclaration de responsabilité des chercheurs de l’étude 
 
Je, ___________________________________ chercheuse principale de l’étude, déclare que je 
suis responsable du déroulement du présent projet de recherche.  Je m’engage à respecter les 
obligations énoncées dans ce document et également à vous informer de tout élément qui serait 
susceptible de modifier la nature de votre consentement. 
 
Je certifie également avoir expliqué à la participante ou au participant intéressé(e) les termes du 
présent formulaire, avoir répondu aux questions qu’il ou qu’elle m’a posées à cet égard et lui 
avoir clairement indiqué qu’il ou qu’elle reste, à tout moment, libre de mettre un terme à sa 
participation au projet de recherche décrit ci-dessus. Je m’engage à garantir le respect des 
objectifs de l’étude et à respecter la confidentialité. 
 
 
Signature : ____________________________ 
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Une alternative pour les patient(e)s avec un TDAH qui utilisent sans succès un timbre de nicotine... 
 
Docteur, 
Mon nom est Suzanne Lamontagne, psychologue oeuvrant au sein de la communauté de l'Ouest de l'Île 
depuis plus de 15 ans. Dans le cadre de mon projet de thèse en vue d'obtenir un doctorat en 
psychologie clinique, je mène une étude qui a pour but d'évaluer l'efficacité potentielle d'un traitement 
de neurofeedback chez des adultes atteints d'un déficit d’attention (TDAH) qui utilisent un timbre de 
nicotine, sans réussir à cesser de fumer. 
 
Il est connu que les adultes atteints d’un trouble attentionnel ont des symptômes de sevrage importants 
et ont beaucoup de difficulté à cesser de fumer, malgré l’utilisation d’un timbre de nicotine. Bien que les 
psychostimulants soient le traitement pharmacologique de choix pour le TDAH, les effets secondaires 
indésirables qu’ils procurent en réduisent considérablement leurs utilisations chez ceux qui veulent 
cesser de fumer, surtout lorsqu’ils s'ajoutent à des substances ayant déjà des propriétés stimulantes, 
comme la nicotine. Le neurofeedback qui est une intervention thérapeutique reconnu comme étant 
efficace dans le traitement du TDAH pourrait également contrer les symptômes de sevrage et ainsi 
augmenter les chances de succès avec un timbre de nicotine.  
 
Je vous invite donc à me référer vos patients ou patientes présentant un tel profil. J'évaluerai leur cas 
selon les critères du CADDRA combiné à des mesures cognitives. J’offrirai gratuitement aux personnes 
admissibles un traitement en neurofeedback à mon bureau, dans la ville de Pointe-Claire. Ces personnes 
devront participer à  3 rencontres par semaine, pour une durée de 3 à 5 semaines. 
 
Les critères d'exclusion comprendront un traitement pharmacologique pour le TDAH, la présence d'une 
maladie psychiatrique ou neurologique, la toxicomanie ou un traitement antérieur en neurofeedback. 
 
Si vous désirez obtenir plus d'information sur le neurofeedback, il me fera grand plaisir d'en discuter 
avec vous. Vous pouvez également consulter le site du International Society for Neurofeedback Research 
au www.isnr.org pour apprécier les avantages de la neurothérapie. 
 
Le projet de recherche a été approuvé par le Comité d’éthique de la recherche Lettres et Sciences 
Humaines de l’Université de Sherbrooke et sera supervisé par Docteur Dominique Lorrain, Ph.D., 
psychologue et professeure titulaire au département de psychologie de l’Université de Sherbrooke et 
chercheure au Centre de recherche sur le vieillissement du Centre de santé et de services sociaux - 
Institut universitaire de gériatrie de Sherbrooke. 
 
Je vous remercie de votre attention et vous prie d'agréer l'expression de mes sentiments distingués. 
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QU'EST-CE QUE LE NEUROFEEDBACK ? 
 
Le neurofeedback est un biofeedback qui permet l’entraînement des ondes cérébrales pour 
améliorer certaines capacités cognitives tel que l’attention. Le biofeedback est une technique 
permettant d’apprendre à contrôler des fonctions physiques et mentales qui ne peuvent être 
ressenties ou influencées consciemment car elles sont gérées automatiquement. Cette méthode 
d’autorégulation par l’utilisation d’appareils (électroniques ou informatiques) favorise 
l’observation et la modulation volontaire des fonctions du corps. Les appareils captent et 
amplifient l’information (température corporelle, rythme cardiaque, activité musculaire, ondes 
cérébrales, etc.) et les traduisent en signaux auditifs ou visuels. Le patient peut graduellement 
apprendre quels types de respiration, quelles pensées, quelles postures et quelles attitudes lui 
procurent les meilleurs résultats.  
Dans le cas du neurofeedback, l’électroencéphalographe (EEG) est l’appareil qui capte 
les ondes du cerveau. Des capteurs/électrodes posés sur le cuir chevelu digitalisent les courants 
neuroélectriques du cerveau et les envoient à un ordinateur qui traite le signal et fournit un 
feedback approprié. La rétroaction des signaux est révélée par moyen d’un jeu à l’écran de 
l’ordinateur et par de la musique. Quand la personne produit les ondes désirées, le jeu avance et 
la musique joue. Si elle n’arrive pas à produire les ondes désirées, le jeu et la musique arrêtent. 
De cette façon, on peut apprendre comment contrôler ses ondes cérébrales pour, par exemple, 
mieux gérer son attention. 
 
L’ÉLECTROENCÉPHALOGRAMME QUANTITATIF (EEGq) 
 
L’évaluation de l’activité neuroélectrique se fait avec une analyse quantifiée des ondes 
cérébrales (EEGq).  L’emphase principale du neurofeedback n’est pas la qualité des ondes 
cérébrales (tel qu’analysé par les neurologues pour détecter des crises d’épilepsie ou autres 
maladies neurologiques), mais plutôt la proportion de certaines ondes cérébrales en relation avec 
d’autres ondes. L'EEGq est un examen indolore et non invasif. Des électrodes (petits disques de 
métal) sont posées sur la tête du participant en position assise.  Un gel est introduit dans chaque 
électrode pour assurer un bon contact entre celles-ci  et le cuir chevelu. On peut alors étudier 
l'influence de l'ouverture des yeux par rapport aux yeux fermés sur l’activité cérébrale. Le but du 
EEGq pour cette étude sera de confirmer la présence d’ondes ‘chez les participants et de 
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s’assurer qu’il n’y a pas déjà un excès d’ondes là ou nous voulons les encourager. Sans la 
présence de ce schéma,  l’entraînement proposé serait une perte de temps pour le participant. 
 
 
 
L’ENTRAÎNEMENT EN NEUROFEEDBACK 
 
Avant de commencer chaque séance d’entraînement, des électrodes sont posés à deux 
endroits sur le cuir chevelu et maintenus en place à l’aide d’une pâte adhésive. Des électrodes sur 
les lobes d’oreilles servent de références et une électrode posée sur le front sert de mise à la terre. 
En séance d'entrainement, la personne doit arriver à se concentrer pour diminuer les ondes 
thêta/alpha ciblées, et augmenter un autre type d’activité cérébrale, soit les ondes SMR. Quand la 
personne arrive à le faire, un jeu à l’écran de l’ordinateur qui donne la rétroaction avance et la 
musique joue. Si la personne n’arrive pas à produire les ondes désirées, le jeu et la musique 
s’arrêtent. De cette façon, le participant peut apprendre à modifier de façon consciente et 
volontaire l’activité électrique de son cerveau et améliorer son attention. Pendant une séance de 
neurofeedback le cerveau est entraîné à mieux fonctionner. Après plusieurs séances, le cerveau 
opte pour ce meilleur fonctionnement. 
